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 RNAs regulate numerous cellular processes making them highly sought 
therapeutic targets. One mechanism to inhibit functional RNAs is to alter their structura-
dynamics using small molecule binders. While structure based drug design is often used 
to discover small molecule inhibitors, difficulties arise because, unlike proteins, RNAs 
undergo large conformational changes between the free and ligand-bound states that 
cannot be determined a priori. The spatial and temporal complexity of these 
conformational changes precludes accurate characterization that would allow one to 
visualize the conformational changes. While no method currently exists that can fully 
interrogate complex RNA dynamics, nuclear magnetic resonance (NMR) is a prime 
candidate because of its ability to site-specifically report on dynamics over a wide range 
of timescales (picoseconds-minutes). However, the number of measurable observables 
by NMR pales in comparison to the number of parameters needed to fully describe 
complex dynamic motions. Molecular dynamics (MD) can provide an all-atom description 
of RNA dynamics, but the force-fields governing the theoretical description are 
inaccurate and simulations remain limited to ~100 nanosecond timescales.  
 xiv 
Using NMR and MD we aim to uncover the biophysical principles governing HIV-
1 transactivation response element RNA (TAR) mediated ligand recognition and 
discover new TAR binding small molecules. First, we present an adapted Sample and 
Select (SAS) approach, which combines NMR residual dipolar couplings (RDCs) and 
MD to provide an accurate all-atom description of RNA dynamics over sub-millisecond 
timescales. RDCs measured on elongated TAR molecules are used to separate internal 
and overall motions and impose a helix-anchored reference frame. Using the SAS 
method, refined RNA ensembles that re-capitulate experimental RDCs are generated 
from an MD trajectory. Specific snapshots of the ensemble closely agree with previously 
determined ligand-bound TAR structures suggesting that the bound state conformations 
are sampled in the absence of ligand. In a second study we investigate the sequence 
dependence of TAR dynamics and show that a modest mutation greatly perturbs global 
and local dynamics giving rise to changes in small molecule binding affinity while still 
forming the same bound state RNA conformation. This suggests that RNA dynamics are 
sequence encoded and lead to pre-tuned functional dynamic ensembles. Lastly, the 
SAS ensemble structures are used in RNA structure-based drug discovery. 
Computational docking simulations are used to discover 11 TAR-binding small 
molecules, 8 of which have never before been shown to bind TAR and 2 never before 
been shown to bind RNA. NMR chemical shift perturbations and fluorescence 
polarization measurements verify that the small molecules bind TAR and inhibit the TAR-
Tat interaction with inhibition constants ranging 0.627-300 µM. RDCs measured on TAR 
bound to the small molecule netilmicin suggest that docking against the SAS structures 
accurately re-capitulates the bound-state. Remarkably, netilmicin is also shown to inhibit 
TAR-mediated HIV-1 LTR expression and HIV-1 replication in an HIV-1 indicator cell 












1.1 Central Role of RNA in Biology 
Watson and Crick’s discovery of the DNA structure more than 50 years ago(1) 
led to the formulation of the central dogma of biology. While it was long thought that 
DNA molecules hold the library of genetic codes that are converted into “single-tasked” 
mRNAs specifying the protein sequences responsible for carrying out cellular functions, 
an increasing number of studies have revealed that RNA plays a much more important 
regulatory role. Discovery of the self-splicing pre-ribosomal catalytic RNA in the early 
1980s(2,3) triggered an explosion in the number of studies aimed at understanding the 
role non-coding RNAs (ncRNAs) play in regulating and affecting cellular processes. 
Examples of ncRNAs include: catalytic RNAs that play key roles in protein synthesis, 
tRNA maturation, self-splicing intron removal, and viroid replication; small nuclear RNAs 
(snRNAs) that comprise the intron removal pre-mRNA splicing machinery; telomerase 
RNA required for chromosome end replication; guide RNAs critical to RNA editing; the 
signal recognition particle RNA necessary for protein translocation; small nucleolar 
  2 
RNAs responsible for ribosomal RNA (rRNA) modification; interfering and micro RNAs 
(RNAi and miRNA) that underlie an entirely new genetic network for regulating gene 
expression(4); and riboswitches that regulate transcription(5), translation initiation(6), 
self-cleavage(7,8), degradation(9,10), and antisense mRNA production(11). While this 
list does not cover the entire breadth of regulatory RNA molecules, it illustrates the 
broadening of RNA functions beyond the traditional roles ascribed to mRNA, tRNA, and 
rRNA in the central molecular dogma  
 
 
Figure 1.1. Cellular ncRNA increases with developmental complexity. As organisms 
exhibit more complex biology the ratio of transcribed ncDNA to coding DNA increases. 
 
Recent studies indicate that the amount of transcribed ncRNA increases 
significantly with organismal complexity, and that as much as 96% of gene products in 
humans could correspond to ncRNAs whose functions remain to be elucidated. In 
comparison, only 2% is translated into proteins, leaving as much as 96% ncRNA 
available to perform diverse tasks (Figure 1.1)(12-14). Given the increasing importance 
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of ncRNAs, it is easy to appreciate the increasing scientific focus devoted to 
understanding the roles RNA plays in biology and how they can be exploited as drug 
targets. 
 
1.2 RNA as a Therapeutic Target  
A growing number of RNAs and RNA-mediated processes are emerging as 
targets for antibacterial and antiviral therapies. Targeting rRNA is already a paradigm for 
developing antibiotics. For example, preferential binding of aminoglycoside molecules to 
the bacterial A-site in the 30S ribosomal subunit leads to mistranslation of protein genes 
and provides one avenue to combat bacterial infections (other avenues for targeting 
rRNA for antibacterial treatment are reviewed in(15,16)). Many RNA structural elements 
located in the untranslated region (UTR) of retroviral genomes are considered opportune 
anti-viral targets. In the case of the human immunodeficiency virus (HIV), this includes 
the transactivation response element (TAR)(17-19), which regulates HIV transcriptional 
fidelity by forming a catalytic ribonucleoprotein complex that hyperphosphorylates RNA 
polymerase II; the rev response element (RRE)(20), which serves as the recognition site 
for the Rev protein responsible for exporting the transcribed HIV genome outside the 
nucleus; and the dimerization initiation site (DIS)(21-23), which is a key recognition site 
for HIV genome dimerization prior to capsid formation and viral maturation.  
A growing number of genetic disorders are being associated with RNA 
dependent processes. Aberrant mRNA function(s) has been linked to the genetic 
diseases Fragile X syndrome, Huntington’s disease, and Autism to name a few (an 
extensive list of such diseases can be found in the review(24)). In these genetic 
disorders it is known that specific mutations lead to defective RNA-protein recognition 
that disrupt normal alternative splicing(24). Cancer therapies aimed at targeting RNA 
have gained traction recently due to the discovery that cellular levels of miRNA are 
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directly related to cancerous cell phenotypes and therefore could potentially be targeted 
for anti-cancer therapies(25-28). Also, the ability to target telomerase RNA with small 
molecules and oligonucleotides has been explored as a potential avenue for anti-cancer 
development(29,30). In fact, the Geron corporation has developed a human telomerase 
binding oligonucleotide that has proven successful in phase III clinical trials(30).  
Targeting RNA for drug development could alleviate some of the difficulties in 
inhibiting protein function(s). While the percentage of the proteome that is druggable is a 
matter of debate, a recent study indicated that all FDA approved small molecule drugs 
target only 207 proteins, 50% of which are G-protein coupled receptors(31-38). This 
number is strikingly small compared to the 1620 known proteins that are directly linked 
to genetic disease and the hundreds of thousands of proteins translated in human 
cells(35). A recent computational study suggests that out of the entire known proteome, 
only 15% contains a druggable binding pocket(33), and the disruption of protein-protein 
interactions, which feature large interaction surfaces, has proven quite difficult(39). Thus, 
while proteins have been and will continue to be the central focus for most drug 
discovery efforts in the near future, the increasing number of potential RNA targets 
provides an alternative route for therapeutic development. 
The potential of RNA as an alternative drug target has spurred numerous studies 
aimed at understanding the molecular principles that underlie RNA-small molecule 
recognition. Figure 1.2 shows a timeline of important discoveries that have advanced the 
field of RNA-targeted drug discovery. While studies in the 1960s by Weinstein I. B. and 
Finkelstein I. B. showed the drug proflavine binds tRNA(40,41), appreciation for RNA as 
a bona fide drug target did not come to fruition until the validation that many known 






Figure 1.2. Timeline of important discoveries in RNA-targeted drug discovery. Nobel Prize medals indicate discoveries that 
were awarded a Nobel Prize. (2,3,6,7,40-42,47-75) 
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oxazolidinones(76) exert their function by binding rRNA. The mechanism of action has 
been extensively studied for aminoglycosides, where reports have shown that many bind 
the 30S ribosomal A-site and disrupt the translational fidelity resulting in the 
incorporation of the incorrect amino acid and thus the synthesis of aberrant proteins and 
ultimately cell death. These findings are encouraging for the field of RNA-targeted drug 
discovery, but they are also an example of the ideal situation since rRNA is catalytically 
active and abundant in cells. The “holy-grail” in RNA-targeted drug discovery is to 
specifically target a catalytically inactive low abundance RNA, which has yet to be 
realized. 
Table 1.1. Examples of RNA therapeutic targets.(16,24,77-83) 
Disease RNA Type RNA Function 
Bacterial Infection rRNA A-site translation 
Bacterial Infection rRNA 
Peptidyl-transferase 
center translation 
Bacterial Infection mRNA Riboswitch 
transcription, translation, 
splicing, mRNA degradation 
Bacterial Infection ncRNA RNase P RNA cleavage 
HIV Viral RNA 
Trans-activation 
response element transcription 
HIV Viral RNA 
Dimerization 
initiation site genome packaging 
HIV Viral RNA 
Rev-response 
element genome export 
Hepatitis C Virus mRNA 
Internal ribosome 
entry site translation 
Spinal Muscular 
Atrophy ncRNA SMN2 pre-mRNA splicing 
Amyotrophic Lateral 
Sclerosis ncRNA TARDBP RNA splicing, transport 
Wolcott-Rallison 
Syndrome mRNA EIF2AK3 translation 
Prostate Cancer mRNA SNHG5 ribosome biogenesis 
Cancer ncRNA miR-372 RNAi 
Cancer ncRNA RBM5 RNA splicing 
 
1.3 Current RNA Drug Targets 
1.3.1 Antibiotics 
Ribosome-targeting antibiotics remain the only validated success story in RNA-
targeted drug discovery. To date, all of the FDA approved RNA-targeting drugs bind 
  7 
rRNA. In fact, nine years ago the FDA approved the use of the gram-positive targeting 
small molecule linezolid (Pfizer), which is an oxazolidinone that is thought to prevent 
initiator tRNA binding to the ribosome and thus inhibit protein synthesis(62,84,85). 
Currently there are 1604 open clinical trials investigating antibiotics, some of which likely 
employ rRNA-targeting small molecules(clinicaltrials.gov).    
Since the discovery of streptomycin in 1944(47,48) numerous studies have 
focused on developing novel rRNA-binding small molecule antibiotics. The advances in 
X-ray crystallography by Steitz T. A., Ramakrishnan V., and Yonath A. D. and other 
groups allowed the atomic resolution visualization of the ribosome in the apo-state and 
bound to various anitbacterials(67,69-71,86-95). Differences between the apo and small 
molecule bound ribosome structures answered many questions about rRNA-targeting 
antibacterial mechanism(s) and agreed with many of the previously determined rRNA-
targeting small molecule antibiotic mechanisms, including the pioneering NMR work by 
Puglisi and co-workers(42,96-98). This Nobel Prize winning accomplishment is providing 
the basis for further structure-based design of new antibiotics. The realization that 
proposed models for antibacterial aminoglycosides targeting the A-site matched those 
revealed by the ribosome crystal structures (discussion of the inhibitory mechanism of 
aminoglycosides that target the bacterial A-site can be found in section 1.4) also 
highlights an important development for RNA-targeting drug discovery -- the modularity 
of RNA allows for extensive biochemical and biophysical studies of RNA targets outside 
of more biologically relevant contexts. This motivates consideration of other RNAs as 
targets for antibiotic development. 
Many RNAs outside the ribosome are targets for small molecule antibiotics 
including tRNA(99-103), non-rRNA catalytic RNAs(78,104), and mRNA elements 
including riboswitches. Some studies are also focused on binding RNAs in the ribosome 
assembly pathway(105-110). Inhibiting aminoacyl-tRNA synthetase enzymes, which are 
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responsible for coupling the correct amino acid to the corresponding tRNA, is considered 
an attractive target for antibacterial development(99). Rather than targeting the enzyme, 
specific binding to the tRNAphe variable loop has been shown for neomycin, potentially 
indicating specificity to inhibit tRNA-amino acid charging. The catalytic nature  
 
Figure 1.3. Riboswitch mediated gene control. (a) The guanine riboswitch regulates 
gene transcription by binding the guanine nucleobase resulting in the formation of a 
terminator hairpin that prevents transcription of the open reading frame(5) and (b) the 
TPP riboswitch regulates translation of the ORF by sequestering the Shine-Dalgarno 
(SD) sequence on binding the TPP metabolite(6). 
 
of ribozymes affords easy readout for monitoring small molecule mediated inhibition. 
This combined with the multiple X-ray structures of ribozymes provides the basis for 
structure based drug design and an excellent case study for understanding RNA-ligand 
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interactions. Small molecule inhibition of ribozymes has been extensively studied since 
1991 with the first report of aminoglycoside inhibition of the group I intron(58). Since this 
initial report many studies have investigated antibiotic ribozyme particularly in the case 
of the hammerhead ribozymes(104) and the RNase P ribozyme(78). 
Along with RNAs involved in antisense-mediated translational control(111), the 
regulatory functions controlled by riboswitches serve as a very attractive mRNA 
antibacterial target. Riboswitches are generally found in the 5’ UTR of bacterial mRNA 
transcripts and bind specific cellular metabolites (e.g. guanine, adenine, S-adenosyl 
methionine, and lysine) to regulate gene expression at the transcriptional or translational 
level(112). The genes that are downstream of the riboswitch are usually involved in 
transport or synthesis of the cognate metabolite and thus are direct regulators of cellular 
metabolite concentrations. Most often if the metabolite is not present the gene is “on” 
and transcription or translation will persist, however when the metabolite is in sufficiently 
high concentration then the riboswitch will bind the metabolite and turn the gene “off” by 
forming an RNA structure that will suppress further transcription or translation(Figure 
1.3). The structure that forms on binding the cognate metabolite is often in the form of a 
terminator hairpin (GC rich helix followed by a stretch of uridines) (Figure 1.3a) when 
inhibiting transcription, or results in sequestering the Shine-Dalgarno sequence (Figure 
1.3b) to prevent ribosome recognition and thus translation of the mRNA transcript. A 
viable antibacterial drug-discovery approach would be to target these riboswitches 
thereby inducing a desirable change in metabolite regulation to kill infectious bacteria in 
the host. In a recent study, Breaker R. R. and co-workers found five lysine analogs that 
bind the lysine riboswitch within 40 fold of the native lysine binding affinity (360nM) (77). 
This study further showed that three of the compounds inhibit bacterial growth with 
minimum inhibitory concentrations ranging from 26-938µM. Mutating the riboswitch 
confirmed that these lysine analogs bind the aptamer domain of the riboswitch to inhibit 
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cell growth, which significantly increased the minimum inhibitory concentrations (1.56-
5mM) but did not affect lysine binding. This also suggested that the binding mode of 
these small molecules was different than that of lysine. Thus, it is plausible that 
riboswitch mediated regulation is a kinetically and not necessarily a thermodynamically 
controlled process, explaining why relatively weak binders can inhibit bacterial growth 
likely through formation of kinetically trapped alternative conformations. This is also 
supported by other reports(113-117). Thus, while still an infant field for antibacterial 
therapeutic development, the ability and desire to target riboswitches will likely gain 
much more traction in the near future. 
  
1.3.2 Anti-cancer 
RNA-targets provide an alternate route for anti-cancer therapies. Various cellular 
processes are being targeted for anti-cancer small molecule development including RNA 
splicing (118), translocation(119), miRNA regulation(25-28), ribosome assembly(120), 
and transcription(121-124). For example, an attractive anti-cancer mRNA drug target 
that exists in mammalian cells is the thymidylate 
synthase (TS) RNA. The TS protein is involved in 
regulating the generation of thymidine 
monophosphate that becomes further 
phosphorylated to form thymidine triphosphate 
used in DNA synthesis and repair. Inhibiting the 
TS mechanism has been at the forefront of many 
pharmaceutical research companies for years as a 
target for anti-cancer therapy(125,126). While the 
TS protein can be targeted in cells, certain classes of TS inhibitors make the TS protein 
unable to regulate its own translation, resulting in unregulated expression. Thus, as the 
 
Figure 1.4. TS RNA is an anti-
cancer target. Aminoglycosides 
have been shown to bind the 1X1 




concentration of TS increases in cells, these inhibitors exhibit reduced efficacy(121-123). 
Rather than targeting the enzyme, an alternative approach would be to target the TS 
RNA. Briefly explained, the TS protein binds to the TS mRNA at two distinct sites, the 
first of which is a stem-loop RNA with two symmetric internal loops and a seven-
nucleotide apical loop (Figure 1.4) (127,128). Located within this first TS protein binding 
site RNA is the AUG start codon(127,128). Thus, the likely transcription-regulation 
mechanism for this protein is to bind its own RNA, thereby sequestering the start codon 
as a negative feedback for its own production(127). The first study targeting the TS RNA 
with small molecules to stabilize the TS RNA hairpin showed varying affinities for a 
library of aminoglycosides (Kd0.9-2.7 µM) and mutational studies indicate that the 
aminoglycosides bind the 1X1 internal loop and not the 2X2 or apical loops (Figure 
1.4)(124).  
 
1.3.3 Anti-viral  
Some of the classically studied RNAs are directly involved in the life-cycles of 
viruses and for many years have been sought as anti-viral therapeutic targets. As 
previously mentioned, three such RNAs are the TAR, RRE and DIS in the HIV genome. 
Briefly, TAR is located in the 5’ LTR sequence of the HIV genome and forms a stem-loop 
structure that serves as a scaffold for binding regulatory proteins, namely Tat, Cyclin T1, 
and Cdk9, that together ensure the fidelity of gene expression by hyper-phosphorylating 
RNA polymerase II(Figure 1.5)(129,130). Anti-HIV drug discovery efforts have focused 
on binding TAR or Tat and thus preventing their association leading to decreased viral 
efficacy. Tat forms specific and tight interactions (Kd low-sub nM) with TAR through its 
arginine rich motif (69,131-135), and numerous reports have focused on understanding 
the TAR-Tat recognition mechanism and the mode of action for many known 
inhibitors(59,136-147) (see further discussion in section 1.8). While there is debate over 
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the action of many TAR-binding small molecule inhibitors, it is likely that many small 
molecules allosterically inhibit TAR-Tat binding by locking TAR into alternate 
conformations that prevent Tat binding(148).  
 
 
Figure 1.5. TAR regulates HIV transcription fidelity. TAR is located in the 5’ LTR of 
the HIV genome (on bottom) and regulates HIV Transcription through the formation of a 
ribonucleoprotein complex. In the absence of TAR truncated transcripts are produced, 





1.4 RNA Structural Adaptation on Small Molecule Binding  
Structure-based drug design is one of the most ambitious approaches for drug 
discovery and is based on rationally using knowledge of a molecule’s 3D structure in 
identifying small molecules capable of binding that structure. Highly flexible RNA 
structures pose a unique challenge in this regard because even related ligands can bind 
very different RNA conformations that cannot, in general, be determined a priori. The 
earliest observations of post-folding rearrangements in RNA structure were made in the 
1980s by Steitz T. A., Soll D. and co-workers who showed that tRNA undergoes 
changes in the alignment of its helices on binding to glutaminyl-tRNA synthetase(55). In 
subsequent NMR studies, Williamson J. R. and Puglisi J. D. showed that even a small 
ligand, such as argininamide, can induce large changes in the conformation of TAR 
(TAR) involving large changes (~40º) in the orientation of A-form helices coupled with 
local formation of a base-triple (59). In an elegant series of NMR studies, Puglisi and co-
workers demonstrated that small molecule aminoglycoside antibiotics exert their activity 
by inducing conformational changes in the A-site RNA, underscoring the importance of 
structural transitions in RNA targeting (42,96,98,149). Briefly, the A-site (Figure 1.6) is 
located in the small 30S subunit of the ribosome and is responsible for ensuring the 
transcript codon matches the incoming tRNA anticodon to ensure correct amino acid 
incorporation. If a match is present then the two critical internal loop adenine bases 
(A1492 and A1493) flip out and permit incorporation of the amino acid, which is attached 
to the tRNA, into the polypeptide chain. When a match is not found then the adenine 
bases remain looped inside thus rejecting the tRNA and another matching event occurs. 
The A-site is the target for many antibiotics (e.g. paromomycin – Kd~200nM)(150), which 
exert their activity by binding the internal loop and stabilizing a looped out conformation 
for the two universally conserved adenine residues A1492 and A1493, thereby allowing 
incorporation of incorrect amino acids leading to the production of aberrant proteins and 
  14 
eventually cell death. Remarkably, a single substitution of internal looped adenine A1408 
with a guanine residue, which is found in humans and mutated bacterial strains, confers 
antibiotic resistance through mechanisms that are not fully understood.  
 
Figure 1.6. A-site structural adaptation on small molecule binding. Translation 
regulation by the A-site is inhibited by the aminoglycoside paromomycin (orange). On 
binding paromomycin the internal loop adenines (yellow) loop outside the helix and 
interact with the tRNA (red) and the mRNA transcript (blue) resulting in incorporation of 
aberrant amino acids in the polypeptide. Note that A-site base numbering is truncated for 
clarity (e.g. 1492 is shown as 92). 
 
An extreme example of structural rearrangements on interaction with a small 
molecule is observed in RNA aptamers (Figure 1.7). Non-biologically native RNA 
aptamers are developed to specifically bind a small molecule ligand using the SELEX 
protocol(56,57). Largely unstructured in the free state, these aptamers fold on contact 
with the ligand to form complex tertiary structures, with multiple specific RNA-small 
molecule interactions that confer tight binding affinities (nM-µM)(151). Often times the 
small molecule ligand is almost completely buried inside the RNA. Analogously, large 
structural rearrangements are seen in the naturally occurring aptamer domains of 
riboswitches. As previously mentioned, when the concentration of the cognate 
metabolite is sufficiently high the riboswitch aptamer binds the ligand via numerous 
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specific interactions. On binding the metabolite, the aptamer induces formation of an 
RNA structure that impedes transcription or translation(112). However, in the absence of 
the metabolite an alternate aptamer conformation is adopted and transcription or 
translation proceeds (see Figure 1.3 for an example of the riboswitch 
mechanism)(5,112,152).   
 
Figure 1.7. Structural rearrangement of the malachite green aptamer. On interaction 
with the small molecule malachite green, the unstructured free RNA folds into a complex 
tertiary structure that exhibits specific stacking and hydrogen bonding interactions(154). 
 
Given that many small molecules exhibit their activity non-competitively by 
stabilizing inactive RNA conformations(155), identifying RNA-targeting small molecules 
presents a difficult challenge because high affinity does not guarantee high activity. For 
example, fluorescence studies provide strong evidence that the aforementioned 
antibacterial activity of aminoglycoside antibiotics that bind the ribosomal decoding-site, 
some of which exhibit nM binding affinity, is not determined by their binding affinity, but 
by the dynamics of the internal loop adenines in the bound RNA structure(156). 
Likewise, studies have shown that neomycin B inhibits the interaction between TAR and 
Tat by binding to TAR and preventing necessary conformational changes from taking 
place(146). Thus, the development of methodology for identifying allosteric small 
molecules is of great importance to advance the field of RNA-targeted drug discovery. 
  16 
Numerous studies over the past two decades have focused on understanding the 
physical principles guiding RNA structural changes that take place on ligand 
binding(139,151,157,158). A deeper understanding of these transitions will not only 
provide a more thorough description of the complex mechanisms that guide RNA-
mediated biological processes, but will also serve to advance the field of RNA-targeted 
structure based drug design. Two mechanisms have been used to describe these 
structural adaptations(139,158,159). The “induced-fit” model, first described by Koshland 
D. E. in the 1950s to explain the decreased rates of protein enzyme catalysis observed 
when using substrate analogs(160), was used to explain many of the initial discoveries 
of RNA structural changes on ligand binding. Using the induced-fit model it was 
assumed that the bound state RNA conformation is not largely populated in the unbound 
state because it is thermodynamically unstable and/or separated by very high kinetic 
barriers; factors that are overcome via favorable interactions with ligands. However, 
there was also evidence that ligands do not induce the change in RNA structure but 
instead capture existing RNA conformations. An early example of “conformational 
selection” or “tertiary capture”, first introduced by Foote J. and Milstein C.(161) to explain 
kinetic data on a set of antigen-antibody interactions, was the observation that free-state 
conformations of RNA stem-loop structures are stabilized on binding the ColE1 Rom 
protein(162). Subsequently, Weeks K. M. and Cech T. R. also used conformational 
selection to explain adaptive recognition in the assembly of the CBP2-group I intron 
ribonucleoprotein complex(163,164). More recently, Al-Hashimi H. M. and co-workers 
used Elongated RNA (E-RNA) NMR to provide compelling evidence that the 
conformational selection model best describes TAR small molecule binding events(74). 
It is likely that many RNA-small molecule binding events are governed by a 
conformational selection mechanism. Thus, knowledge of free-state RNA dynamics is 
critical to discovering novel RNA-targeting small molecules. 
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1.5 Structural Basis for RNA-Small Molecule Recognition 
 In the early 1990s, NMR structures were reported for RNA in complex with small 
molecules that began to reveal the structural basis for RNA-small molecule recognition. 
Importantly, these studies allowed for interrogation of small molecule properties that lead 
to specific interactions with RNA. Structures of TAR in complex with argininamide 
revealed large global and local conformational rearrangements on binding that give rise 
to a network of specific interactions. Unbound TAR exhibits an inter-helical bend angle of 
~47o, however on binding argininamide rearranges into a coaxially stacked state that is 
nearly linear with a bend angle of ~11o (59,74,142,157,165). The global rearrangement 
is accompanied by a conformational change in the inter-helical bulge where the residue 
U23 moves from being stacked inside the bulge with A22, to being looped into the major 
groove of the upper helix forming a base triple with bases A27 and U38. These RNA 
structural rearrangements result in specific interactions that confer binding specificity 
including direct stacking interactions between U23 and argininamide, hydrogen bonding 
between the guanidinium group of argininamide and G26, and hydrogen bonding 
between argininamide and the phosphate backbone of A22 and U23(59). Subsequently, 
NMR structures of the A-site rRNA and other RNA elements in complex with 
aminoglycosides revealed the importance of hydrogen bonding, electrostatic 
interactions, and the complementarity between small molecules and the RNA 
surface(42,96,98,149,166). Studies of artificial and more recently natural RNA aptamers, 
which bind to a variety of ligands, also revealed complex RNA conformations giving rise 
to deep binding pockets and a multitude of specific small-molecule RNA interactions 
resulting in high affinity (nM-µM) binding(151,167,168).  
Much like proteins, RNAs have many structural features that make it a suitable 
target for small molecules. DNA and RNA are made up of only four chemically similar 
building blocks that tend to form regularized structures such as helices. However, the 
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DNA B-form helix differs substantially from the RNA A-form helix. While the DNA B-form 
helix has a shallow and widened major groove making it amenable to small molecule  
 
Figure 1.8. The higher order structure of RNA differs from DNA and provides more 
complex folding architectures. (a) The shallow and wide major groove of the B-form 
DNA helix makes it more amenable to small molecule binding compared to the deep and 
narrow A-form RNA major groove. (b) The TPP riboswitch exemplifies how junctions in 
RNA elements give rise to complex tertiary structures and provide highly specific small 
molecule binding pockets(169). 
 
binding, the RNA A-form helix has a narrower and deeper major groove that is less 
accessible for small molecule binding(Figure 1.8a)(170-172). However, unlike DNA, the 
interruption of RNA A-form helices by bulges, internal loops, and junctions results in 
more complex folds with deeper and more accessible binding pockets capable of 
forming tight interactions with other RNAs(173,174), proteins(175), and small 
molecules(176) (Figure 1.8b). These tertiary structures give rise to complex 
electronegative surface potentials that are more similar to those of proteins compared to 
DNA(177), albeit the contours are predominantly negative potentials in RNA whereas 
proteins exhibit both positive and negative potentials. That said, the varying 
electronegativity seen across the known RNA tertiary structures could give rise to the 
necessary specificity needed to develop high-affinity RNA-targeting drugs. 
 Many RNA-binding small molecules resemble nucleic acid structures in that they 
contain pyrimidine-like moieties, purine-like moieties, phosphates, or sugars (reviewed in 
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(81)). These moieties specify the types of interactions known to confer specific RNA 
binding. Hydrogen bonding likely gives rise to the majority of specificity in RNA-small 
molecule complexes. The large amount of energy held within hydrogen bonds (~1-3 
kcal/mol), which are often formed with exposed nucleobases and/or the phosphate 
backbone, largely determines the small molecule binding conformation(s). An example 
of such specificity is seen in the guanine and adenine riboswitches where out of nine 
potential hydrogen-bond donors and acceptors in the nucleobase ligand, eight are 
occupied by hydrogen bond interactions with the RNA, three of which are in exact 
Watson-Crick (WC) geometry between the ligand and the RNA(Figure 
1.9a)(152,153,178). Batey R. and co-workers show that mutating the C74 residue, which 
forms WC base-pairing with the guanine ligand, to U74 changes the specificity of the 
guanine riboswitch to bind adenine through the formation of an adenine-U74 WC base-
pair(113,179). They also show that the guanine analog benzimidazole, which has only 
two of the nine hydrogen bond donors and acceptors, does not bind the riboswitch, likely 
due to the lack of specificity(179). Aminoglycoside recognition by the A-site also 
highlights the importance of hydrogen bonding in small molecule recognition where ring-
1 of the aminoglycoside paromomycin forms two hydrogen bonds with the WC face of 
A1408 and on mutation of A1408 to a guanine eliminates paromomycin binding(180-
182). It should be mentioned that water mediated hydrogen bonds are also highly critical 
to recognition of RNA-binding small molecules especially in solvent-exposed complexes, 
which are often seen in the aminoglycoside-A-site crystal structures(150). 
Electrostatic interactions also play a critical role in small molecule-RNA 
recognition. Cationic functional groups in small molecules often compete for metal ion 
binding sites. For example, studies show that tobramycin competes for Mg2+ binding to 
tRNAAsp(103), and neomycin and pentamidine compete for Mg2+ or Ca2+ binding to the 
group I intron(183,184). As expected, the addition of metal ions significantly reduces the 
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binding affinity of these small molecules. A-site recognition of aminoglycosides is 
another example of a highly electrostatically dependent binding mechanism, where most 
of the amino groups that are charged at physiologically pH(185) are directly involved in 
dipole-dipole or charge-charge interactions with the RNA backbone phosphates and 
water molecules(68,166,180-182). Electrostatic interactions via metal ion coordination 
also plays a major role in RNA-small molecule recognition as seen in the TPP 
riboswitch, where the ligand phosphates are recognized by small molecule-RNA bridging 
Mg2+ ions(6).  
Stacking (π-π) interactions that are critical for the formation of DNA and RNA 
helices and complex tertiary structures are often observed in RNA-small molecule 
complexes(1,49,53,186-190). In fact, all riboswitches that bind nucleic-acid-like small 
molecules exhibit significant RNA-ligand π-π stacking interactions. The guanine and 
adenine riboswitches, which recognize their respective cognate ligands via hydrogen 
bonding and extensive π-π stacking on both sides of the purine ring (Figure 1.9b), result  
 
Figure 1.9. Hydrogen bonding and  π-π  stacking interactions are critical for 
conferring small molecule-RNA binding specificity. (a) Eight out of nine possible 
hydrogen bond donors and acceptors specify the guanine orientation in the guanine 
riboswitch binding pocket. (b)  Significant π-π stacking interactions are also observed in 
the guanine riboswitch, depicted by the space-filling representation, resulting in ~98% 
burial of guanine(153). 
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in ~98% burial of the small molecule(153). Significant π-π stacking is also observed in 
the binding of acetylpromazine by TAR where the anthracene-like moiety stacks with 
U25, G26, and U40 in the bulge binding pocket(145). Other somewhat ignored stacking 
mechanisms are the CH-π and cation-π interactions which have been observed between 
ring I of aminoglycosides on binding the A-site(166) and GlcN6P and a guanine in the 
GlmS ribozyme(191-193), and in TAR recognition of argininamide(194,195). 
With “drug-like” guidelines in place, the questions remain: do these parameters 
permit the design of RNA-binding drugs given the types of known interactions listed in 
this section, and can a small molecule be designed to bind a specific target RNA? Using 
a library of known clinically tested small molecules, Lipinski laid out the classic Rule of 
5(196) (<5 hydrogen bond donors, <10 hydrogen bond acceptors, molecular 
weight<500, LogP<5), which describes necessary small molecule “drug-like” properties. 
While the recently FDA approved oxazolidinone linezolid(197) meets the “drug-likeness” 
criteria, many of the known RNA-binding small molecules violate the Lipinski rules. 
Difficulties in specifically binding a target RNA arise from the somewhat ubiquitous 
nature of many RNA interaction surfaces and the abundance of tRNA, estimated to 
comprise ~15% of cellular RNA(198). A major challenge in RNA-targeted therapeutic 
development will be to advance the design of small molecules with the necessary 
functionalities that meet the pharmacological criteria developed over the years of 
protein-targeted drug discovery that can bypass off-target binding events.  
 
1.6 Techniques for Discovering RNA-binding Small Molecules 
 Contemporary tools for drug discovery have been designed to target proteins and 
are often inadequate for targeting RNAs, which have unique structural and functional 
properties (reviewed in(111)). Most high throughput drug screening methodology relies 
on measuring enzymatic activity, which is absent for most RNA drug targets. While a 
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variety of assays can be used to probe binding of small molecules to RNA targets, most 
cannot be implemented in a high throughput manner particularly for flexible and 
structurally delicate RNAs. To date, very few studies have been reported that 
successfully utilize modern high-throughput screening technology to identify small 
molecules. The reported high-throughput screens have been focused on well 
characterized RNA targets such as TAR(199,200) and the bacterial A-site(66,201), and 
implementation of a de novo high-throughput screen has not been reported. Initial 
attempts to use microarrays to detect RNA-small molecule binding in a high throughput 
manner failed to reproduce the rank-order of small molecules that bind the A-site RNA in 
solution likely because the glass surface, linker and linker position substantially affect 
the RNA binding properties of small molecules, again underscoring the structural 
delicateness of highly dynamic RNA systems(201). The inability to use high-throughput 
screening techniques against RNA targets explains the largely unexplored chemical 
space of RNA-binding small molecules.  
The most common biochemical assays aimed at identifying RNA-specific small 
molecule binders utilize fluorescence. Often a fluorescent tag is inserted into an RNA 
sequence or appended to the terminus with the premise that conformational 
rearrangements on small molecule binding can be monitored by the changes in 
fluorescence intensity. Due to the chemical similarity of 2-aminopurine to pyrimidines, 
the fluorophore is often substituted in the RNA sequence giving site-specificity and has 
been used to monitor ligand binding in numerous studies(202-206). In the event that the 
binding site is not known for a particular RNA system a bulkier fluorescent tag, such as 
fluorescein or pyrene, is often attached to the terminus and in some cases to the 2’ 
position of the ribose(73,207-211). Although these assays are relatively straightforward 
and provide an accurate measurement of small molecule binding, a major flaw in both of 
these fluorescence-based assay examples is the need to modify the RNA construct in 
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order to monitor small molecule binding. An alternative to labeling the RNA with a 
fluorescent tag is to fluorescently label a native binding molecule and monitor its 
fluorescence on competition with an inhibitor(212). While fluorescently labeling a native 
binding molecule can overcome the need to chemically modify the target RNA, not all 
systems are amenable to such methods for de novo drug discovery. Other techniques 
for measuring binding, including surface plasmon resonance, isothermal titration 
calorimetry, NMR, and footprinting, cannot be implemented in a high throughput manner 
and are more appropriately used as validation rather than lead discovery tools.  
Computational docking provides the means to rapidly screen millions of small 
molecules against an RNA target, however prior knowledge of the 3-D RNA structure is 
required. Using a 3-D static RNA structure as a small molecule receptor, computational 
docking simulates the binding of a small molecule to the target by optimizing the 
interactions based on a force-field that describes intermolecular interactions (e.g. 
hydrogen bonding, electrostatic interactions, Van der Waals contacts) and small 
molecule properties (e.g. configurational entropy and solvent dissociation on binding) to 
determine the optimal small molecule binding pose. Although computational docking has 
proven quite successful in protein docking studies, the much larger conformational 
rearrangements that occur on RNA-ligand binding events prevent widespread success. 
Numerous successes have been realized from protein docking efforts(213,214). 
For example, small molecule inhibitors against DNA gyrase(215), tyrosine 
phosphatase(216), dihydrodipicolinate reductase(217), and HIV integrase(218,219), 
which led to the FDA approved drug Isentress (Merck & Co.), were discovered using 
computational docking. In a more recent study(220), Jorgensen W. L. and co-workers 
docked 41,000 small molecules into the macrophage migration inhibitory factor, which is 
a cytokine that binds the cell surface receptor CD74 and plays key roles in inflammatory 
diseases and cancer(221,222). Out of the 23 commercially available small molecules 
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found 11 were confirmed to inhibit protein-protein binding with IC50 values <5 µM. The 
ability to predict protein-binding small molecules based on crystal structure or homology 
model receptors is likely in part due to smaller dynamic motions in protein binding 
pocket(s) and the use of protein-centric small molecule virtual libraries.  
Despite the limitations in accurately accounting for RNA structural adaptation on 
small molecule binding, a few success stories have been reported. James T. L. and co-
workers have reported two such studies, one targeting TAR(72,145,223) and a second 
where they developed a docking software named MORDOR(224). In the former study a 
static structure of TAR was used to screen against 181,000 small molecules in which 
they identified acetylpromazine that binds TAR with a Kd of 270 µM and inhibits TAR-Tat 
mediated HIV transcription in-vitro. In the latter report James T. L. and co-workers 
implement a “fully flexible” docking scheme that first holds the RNA static while docking 
the small molecules, and then implements an all atom docking simulation that allows for 
RNA and small molecule fluctuations simultaneously with restricted movement of the 
RNA atoms in an attempt to account for structural adaptation on binding(30). Using this 
protocol they screened 5750 small molecules against the human telomerase RNA and 
found 48 small molecules that bind the RNA, which were confirmed using saturation-
transfer difference NMR experiments (no binding affinities were reported). Other studies 
have focused on developing RNA specific docking software by modifying the existing 
Autodock code with knowledge based potentials(225) and another using empirical 
potentials that include RNA-specific interaction terms (e.g. π-π stacking)(226). The most 
recent study reported modifications to the DOCK6 software that implements high-level 
solvent approximations and RNA flexibility as a subsequent docking step analogous to 
that reported by James T. L. to account for local adaptation on small molecule 
binding(227). In this report, they find that the accuracy of predicting the correct docking 
pose of a small molecule compared to the experimentally determined crystal or NMR 
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structure strongly depends on the number of small molecule flexible bonds, with the 
most accurate predictions for rigid molecules. This was also discovered in the Al-
Hashimi lab and is discussed in Chapter 4.  
While recent developments make it possible to accommodate limited flexibility in 
proteins(228) with little sacrifice in computational speed, no method exists to 
accommodate the inherently much greater RNA flexibility. Indeed, the current inability to 
predict how RNA structures adapt following small molecule binding is a major obstacle 
for identifying RNA-binding small molecules using computational docking. Recent 
developments in the Al-Hashimi lab have resulted in the generation of the first ever 
experimentally generated structural ensemble of TAR providing the necessary global 
and local conformational details to accurately predict small molecule-RNA binding 
affinities and is the focus of this dissertation. 
 
1.7 Structure, Dynamics, and Intermolecular Interactions Using NMR 
The site-specific resolution afforded by NMR is a unique advantage over other 
techniques and provides the ability to critically investigate interactions between proteins 
or nucleic acids and ligands. Chemical shifts are exquisitely sensitive to their electronic 
environment and perturbations can easily be monitored using NMR. They are often the 
first step to identify critical regions of macromolecules involved in ligand binding. 
Experiments to more accurately identify direct RNA-ligand or protein-ligand interactions 
include NOEs, saturation transfer, transfer-NOE, and cross relaxation experiments(229-
231). In Appendix 1 we present a study on the oligomycin sensitivity conferral protein 
where binding to the small molecule inhibitor Bz-423 is investigated by monitoring 
chemical shift perturbations and cross-relaxation. Using these two techniques we are 
able to identify the most likely small molecule binding site and provide insight into the 
inhibitory mechanism. 
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The ability to monitor structural and dynamic fluctuations from ps-m timescales 
makes NMR one of the most powerful techniques to study the behavior of biomolecules. 
Classic spin relaxation measurements monitor the nuclear relaxation rates as a result of 
thermal redistribution (R1), inhomogeneity of the local magnetic field (R2), and the inter-
nuclear dependence of saturation on relaxation rates between bonded species 
(NOE)(232). These techniques have been widely used to probe the ps-ns timescale 
motions of biomolecules, and information regarding site-specific internal motions can be 
obtained using these relaxation rates in a model-free analysis(233,234). Relaxation 
dispersion measurements, which utilize an external radiofrequency field to spin-lock 
magnetization in the rotating frame (R1ρ) (235,236) or implement a train of 180o pulses 
with precisely chosen delay times (CPMG)(237,238), are sensitive to exchange 
processes occurring on µs-ms timescales. Other NMR techniques used to probe slower 
motions include: ZZ exchange, which monitors the exchange of longitudinal 
magnetization between multiple populated states on ms-s timescales(239); lineshape 
analysis, which relies on monitoring changes in lineshapes as a result of external 
perturbations (e.g. temperature, denaturant, ligand) and can be used to probe ms-s 
timescale processes(240); and hydrogen-deuterium exchange methods, which probe s-
m timescales and have been widely used in monitoring the global stability and local 
dynamic fluctuations in proteins(241,242). Residual dipolar couplings (RDCs) and 
residual chemical shift anisotropies (RCSAs) can be used to probe motions on the sub-
ms timescales(243-246). Unlike the aforementioned methods, RDC and RCSA 
measurements report on the orientational distribution of bond vectors and a common 





1.7.1 Residual Dipolar Couplings 
  RDCs arise due to incomplete averaging of the dipolar interaction in partially 
aligned molecules(243,245,246). The time-averaged Hamiltonian between two spins (I 
and S) separated by a distance r is given by,  
 
,          [1.1] 
 
where I and S are the spin angular momentum operators, γI and γs are the gyromagnetic 
ratios for the individual spins, µo is the permittivity in a vacuum,   is Planck’s constant, r 
is the inter-nuclear distance, and θ is the angle between the inter-nuclear vector and the 
external magnetic field (Figure 1.10a). This gives rise to the expression for the dipolar 
coupling (Dij) between two directly bonded spin ½ nuclei (i and j),  
 
,           [1.2] 
 
where rij is the inter-nuclear distance between the spins. The angular term in Equation 
[1.2] is the second rank Legendre polynomial, P2(cosθij), and is a function of the angle θ 
between the inter-nuclear vector and the external magnetic field (Figure 1.10a). The 
angular bracket denotes a time average over all angles sampled by the inter-nuclear 
vector due to both overall motions and internal motions occurring at timescales shorter 
than the inverse of the dipolar interaction (<ms). An effective bond length, rij, eff, 
subsumes the effects of distance averaging. 
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Figure 1.10. Measurement of RDCs in partially aligned molecules. (a) Residual 
dipolar couplings between spins i and j provide long-range constraints on the average 
orientation (θ) of the inter-nuclear bond vector relative to the external magnetic field (Bo). 
(b) Measurement of residual dipolar couplings (D) arise as new contributions to the 
splittings of resonances (J) observed upon partial molecular alignment. 
 
 Motional averaging will generally reduce the value of the angular term 
 
and thus the magnitude of observed dipolar couplings (which can be on the order of kHz 
for non-reorienting directly bonded spins). When overall tumbling is isotropic, the angular 
term averages to zero, and dipolar couplings are not observed under solution conditions. 
However, if the molecule can be aligned in the magnetic field, the angular term will no 
longer average to zero. The greater the degree of alignment the greater the value of the 
angular term and magnitude of observed dipolar couplings. As is the case for through-
bond scalar couplings (J), through-space dipolar couplings (D) effectively increase or 
decrease the average magnetic field at a given nucleus, resulting in splitting of 
resonances. Dipolar couplings are therefore often measured as new contributions to 
scalar couplings (J) that are observed under conditions of molecular alignment 
(J+D)(Figure 1.10b). 
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 The measurement of RDCs in solution NMR relies on inducing an appropriate 
degree of alignment(247). Imparting a degree of alignment where approximately 1 in 
10,000 molecules are on average completely aligned (≤10-5) lead to RDCs that are too 
small compared to NMR line widths and do not allow measurements at a useful level of 
precision. At much higher degrees of alignment (≥10-2), extensive dipolar couplings 
render RDCs too large and compromise the spectral resolution needed to analyze large 
biomolecules. In general, an optimum balance is achieved for when 1 in 1000 (~10-3) 
molecules are completely aligned. Under these conditions, many RDCs can be 
measured with optimal magnitude, precision, and with minimal sacrifice in spectral 
resolution. Alignment on the order of 10-4 can allow measurements of a smaller subset of 
RDCs with suboptimal magnitude/precision ratios. 
 
Figure 1.11. Partial alignment of nucleic acids using ordering media. Pf1 phage 
(gray) transmits order through steric and electrostatic mechanisms resulting the principal 
direction of order (Szz) being oriented along the long axis of the molecule. Dimensions of 
phage and a representative dimension of an RNA are shown. 
 
 Most commonly, partial alignment on the order of 10-3 is introduced by dissolving 
the solute in an alignment medium (for reviews see(248,249)). Ordered media can 
transmit some of their order to solute molecules through mechanisms that are believed 
to involve a combination of steric obstruction and charge-charge interactions. This was 
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first demonstrated for liquid crystalline disc-shaped phospholipids called “bicelles”(245), 
which were originally used as a mimic of membrane bilayers in studies of membrane 
associated biomolecules(250,251). While the original neutral bicelle medium has been 
employed in studies of nucleic acids, other media have become more popular. In 
general, media with high tolerance to ionic strength are desired for nucleic acid 
applications. Also, positively charged ordering media are likely not useful as they may 
partake in unfavorable interactions. The most widely used medium to study nucleic acids 
is the filamentous bacteriophage (Pf1) (Figure 1.11)(252-254). Pf1 phage is negatively 
charged reducing the possibility for adverse interactions with nucleic acids and induces 
alignment through electrostatic and steric mechanisms(255,256). Owing to the uniform 
distribution of charge in polyanionic nucleic acids, the steric and electrostatic forces are 
believed to have a similar functional form(255,256). Consequently, nucleic acids 
generally align in ordering media with the principal direction of order (Szz) oriented along 
the long axis of the molecule(Figure 1.11). In general, one expects positive alignment 
(Szz> 0) with the Szz direction being, on average, oriented parallel to the magnetic field. 
Experimentally, RDCs are computed from the difference in splittings measured in the 
absence and presence of ~20-25 or ~6-8 mg/ml Pf-1 phage for ~30 residue and ~80 
residue RNAs, respectively (Figure 1.10b). 
 In nucleic acids, two strategies have been developed and applied for interpreting 
RDCs in terms of the structure and dynamics of RNA. The most widely used approach 
involves a variant of the simulated annealing approach in which individual helical 
domains are allowed to have independent order and/or alignment tensors. Here, RDCs 
and other experimental and non-experimental restraints are combined to simultaneously 
determine the local structure of molecular fragments as well as their order 
tensors(257,258). This approach can be generally applied to a variety of RNA fragments 
provided that a sufficient number of experimental restraints (including RDCs) are 
  31 
measured and care has been taken to exclude RDCs that may have been attenuated by 
local motions. A second approach uses the idealized A-form helix geometry to model 
contiguous stretches of non-terminal Watson-Crick (WC) base-pairs(165,259). The 
validity of this approach was recently supported by a statistical survey(260) of 421 WC 
base-pairs in 40 unbound and bound RNA X-ray structures (solved with < 3Å resolution) 
and the 2.4 Å X-ray structure of the ribosome(261). This study showed that the local 
conformation of two or more non-terminal contiguous WC base-pairs can, for the 
purpose of determining order tensors using RDC accurately, be modeled a priori using a 
standard idealized A-form helix geometry(262,263). These WC base-pairs can be 
experimentally identified/verified using NOESY connectivity and trans-hydrogen bond 
JNN-COSY type NMR experiments for directly detecting N-H--N hydrogen 
bonds(264,265). The study also developed approaches for taking into account structural 
noise in the A-form geometry in the determination of order tensors and provided 
evidence that local motions in such helical fragments will not compromise the accuracy 
of derived order tensors. By eliminating the need to solve the local helix structure, a 
number of applications are possible using the idealized A-form helix geometry. First, one 
can determine the relative orientation and dynamics of helices for RNAs that may be too 
large for complete high-resolution structure determination. Second, the order tensor 
analysis of RDCs can be conducted with high efficiency making possible systematic 
studies of how RNA’s global conformational dynamics varies in response to changes in 
environmental conditions(165,266-270). The latter method is subsequently described. 
The time-averaged angular term in Equation [1.2] can be expressed in terms of 
the time-independent orientation of an inter-nuclear vector relative to an arbitrary frame 
(α) and the five order tensor elements (Skl)(271,272), 
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,          [1.3] 
 
where αn is the angle between the inter-nuclear vector and the nth axis of the arbitrary 
frame. Assuming A-form geometries for a helix-bulge-helix RNA motif, the measurement 
of more than five independent RDCs for each helix allows determination of five elements 
of an order or alignment tensor(272,273). The order tensor consists of five independent 
parameters and describes the average alignment of the two helices relative to the 
external magnetic field. Three Euler angles specify a helix-fixed order tensor frame 
(Sxx, Syy, Szz) that depict the average orientation of helices relative to the external 
magnetic field. The average relative fragment orientations can be obtained by 
superimposing their order tensor frames, assuming that the helical fragments share a 
common view of the magnetic field direction when properly assembled (see refs. 
(165,271,274)). Two principal order parameters(274) define the degree (GDO = 
; |Szz| ≥ |Syy| ≥ |Sxx|) and asymmetry (η = ) of molecular 
alignment and can be used to obtain information on sub-millisecond timescale inter-
helical motions.  
 
1.7.2 Domain-Elongation to Decouple Internal and Overall Motions 
 Use of RDCs in constructing RNA structural ensembles requires the ability to 
predict RDCs for a given proposed structural ensemble in which conformers interconvert 
at timescales shorter than the inverse of the dipolar interaction (<ms). This task is 
considerably simplified when one can (i) assume that internal motions are not correlated 
to overall alignment (the so-called “decoupling approximation”) and (ii) determine the 
overall order or alignment tensor governing partial alignment of the molecule. Studies 
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have shown that the decoupling approximation does not always hold for highly flexible 
and extended nucleic acid structures(275-280). In particular, changes in the relative 
orientation of helical domains can result in large changes in the overall RNA shape, 
which can in turn alter overall alignment of the molecule relative to the magnetic field 
(Figure 1.12a). The ensuing breakdown in the decoupling approximation can make it 
difficult if not impossible to compute RDCs for a proposed structural ensemble.   
 One approach developed in the Al-Hashimi H. M. laboratory to overcome this 
problem is to elongate a target helix such that the overall RNA shape and hence its 
overall alignment is dominated by 
the elongated helix and is no 
longer as sensitive to internal 
motions occurring elsewhere in the 
molecule (Figure 1.12b)(74,279). 
The elongation also serves to 
predefine the overall order tensor 
to be axially symmetric with 
principal direction oriented nearly 
parallel to the axis of the elongated 
helix. The RDCs measured in the 
elongated helix can be used to 
experimentally determine the 
overall order tensor (Skl). Thus, the 
time-averaged angular term in 
Equation [1.4] can be expressed 
for the nth conformer in terms of 
 
Figure 1.12. Decoupling internal and overall 
motions in RNA by domain-elongation.  (a) 
Collective helix motions lead to coupled changes 
in overall alignment as described by the principal 
axis of the order tensor (Szz). (b) Decoupling 
collective motional modes by domain elongation 
effectively renders Szz parallel to the long-axis of 
the RNA. (c) NMR invisible elongation of TAR 
RNA is accomplished using isotopically 
unlabelled residues (gray). Two terminal GC 
base-pairs are added to helix-I in EI-TAR to 
maximize transcription yields. 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the time-independent orientation of an inter-nuclear vector relative to an arbitrary frame 
(αi) and the five order tensor elements (Skl) describing overall alignment(271,272). For a 
structural ensemble consisting of N conformers that interconvert at timescales shorter 
than the inverse of the dipolar interaction (<ms), the observed RDCs will be a 
population-weighted average over the ensemble 
 
.             [1.4]
 
             
 The elongation of an RNA target is typically preformed by extending the length of a 
terminal helix using a stretch of Watson-Crick base-pairs(281). To avoid increasing 
spectral overlap due to elongation residues, an isotopic labeling strategy is used to 
render elongation residues “NMR invisible”(281). Here, two constructs are prepared in 
which stretches of alternating unlabelled A–U/U-A (E-AU-RNA) and G–C/C-G (E-GC-
RNA) base-pairs are employed for elongation using otherwise uniformly 13C/15N labeled 
G–C and A–U nucleotides, respectively (Figure 1.12c)(281). Two G-C base pairs are 
added to the terminal end of E-AU-RNA to facilitate RNA synthesis by in vitro 
transcription. The two constructs thus allow acquisition of NMR data over the entire RNA 
target while keeping elongation residues “NMR invisible”.  
 Care must be taken to ensure that the elongation does not perturb the structural 
and functional integrity of the RNA. This can be conveniently accomplished by 
comparing spectra of elongated and non-elongated RNA samples. In general, elongation 
of terminal helices is not expected to give rise to significant RNA structural perturbations. 
However, depending on the RNA context, elongation of other non-terminal helices, 
which can allow the measurement of independents set of RDCs (and RCSAs) that can 
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be applied to generate structural dynamics with enhanced spatial resolution(74), may 
cause unwanted perturbations and should be carefully analyzed.  
 The degree of helix elongation needed to sufficiently decouple internal and overall 
motions will vary depending on the RNA target. In general, the elongation should render 
a target helix at least 4-5-fold longer than other helices in the RNA. If a structure for the 
RNA target is available, one can perform simulations using programs such as 
PALES(282), using idealized A-form helices to model the elongated helix(74), to 
examine the degree of motional coupling. In these simulations, one computes the 
variance in the predicted overall alignment tensor relative to the elongated helix as a 
function of varying the relative orientation of other shorter helices in the RNA. In general, 
the principal direction of order (Szz) should not vary more than ±7 degrees about the 
elongated axis and the asymmetry (η) should always be <0.15. The secondary structure 
of an E-RNA construct should be verified using a secondary structure prediction 
programs such as mfold 3.3 to make sure that no alternative secondary structures can 
form(283). 
 
1.8 HIV-1 TAR: A Paradigm for Targeting RNA 
TAR is an RNA stem-loop that is located at the 5' end of the HIV-1 genome that 
plays essential roles in the transcription of viral RNA and is a major target for developing 
anti-HIV therapeutics. As previously mentioned, the minimum TAR RNA consists of two 
helices that are linked by a trinucleotide bulge and capped by a hexanucleotide apical 
loop (Figure 1.5). The bulge and apical loop form two distinct protein recognition centers 
that can be targeted in the development of anti-HIV therapeutics(284). The viral 
transactivator protein Tat(129,285) binds residues in and around the TAR bulge (A22, 
U23, G26 and A27) and apical loop (G34) and enhances viral transcription by recruiting 
the positive transcription elongation factor b, which consists of Cyclin T1 (CycT1) and 
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Cdk9(286,287)(Figure 1.5). Tat can bind TAR in the absence of other cellular co-
factors(288) whereas CycT1 does not bind TAR in the absence of Tat and the two 
proteins bind TAR cooperatively by mechanisms that remain poorly understood(129). 
Biochemical studies suggest that CycT1 interacts with the U31 region of the TAR apical 
loop(289) and forms other interactions with Tat. NMR structures of TAR bound to Tat-
derived peptides and ligands indicate that Tat binds residues in and around the highly 
conserved bulge and that recognition leads to large structural rearrangements involving 
reorientation of the two helical stems accompanied by formation of a U23-A27-U38 
base-triple(136-140). There are no structures for HIV-1 Tat (86-101 residues) in complex 
with TAR and there is controversy regarding the unbound structure of Tat, which are 
complicated by use of different conditions and constructs.  
The discovery that small molecules, such as aminoglycosides, can inhibit TAR-Tat 
complex formation(19) and significantly reduce HIV-1 viral replication rates(17,18) 
spurred numerous studies that continue to date and are directed towards the 
development of agents that can bind TAR and disrupt its interaction with Tat (reviewed in 
(17,79)). The collective effort of many investigators over the course of eighteen years 
has resulted in 38 publications reporting TAR-binding small molecules. These studies 
identified 205 small molecules, which bind TAR with Kds ranging between 5nM-5mM 
(80µM average), and 159 small molecules comprising 14 different motifs/scaffolds, 
which bind TAR and inhibit the TAR-Tat interaction with Kis ranging between 39nM-4mM 
or IC50s ranging 20nM-500µM. Although these studies strongly suggest that TAR is a 
druggable target, only two of these compounds have been sufficiently potent to proceed 
to pre-clinical trials showing intraperitoneal acute toxicity LD50s of 320 and 104 mg/kg in 
mice(290).  
TAR exemplifies the major challenges encountered when targeting RNA. In the 
case of TAR, the difficulties in high-throughput screening can be appreciated by noting 
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that none of the TAR binding compounds were discovered by modern high-throughout 
experimental screens. Rather, most TAR binding small molecules have been identified 
by painstaking efforts that are focused on derivatizing specific classes of compounds, 
such as aminoglycosides, using various mimetics of the TAR protein target Tat, 
rationally designing small-molecule scaffolds that have certain electrostatic and 3D 
features, and in a more recent effort using split pool synthesis(199). 
 
Figure 1.13. HIV-1 TAR structural adaptation. The solved TAR structures vary 
significantly in RNA conformation (inter-helical bend angle ranges from ~5o to ~47o) and 
small molecule identity(59,144-147,194,291). The large structural rearrangements 
observed for TAR are likely governed by a conformational selection mechanism. 
 
A major obstacle in employing structure based drug design to develop specific 
TAR binders is the lack of knowledge of the free state beyond the calcium bound crystal 
structure(291,292). Numerous studies have shown that TAR undergoes dramatic 
conformational rearrangements involving large rigid-body movements of its two helical 
domains (averaging ~47° and as large as 71°)(165) that allow it to bind diverse targets in 
and around the bulge, including peptide derivatives of its cognate protein 
Tat(59,141,142), divalent ions(143), and five different small molecules that inhibit the 
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TAR-Tat interaction(144-147) (Figure 1.13). While the structures for these states have 
been solved, the physical principles underlying the structural transitions and the effects 
on the small molecule binding pocket(s) remains poorly understood.  
We recently published the first ever experimentally NMR based ensemble of an 
RNA using the elongation strategy developed in the Al-Hashimi H. M. laboratory(74) 
(Stelzer A. C. was second author on the publication in the journal Nature). We 
transformed the basic 
NMR experiment by 
anchoring frames of 
reference onto individual 
RNA helices and thereby 
measuring their dynamics 
directly as motions of one 
helix relative to the other 
using multiple sets of 
RDCs. The frames were 
anchored using the 
method described in 
section 1.7.2, which involves elongating helices(281) so that they dominate overall 
alignment of the elongated RNA (E-RNA) in ordering media, with the elongated axis 
being on average orientated parallel to the magnetic field (Figure 1.14). This effectively 
disentangles helix motions from overall alignment and renders RDCs dependent on the 
angle (Ω) between bond vectors and the internal elongated axis, and not a detached 
external magnetic field. By anchoring the frame of reference onto different helices, the 
same helix motions can be measured from different helix-centered perspectives, 
opening a new avenue for extending the achievable spatial sensitivity with which 
 
Figure 1.14. Measurement of RNA helix motions in 3D 
using helix-anchored frames and RDCs. (a) NMR 
reference frames are anchored by elongating helices so that 
the RNA aligns with the elongated axis being on average 
oriented parallel to the magnetic field (B0). (b) Independent 
elongation of HI and HII in TAR using a strategy that renders 
elongation residues NMR invisible. 13C/15N labeled and 




motions can be characterized. For example, while RDCs probe inter-helical bending (β) 
and twisting (α) motions of the short helix, they are insensitive to twisting motions (γ) 
around the axially symmetric elongated helix (Figure 1.14a). This vanishing sensitivity 
can be resurrected, and helix motions thereby measured with complete 3D rotational 
sensitivity, by inverting which helix is elongated and measuring RDCs that probe the 
angles β and γ, but not α (Figure 1.14a). By measuring motions in this relativistic 
manner, the helix-anchored frames also allow spatial correlations between motions of 
two or more helices to be directly established. 
Using the two sets of elongated RDCs we were able to visualize the spatially 
non-random inter-helical motions, by performing a search over ensembles(293) with up 
to three (N = 3) equally populated inter-helical conformers that can reproduce the nine 
independent parameters afforded by the RDCs. The conformers within the ensemble 
define key points along the trajectory that serve to capture its essential 3D spatial 
features even if the trajectory involves many more conformations. Loose steric 
constraints were also implemented in the conformational search. Both the search over 
ensembles with N=1 and 2 yielded a very poor RDC fit, confirming the existence of an 
inter-helix motional trajectory that is more complex than a simple two-state jump. In 
contrast, a very good fit was obtained for N=3 with very slight improvements obtained 
with N=4. Strikingly the three state ensemble, which also yields good agreement with 
magnetic field induced RDCs measured in non-elongated TAR(279), gives rise to a 
motional trajectory in which HI and HII twist by ~53° and ~110°, respectively in a highly 
synchronized manner (R=0.97) while simultaneously (R=0.81-0.92) bending by ~94° 
(Figures 1.15a-b), thus the bending motions between the two TAR helices are 
accompanied by a correlated twisting motions about the respective helix axes. 
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Figure 1.15. Correlated TAR dynamics guide ligand-induced transitions. (a) The 
best-fit TAR ensemble (in green) in which each conformer (1, 2 and 3) is specified by 
three Euler angles defining twisting around HI (-γ), HII (α) and inter-helical bending (β). 
The 3D best-fitted line is shown together with its 2D projections along each plane and 
the associated correlation coefficient (R). (b) The three TAR conformers in the best-fit 
TAR ensemble. Helices are elongated for clarity. (c) The three TAR dynamical 
conformers (in green) and the TAR conformation (in gray) bound to peptide derivatives 
of Tat (1ARJ)(144,194), divalent ions (397D) (145), and five different small molecules 
(1QD3, 1LVJ, 1UUD, 1UUI, 1UTS) (59,146,147,291). Shown on each 2D plane is the 
correlation coefficient (R) between angles for the ligand bound conformations. For 
bound structures, the s.d. is over the family of reported NMR models. Only one model 
was reported in structures 397D, 1UUI, and 1UUD, thus no s.d. is reported. (d) 
Comparison of the three TAR dynamical conformers (in green) and ligand bound TAR 
conformations (in gray). Sub-conformers along the linear pathway linking conformers 
1→2, 2→3, and 3→1 are shown in light green and the direction of the trajectory shown 
using arrows. Horizontal view following superposition of HI (top right), vertical view 
down and up the helix axis of HI (bottom right) and HII (bottom left) following 
superposition of HI and HII, respectively.  
 
Visualization of the TAR inter-helical trajectory provided us the means to 
interrogate the role TAR plays in directing ligand-induced structural transitions. 
Specifically, it allowed us to test the hypothesis that TAR samples all of the bound states 
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in the absence of ligand and thus recognition is governed by a conformational selection 
mechanism(157,158). Remarkably, we found that the seven bound TAR conformations 
fall along various positions of the dynamical trajectory (Figure 1.15c). The bound 
conformers also trace out a similar linear trajectory in the 3D inter-helix Euler space 
(R=0.70-0.82), confirming that correlated dynamics is an intrinsic property of the TAR 
structure (Figure 1.15c). The dynamic space traced out by the three TAR conformers 
encapsulates nearly all of the ligand bound conformations (Figure 1.15d), indicating that 
ligands can induce the TAR structural transitions by capturing existing conformers along 
various positions of the free RNA dynamical trajectory. Thus, a highly flexible RNA can 
be spatially tuned to undergo structured motions that direct functional transitions along 
specific pathways. 
While the experimental NMR based three state ensemble provided strong 
evidence that TAR, and possibly many other RNAs, bind small molecules via a 
conformational selection mechanism, currently only rigid body “movies” of A-form helices 
can be generated using this method. One of the objectives of this Dissertation is to 
better understand the physical principles guiding RNA structural transitions on small 
molecule binding and expand the methodology to generate “movies” with the global and 
local conformational details necessary to improve the accuracy of computational docking 
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Filtering MD Trajectories Using Motionally Decoupled NMR RDCs Reveals New 




Characterization of RNA at atomic resolution has been a major focus of structural 
biology and biophysics for many years and ongoing research is aimed at developing new 
techniques to probe the structural architecture, however insights into mechanistic RNA 
structure-function questions have been impeded by the lack of biophysical techniques 
that afford 3D visualization of intrinsic RNA dynamics over biologically relevant 
timescales. NMR spectroscopy is one of the most powerful techniques for characterizing 
structural-dynamics of biomolecules providing comprehensive information regarding the 
amplitude, timescale, and - in favorable cases - direction of motions with site-specific 
resolution(1-3). However, even with the abundant number of measurements that can be 
made using NMR, the total number of parameters that can be directly determined from 
NMR data are much fewer than the total number of observables. While Molecular 
Dynamics (MD) simulations provide an all-atom description of dynamics, the force fields 
that govern the theoretical description of time-resolved dynamic transitions remain to be 
thoroughly validated particularly for nucleic acids and simulation timescales are limited to 
~100 ns(4,5). 
  61 
Because they are complementary on the spatial and temporal scales, the 
limitations inherent to NMR and MD could in principle be overcome by combining the two 
techniques; MD can fill the shortage of information available through NMR data by 
providing an all-atom time-resolved model, and NMR can provide a means for validating 
and potentially correcting force fields and accelerate MD conformational sampling to 
millisecond timescales. Several studies have emerged in which MD and NMR are used 
in concert in studies of nucleic acid dynamics(6-10). The two techniques can also be 
integrated to yield a unified view of structural dynamics. While such combined NMR/MD 
approaches have successfully been used in studies of protein dynamics(11-14), 
extension to RNA can prove very difficult because, unlike globular proteins, overall 
motions in highly flexible RNAs can be strongly coupled to internal motions making it 
difficult, if not impossible, to predict NMR data from an MD trajectory(9,15,16).  
Recently, a domain-elongation strategy was introduced for decoupling internal 
and overall motions in RNA(17,18). As discussed in Chapter 1, a target helix is 
elongated so that the overall motion is slowed down relative to internal motions and 
rendered less sensitive to internal fluctuations in other parts of the molecule. The 
elongation also simplifies analysis of NMR spin relaxation(19) and residual dipolar 
coupling (RDC)(20,21) data because it predefines the overall diffusion or alignment 
tensor to be axially symmetric with principal axis oriented nearly parallel to the elongated 
helix axis. This makes elongated RNAs ideally suited for computing NMR observables 
from a given MD trajectory of a corresponding non-elongated RNA in which snapshots 
are aligned by superimposing the reference elongated helix.  
In this chapter we describe the implementation of a general strategy that 
combines MD simulations and NMR RDCs measured in elongated RNAs for 
constructing atomic resolution ensembles of RNA structures with timescale sensitivity 
extending up to milliseconds. The ensembles of HIV-1 TAR (TAR) and HIV-2 TAR 
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constructed in this manner provide new insights into the bulge-length dependence of 
RNA dynamics and the mechanism of conformational adaptation on target recognition.  
 
2.2 RDC-based Sample and Select Method 
 Simulations of wild-type TAR and HIV-2 TAR were generated using the 
CHARMM package(22) with force field parameter set 27(23). Model 3 of the unbound 
TAR NMR-determined structure (PDB ID# 1ANR)(24) was used as the starting 
coordinates for the simulations. For HIV-2 TAR, starting coordinates were obtained by 
removing argininamide from model 1 of the argininamide-bound NMR-determined 
structure (PDB ID# 1AKX)(25). The RNAs were charge-neutralized using sodium 
counter ions and solvated in a 35 Å and 33 Å sphere of TIP3 water, for TAR and HIV-2 
TAR, respectively(26). A spherical boundary potential was applied to maintain the 
density of water around the RNA site(27). The system was minimized and heated to 
300K while harmonically constraining the heavy atoms of the RNA with a force constant 
of 62 kcal/mol/Å for 100 ps, after which constraints were removed and the system 
equilibrated for 1 ns. A Nosé-Hoover thermostat(28,29) was used to maintain a constant 
temperature of 300 K throughout the simulation, with a 1 fs time-step and a coupling 
constant of 50 ps-1. 50 distinct trajectories were initiated from this equilibrated structure, 
by assigning different initial velocities. It has previously been demonstrated that this 
technique can be used to enhance conformational sampling relative to a single trajectory 
of the same total duration(30,31). The first 0.5 ns of each trajectory was discarded and 
next 1.6 ns used for analysis. Conformations from each of the 50, 1.6 ns, trajectories 
were pooled to give a total effective simulation time of 80 ns. These 80,000 
conformations were used as a structural pool for the “selection” phase of the select-and-
sample strategy (SAS, see below).  
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In the original implementation, Chen and coworkers used S2 NH spin relaxation 
order parameters to select structural ensembles for a series of protein systems(11). We 
adapted this “sample and select” (SAS) approach to allow use of RDC data which probe 
the orientational dynamics of individual bond vectors over timescales extending up to 
milliseconds. In the SAS approach, one generates a set of conformations for the system 
of interest, in which we use MD to generate such structures. One then searches for an 
N-membered subset of structures that minimizes a cost function. Specifically, an N-
membered subset of structures is randomly selected from a total pool of M structures 
and an initial  χ2 value is evaluated using Equation [2.1]. Next, one of the N-membered 
structures is randomly chosen and replaced, by a random structure from the remaining 
M-N conformational pool. The “move” from step k to k+1 is then accepted if χ2(k+1) < χ2(k). 
If χ2(k+1) > χ2(k), the move is accepted with a probability p = exp((χ2(k) - χ2(k+1))/Teff), where 
Teff is an effective temperature that is linearly decreased in a simulated annealing 
scheme. The cost function is, 
 
,
            [2.1] 
 
where   and  are the calculated and measured RDCs, respectively, L is the total 
number bond vectors, and  is calculated using, 
 
 ,           [2.2] 
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where γi or j is the gyromagnetic ratio of the ith or jth nucleus, rij is the bond length, θ is the 
angle between the internuclear bond vector and the external magnetic field and the 
angular brackets denote a time-average over all sampled orientations. As described in 
Chapter 1, the time-averaged angular term can be expressed in terms of the time-
independent orientation of an internuclear vector relative to an arbitrary frame and the 
five order tensor elements (Skl)(32,33), 
 
,
          [2.3] 
 
where 〈n is the angle between the internuclear vector and the nth axis of the arbitrary 
frame. Equation [2.3] assumes that internal motions do not affect overall alignment of the 
molecule. This assumption can break down in RNA because collective motions of helical 
domains can lead to large changes in the overall shape and thus overall alignment of the 
molecule(15,16,34). This can make it impossible to accurately compute Dijcal for a given 
ensemble and thus to use RDCs in selecting conformers from an MD trajectory. Domain-
elongation allows one to overcome this problem by rendering the overall shape of the 
molecule far less sensitive to internal motions(17,18). Elongation also predefines the 
overall order tensor to be axially determined with principal direction oriented 
approximately parallel to axis of the elongated helix(17). This overall order tensor can be 
conveniently determined experimentally using RDCs measured in the elongated 
helix(17).  
 The SAS RDC approach was implemented using C++ programs written by Frank 
A. T. F. The previously reported(17) 47 and 35 TAR one-bond base and sugar C-H 
RDCs measured in elongated helix-I TAR (EI-TAR) and elongated helix-II TAR (EII-
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TAR), respectively, were used independently or in combination to select an TAR 
structural ensemble from a pool of 80,000 conformers derived from the combined 80 ns 
MD trajectory. For HIV-2 TAR, 35 RDCs measured in helix-1 elongated HIV-2 TAR (HIV-
2 EI-TAR) were used. Note that although RDCs were measured on a TAR construct in 
which the apical loop was replaced by a UUCG loop, a detailed NMR study recently 
showed that this apical loop replacement does not affect interhelical motions or local 
motions at the TAR bulge(35). When used in combination, both the EI-TAR and EII-TAR 
sets of RDCs were used (L =47+35=82) in computing the χ2 in Eq. [1]. In all cases, the 
overall alignment tensor was assumed to be axially symmetric (η=0) with principal 
direction (Szz) oriented parallel to the elongated helix axis as computed using the 
program CURVES(36,37). The magnitude of Szz was obtained from an order tensor 
analysis as described previously.  
 Each RDC-SAS run was initiated from N randomly selected conformers. A Monte 
Carlo (MC) simulated annealing scheme was then used to minimize the cost function in 
Eq. [1] as described above. Simulations were started at a high effective temperature 
where the MC acceptance probability was high (~0.99), and slowly decreased until the 
MC acceptance probability was ~10-5. At a given effective temperature 105 MC steps 
were carried out. The effective temperature was then decreased, with Ti+1 = 0.9Ti. The 
same protocol was used for HIV-2 TAR, except that only 35 RDCs measured in the 
helix-I elongated sample were used in the SAS analysis. Here, there was less motivation 
to acquire an additional set of helix II elongated RDCs given the near linear alignment of 
the two helices which renders the two sets of data degenerate. 
 The base angles, buckle (κ), opening (σ), propeller twist (ω) and twist (Ω), were 
calculated for eight non-terminal base pairs for each of the SAS selected TAR 
conformers using the program 3DNA(38). The interhelical Euler angles 〈h, βh, and  γh 
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were also computed for each member of the ensemble, using the lower helix as a 
reference, as previously described(39). Note that degenerate sets of Euler angles reflect 
the same interhelical orientation(39) and the set of Euler angles were selected to 
minimize the equation . 
 
2.3 Selection of  Distinct Conformers from a Large Conformational Pool 
 The ability to select discrete conformers to capture distinct features of a large 
conformational pool was investigated using 20 ns of the 80 ns TAR MD trajectory, 
resulting in a total conformational pool 
of 20,000 structures. For thee 
simulations, all 20,000 conformers 
were considered as the TAR 
ensemble. RDCs for bond vectors 
that were experimentally measured 
(47 from EI-TAR and 35 from EII-
TAR) were back-calculated from each 
conformer assuming helix-1 and helix-
2 alignment tensors from measured 
EI-TAR and EII-TAR RDCs, 
respectively(17). The 20,000 sets of 
RDCs were then averaged 
independently for each elongation to 
give the final input RDCs. Using all 
20,000 conformers as the selection 
pool, we performed a series of SAS 
 
Figure 2.1. SAS selection of 20 structures 
to model a structurally diverse ensemble. 
(a) A selected ensemble size of N=20 
minimized the cost function below 1 Hz 
RMSD. (b) The 20 selected conformers span 
the range of Euler angles and are more 
densely populated in regions that are often 
sampled in the MD trajectory. 
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simulations with various ensemble sizes of N=1, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 
100, and calculated the root mean square derivation (RMSD) between measured and 
predicted RDCs. An ensemble size of N=20 minimized the cost function below 1 Hz with 
minimal decrease on increasing the ensemble size and was used as the final set of 
selected conformers (Figure 2.1a). Euler angles were used to compare the 20 selected 
conformers to the MD trajectory. The relative orientation of two helices i and j can be 
defined using three interhelical Euler angles that describe the twist angle  〈h about helix i, 
the interhelix bend angle  βh, and the twist angle  γh about helix j(17,39). Indeed, the 
Euler angles of the 20 discrete conformers largely span the range of conformations 
sampled in the trajectory and are more densely populated in regions that are often 
sampled in the MD trajectory (Figure 2.1b). Thus, using SAS, a discrete set of structures 
can be used to model an ensemble of many conformations. 
 The ability to select a particular set of 20 from the pool of 20,000 was examined by 
using the first 20 conformers of the trajectory to represent the “known” theoretical 
ensemble. RDCs for the 20 structures were calculated as previously described. The 20 
sets of RDCs were then averaged independently for each elongation to give the final 
input RDCs. All 20,000 conformers were used as the selection pool and SAS simulations 
run using input RDCs from theoretical EI-TAR, EII-TAR, and both EI-TAR and EII-TAR 
RDCs. For all three SAS simulations, the RMSD between input and selected RDCs was 
<1 Hz. Only 8 of the 20 conformers were selected using EI-TAR RDCs, and the 
remaining 12 selected conformers are within 3Å backbone heavy-atom RMSD to the 
unselected structures  (Figure 2.2a). When only considering EII-TAR RDCs, 3 of the 20 
conformers are selected and the remaining 17 conformers exhibit a backbone heavy-
atom RMSD < 3Å to the remaining structures (Figure 2.2b). Remarkably, when EI-TAR 
and EII-TAR RDCs are used all 20 conformers are selected (Figure 2.2c). The ability to 
more accurately select the correct structures using EI-TAR and EII-TAR RDCs is most 
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likely a result of the increased sensitivity to helical motions that is realized when 
combining both elongations(17). To simulate experimental error, a 3 Hz error was added 
to the theoretical RDCs. When using EI-TAR and EII-TAR theoretical RDCs with 
simulated 3 Hz experimental error, 16 of the 20 structures are selected and the 
remaining 4 are within 4Å backbone heavy-atom RMSD to the unselected theoretical 
structures (Figure 2.2d). Thus, experimental error does not preclude selecting most all of 
the 20-members of the ensemble using SAS. 
 
Figure 2.2. Using SAS to select a 20-member ensemble. Back-calculated RDCs from 
the first 20 MD conformers represent the “known” TAR ensemble and are used as input 
for the SAS selection. Results from SAS simulations using (a) EI-TAR RDCs, (b) EII-
TAR RDCs, (c) EI-TAR and EII-TAR RDCs, and (d) EI-TAR and EII-TAR RDCs 
including a simulated 3 Hz experimental error are shown. 
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 The SAS methodology can be used to accurately select 20 conformers provided 
that enough input experimental RDCs are measured in different reference frames. 
However, the first 20 conformers of MD trajectory are quite similar and cover relatively 
limited conformational space(Figure 2.3a). For example, the interhelical bend angles 
range only 24.3-36.7o. To test the ability to select 20 conformers that cover a wide range 
of conformational space, 20 structures were randomly chosen from the MD trajectory. 
Interhelical angles for the 20 random conformers range 12.4-60.9o (Figure 2.3a). 
Simulated EI-TAR and EII-TAR RDCs were calculated as stated above and combined to 
give the input RDCs. To simulate experimental conditions, a second set of “known”  
 
Figure 2.3. SAS selection of  structurally diverse conformers. (a) The first 20 
snapshots from the MD trajectory (red) cover a small conformational space as shown by 
the Euler angles, whereas the 20 randomly selected conformers (green) span more of 
the Euler angle space in the MD trajectory (gray). (b) SAS-selected 20-member 
ensembles selected assuming no experimental error (orange) and a 3 Hz error (blue) 
exhibit Euler angles in close agreement with the 20 randomly selected snapshots. (c) 
Most of the 20 randomly selected conformers are selected within 3Å backbone heavy-
atom root mean square deviation (RMSD). 
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RDCs was generated by adding 3 Hz to each RDC. Although the exact 20 conformers 
are not selected using either set of “known” RDCs, the RMSD between the input and 
selected RDCs for both data sets is <1 Hz. Thus, for structurally diverse ensembles, 
there exist degenerate solutions that minimize the cost function.    
 Success in selecting the input structures was verified by comparing Euler angles 
and backbone heavy-atom RMSD for the input and selected structures(Figure 2.3). Euler 
angles for the input and selected conformers are in close agreement (Figure 2.3b). The 
average 〈h, βh, and γh angles for the input structures (26.0o, 35.1o, 10.6o) are in close 
agreement with those selected using the input RDCs assuming no experimental error 
(26.0o, 34.7o, 6.2o) and an error of 3 Hz (29.0o, 34.0o, 6.2o).  Standard deviations for the 
〈h, βh, and γh are also similar for the input structures (24.9o, 11.9o, 28.4o), structures 
selected using RDCs with no experimental error (24.1o, 10.8o, 33.7o), and the structures 
selected assuming a 3 Hz error (20.8o, 10.6o, 30.4o). While the exact structures are not 
selected using either set of input data, small backbone heavy-atom RMSDs are 
calculated between the input and selected conformers. We define the success rate as 
the percentage of structures selected within a defined heavy atom RMSD cutoff. Using a 
cutoff of 3 Å, 13 of the 20 conformers are selected using input RDCs assuming no 
experimental error, and 16 of the 20 conformers are selected when a 3 Hz experimental 
error is introduced (Figure 2.3c). All 20 conformers are selected at an RMSD of 6 Å 
assuming no experimental error and 8 Å assuming an error of 3 Hz (Figure 2.3c). Thus, 
the SAS methodology can be used to select 20 conformers that sufficiently re-capitulate 
the input data, and it is likely that more RDC data will minimize the differences between 
the input and selected conformers and eliminate the degenerate solutions for structurally 
diverse ensembles. Note that in all experiments discussed in section 2.3, similar results 
were obtained using all 80,000 conformers from the TAR MD trajectory, but only 20,000 
were used to ensure computational efficiency. 
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2.4 Analysis of E-TAR SAS Ensemble 
In Figure 2.4, we compare the RDCs measured previously(26) in EI-TAR and EII-
TAR with those predicted based on the combined 50 x 1.6 = 80 ns MD trajectory. 
Though some correlation is observed between the measured and predicted RDCs for 
both EI-TAR (Figure 2.4b) and EII-TAR (Figure 2.4c), the deviations (RMSD ranging 
between 13-16 Hz) remains substantially larger than the estimated RDC measurement 
uncertainty (~3-4 Hz). The MD trajectory does not systematically under or overestimate 
the RDCs measured throughout the RNA, indicating that it does not significantly over or 
underestimate the amplitude of motions present. This is the case even though the RDC 
timescale sensitivity to motions (<ms) is greater than that of MD (~80 ns). Thus, it 
appears that the motions in TAR saturate at nanosecond timescales consistent with 
relaxation dispersion studies that provide no evidence for s-ms motions in the helix-
bulge-helix element of TAR(35).  
We examined if SAS could be used to pull out sub-ensembles from the MD 
trajectory that satisfy the measured RDCs. Similar to the validation simulations in section 
2.3, we first conducted a series of SAS runs with various ensemble sizes of N=5, 10, 20, 
30, 40, 50 and 100. The RMSD between measured and predicted RDCs when 
combining the EI-TAR and EII-TAR RDCs is shown in Figure 2.4d as a function of N. 
Increasing the ensemble size beyond N=20 did not lead to significant improvements in 
the fit and in fact a deterioration was observed for N >20. This is likely due to sampling 
problems during the Monte Carlo simulated annealing minimization of the cost function 
as the number of possible combinations increases steeply with N and the cost function 
exhibits, due to the frustration stemming from the underdetermined nature of the 
problem, a vast number local minima. An ensemble size of N=20 was used in all 
subsequent SAS runs. 
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Figure 2.4. SAS selection of E-TAR RDCs. (a) Secondary structure of TAR with helix-I 
highlighted in red, helix-II in green and tri-nucleotide bulge in orange. HIV-2 TAR lacks 
bulge residue C24. (b-c) Plots of experimental RDCs versus values computed from the 
80 ns MD trajectory for (b) EI-TAR and (c) EII-TAR. Data for helix-I, helix-II, and bulge, 
are shown in red, green and orange, respectively. Also shown is the root mean square 
deviation (RMSD) and correlation coefficient (R). (d) RMSD (Hz) between calculated and 
experimental RDCs as a function of N, following a SAS analysis using both EI-TAR and 
EII-TAR RDCs. (e-g) Plots of experimental RDCs versus values calculated from the 
N=20 SAS ensemble using (e) EI-TAR (f) EII-TAR, and (g) EI-TAR and EII-TAR RDCs. 
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The RDCs calculated using a 20-member ensemble selected using the SAS 
approach exhibit a markedly improved fit to the EI-TAR (Figure 2.4e), EII-TAR (Figure 
2.4f) and EI-TAR+EII-TAR (Figure 2.4g) RDCs as compared to those calculated from the 
entire MD trajectory. Importantly, sub-ensembles can be determined that simultaneously 
reproduce the EI-TAR and EII-TAR RDCs with an RMSD (4.8 Hz) that is comparable to 
the estimated experimental RDC uncertainty (~3-4 Hz) (Figure 2.4g). The SAS selected 
conformers also did not lead to any steric collisions with the elongated helices for both 
EI-TAR and EII-TAR despite the fact that the helices were not actually elongated in the 
MD simulations (data not shown). 
 
Figure 2.5. Interhelical Euler angles of SAS selected TAR conformers with N = 10, 
20, and 40. 
 
As shown in section 2.3, degenerate solutions exist for structurally diverse 
ensembles with N=20. To examine the uniqueness of the selected TAR ensemble, we 
carried out 100 independent N = 20 SAS runs. Here, a maximum of 2000 unique 
snapshots can be selected. However, repeated runs resulted in selection of a narrow set 
of similar conformations. The total number of unique snapshots selected by the RDC-
SAS optimization algorithm was 422, 48, and 121 for EI-TAR, EII-TAR, and EI-TAR+EII-
TAR RDCs, respectively. Thus, the RDC data favors selection of specific conformations 
from the available pool. As expected, the conformers selected did vary when changing 
the value N. However, the overall distribution of conformations remained similar as 
shown for example for the interhelical orientation in Figure 2.5. 
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2.5 SAS Ensemble Provides Details of Local and Collective Motions  
In Figure 2.6a, we plot (in black) the average and standard deviation for various 
base angles computed for the 121 unique TAR conformers obtained from 100 N=20 
SAS runs. For comparison, the mean value and standard deviation for idealized A-form 
helical geometry computed from a statistical comparison of high-resolution X-ray 
structures is shown in red(40). For the majority of the residues, very good agreement is 
observed between the SAS ensemble and canonical values. Large deviations are 
however observed for the junctional A22-U40 base-pair, which in the MD simulation 
frequently deviates from a hydrogen bonded alignment. This is in excellent agreement 
with previous NMR data showing that while the junctional G26-C39 base-pair forms a 
detectable hydrogen bond, the A22-U40 base-pair is flexible and does not form the 
expected base-pair in TAR(41-43). 
 The bulge residues exhibit different levels of motions. As shown in Figure 2.6b, 
the highly conserved U23 bulge stacks onto A22 in the majority of the conformations, 
consistent with observation of NOE connectivity between A22 and U23. These two 
residues undergo limited motions consistent with previous 13C relaxation studies of 
dynamics in elongated TAR(42). Interestingly, select conformations exist in which U23 
adopts a looped out conformation as observed in several ligand bound TAR structures 
(PDB ID# 1QD3, 1UTS, and 397D) In contrast, residues C24 and U25 predominantly 
exist in a looped out conformation and are significantly more flexible, again in agreement 
with the previous 13C relaxation studies(42).  
We computed the three interhelical Euler angles for the 121 SAS selected TAR 
conformers and compared them to angles obtained for the entire MD trajectory. As 
shown in Figure 2.7a, the MD trajectory spans a large range of interhelical angles. The 
SAS conformers are widely distributed across the MD trajectory (Figure 2.7a). For both 
the MD trajectory and SAS ensembles, significant correlation is observed between the  
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Figure 2.6. Local motions in the TAR dynamical ensemble. (a) Shown in black are 
the mean values for the base opening (⌠), buckle (), propeller twist () and twist (∧) 
angles and their standard deviation calculated over 121 TAR conformers obtained from 
multiple N=20 SAS runs. For comparison, shown in red are corresponding values for an 
idealized A-form helix as obtained from a statistical survey of high resolution X-ray 
structures(40). (b) Average conformation of the TAR bulge and neighboring base-pairs 
calculated from the 121-membered SAS ensemble. The bases of the bulge and flanking 
base pairs are color coded based on the root mean square fluctuations (RMSF) 
calculated over the ensemble. 
 
three interhelical angles, particularly between the twist angles 〈h and  γh. Such spatial 
correlations were reported previously based on an a three-state rigid-body refinement of 
the TAR interhelical orientation(17). As shown in Figure 2.7b, the conformations 
obtained by SAS sample orientations that are in very good agreement with those 
obtained by a previous 3-state analysis of the RDCs(17). The only significant deviations 
are observed in the 〈h-γh plane for the near coaxial conformer (βh~-21°). This is not 
surprising given that for this near coaxial conformer, the RDCs measured in both EI-TAR 
and EII-TAR are highly insensitive to the twist angles 〈h and γh. We also examined if 
there exists any correlation between the geometry of base-pairs at the junction and the 
interhelical bend angles. The only significant observation was anti-correlation (R ~-0.70) 
between the base-pair step angle (Ω) at the G26-C39 junctional base-pair and 〈h the 
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twist angle about helix II. Thus, the unraveling of the G26-C39 base-pair may give rise to 
twisting motions around the axis of helix II.  
 
Figure 2.7. Global interhelical dynamics in the TAR dynamical ensemble. (a) 
Shown in gray are the interhelical twist (〈h and γh) and bend (βh) angles for 80,000 TAR 
conformers derived from an 80ns MD trajectory (conformer selected every 1 ps). In blue 
are the corresponding SAS selected conformers. The correlation coefficient (R) is shown 
on individual planes. (b) Comparison of the SAS selected interhelical angles and those 
derived previously(26) based on a 3-state rigid body ensemble analysis of E-TAR RDCs.   
 
2.6 Comparison of TAR and HIV-2 TAR SAS Ensembles 
We used the SAS approach to analyze RDCs previously measured in HIV-2 EI-
TAR(26) in which the bulge residue C24 is omitted. Poor agreement (RMSD = 15.1 Hz) 
was again observed between the measured EI-TAR RDCs and values computed using 
entire MD trajectory (Figure 2.8a). By using SAS, we were able to find an N=20 sub-
ensemble that yields an RMSD of 1.7 Hz (Figure 2.8b). Compared to TAR, repeated 
SAS runs resulted in selection of a larger number (276) of unique conformers for HIV-2 
TAR. This could be attributed to a smaller RDC sensitivity to twisting motions both 
because the HIV-2 TAR structure is more linear and because only RDCs measured in 




Figure 2.8. HIV-2 TAR dynamical ensemble. Plot of experimental HIV-2 EI-TAR RDCs 
versus values calculated from (a) an 80 ns MD trajectory of HIV-2 TAR and (b) following 
SAS selection of N=20 conformers from the MD trajectory based on HIV-2 EI-TAR 
RDCs. Coloring scheme is same as in Figure 2.4. (c) Shown in black are the mean 
base-pair angles and their standard deviation calculated over a 279-membered HIV-2 
TAR SAS ensemble. For comparison shown in green are corresponding angles for an 
idealized A-form helix as obtained from a statistical survey of high resolution X-ray 
structures(48). (d) Average conformation of the bulge of HIV-2 TAR calculated from the 
279-membered HIV-2 TAR SAS ensemble. Bases of the bulge and flanking base pairs 
are color coded based on the root mean square fluctuations (RMSF) calculated over the 
ensemble. (e) Comparison of SAS selected TAR (blue) and HIV-2 TAR (red) interhelical 
conformations. The correlation coefficient (R) is shown on individual planes. 
 
Comparison of the SAS selected HIV-2 TAR conformers with those obtained for 
TAR revealed that reducing the length of the bulge in HIV-2 TAR led to a marked 
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decrease in the local motions in the junctional A22-U40 base-pair (Figure 2.8c). In TAR 
the standard deviations are approximately 30°, 45°, 13°, 16° for the base angles κ, σ, ω 
and Ω respectively. In HIV-2 they reduce to 10°, 6°, 8°, and 6° respectively. In contrast, 
we observe significant static deviations in the opening angle for the G26-C39 junctional 
base-pair. Likewise, a significant reduction is observed in the local dynamics of bulge 
residues U23 and C25 (Figure 2.8d). U23 is less flexible and forms more stable stacking 
interactions on an also less flexible A22. The root mean square fluctuations (RMSF) of 
the atomic positions of U23 and U25 decrease from 1.89 Å and 3.49 Å respectively in 
TAR to 1.45 Å and 1.49 Å respectively, in HIV-2 TAR.  
 The reduction in the local motions in and around the bulge linker is as expected, 
accompanied by a reduction in the interhelical motional amplitudes, as shown in Figure 
2.8e. Such a reduction is clearly observed for the interhelical bending which decreases 
in standard deviation from ~33° to ~12°. This is in agreement with an order tensor 
analysis of RDCs, which 
reported a reduction in the 
GDOint (which ranges 
between 0 and 1 for 
maximum and minimum 
interhelical motional 
amplitudes, respectively) 
from 0.45±0.10 to 
0.77±0.04(17). As expected, 
the HIV-2 conformers cluster 
more tightly around more 
linear (h~0°) conformations 
 
Figure 2.9. Interhelical Euler angles of the HIV-2 
TAR dynamical ensemble. Euler angles obtained from 
an 80 ns MD trajectory are shown in gray and the SAS 
selected structures shown in red. The correlation 
coefficient (R) is shown on individual planes. 
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(Figure 2.9). While we do not observe a significant reduction in the amplitude of twisting 
motions about the two helices (αh and γh) in HIV-2, the RDC sensitivity to these angles is 
diminished in HIV-2 TAR both because the structure is on average more linear and 
because RDCs were only measured on the helix-I elongated construct (Figure 2.9). 
Nevertheless, we observe a stronger correlation between the twisting motions indicating 
that the 〈h and γh correlations originates in part from the steric drag one helix exerts on 
the other.  
 
2.7 Insights into TAR-Ligand Recognition by Conformational Selection 
Numerous studies have shown that TAR undergoes large conformational 
rearrangements that allow binding of diverse targets in and around the bulge, including 
peptide derivatives of its cognate protein Tat(44-46), divalent ions(47), and five 
chemically distinct small molecules(48-51). The three interhelical conformers obtained 
by a 3-state ensemble analysis of RDCs measured in unbound TAR revealed a global 
interhelical motional trajectory that encapsulated many of the ligand bound 
conformations(17). As shown in Figure 2.10a, the SAS selected interhelical conformers 
trace orientations similar to the ligand-bound TAR conformations, supporting the notion 
that unbound TAR can dynamically access its ligand-bound global conformations. This 
can also be seen in Figure 2.10b in which we compare the best matching ligand-bound 
TAR conformers and SAS-selected conformers as determined by superimposing all 
heavy atoms excluding the flexible terminal base-pairs (G17-C45) and the apical loop. 
 The SAS dynamical ensembles also allowed us to examine to what extent are 
local features of the ligand binding pocket dynamically preformed in the absence of 
ligands. In Figure 2.10c, we compare the best matching ligand-bound TAR conformers 
and SAS-selected conformers as determined by superimposing heavy atoms in the 
bulge and immediately neighboring base-pairs. In general, the largest deviations are 
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seen for the highly flexible residues C24 and U25, which are also known to be flexible in 
many of the ligand bound TAR conformations(17,52,53). Overall, these results suggest 
that local dynamics in and around the TAR bulge likely facilitate formation of the ligand 
binding pocket.  
 
 
Figure 2.10. Comparison of the SAS derived TAR dynamical ensemble and ligand-
bound TAR conformations. (a) Shown in blue are the SAS selected angles and  seven 
distinct ligand-bound TAR structures in gray. (b, c) Shown is the comparison of the (b) 
global and (c) local structure of SAS TAR conformers and seven distinct ligand-bound 
TAR conformations (PDB ID#s 1QD3, 1UUI, 1UTS, 1UUD, 1ARJ, 1LVJ, and 397D). 
Shown are the pairs yielding the lowest RMSD fit when superimposing (b), all heavy 
atoms excluding terminal base-pairs G17-C45 and the apical loop and (c), all heavy 
atoms in the bulge and immediately adjacent base-pairs. Every model in the ligand 





RNA elongation provides a reliable approach for computing time-averaged RDCs 
in highly flexible RNAs providing a basis for integration with MD as we showed here 
using the SAS approach. That the measured RDCs in both TAR and HIV-2 TAR can be 
satisfied using conformers selected from the MD trajectory suggests that neither TAR 
nor HIV-2 TAR undergo significant s-ms motions that are not sampled in the MD 
trajectory. This is consistent with relaxation dispersion NMR studies of TAR, which 
provide no evidence for s-ms motions in and around the bulge(35).  
However, it should also be noted that the SAS conformers represent a “discrete” 
approximation to what is more likely a continuous complex distribution of many more 
conformations. The SAS conformers can be thought of as discrete points along the 
configuration space that may help define salient features of the motional trajectory(54). It 
should be kept in mind that averaging over such a discrete number of conformers leads 
to efficient averaging of the RDCs. A correspondingly larger continuous distribution of 
many more conformations will likely be required to accomplish the same level of 
motional averaging. It is therefore not surprising that the MD trajectory evolves outside 
the envelope defined by the SAS conformers and that the SAS envelope increases with 
the size of the ensemble (Figure 2.7). Thus, the most likely source of discrepancy 
between the measured RDCs and the MD simulation is the assignment of the relative 
weights to the various conformers. RDC studies of partially unfolded proteins have 
emphasized the exquisite sensitivity of RDCs to the underlying conformational 
distribution(55). 
The comparison of the dynamical ensembles generated for TAR and HIV-2 TAR 
provide fundamental new insights into the dependence of RNA dynamics on the bulge 
length. As would be expected, reducing the length of the TAR trinucleotide bulge by a 
single nucleotide led to a significant reduction in the local motions in and around the 
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bulge, as well as global interhelical motions. In both TAR and HIV-2 TAR, we observe 
spatial correlations between twisting motions about individual helices, and to a lesser 
extent between twisting and bending as first reported based on the 3-state ensemble 
analysis of the RDCs(17). Importantly, the spatial correlations between the twisting 
motions increase significantly in HIV-2 TAR (Figure 2.8e). This is expected if one were to 
consider limiting cases for the bulge length; at the limit of not having a bulge linker, the 
twisting dynamics becomes perfectly correlated, whereas for an infinitely long bulge, one 
would expect little correlation.  
 The TAR dynamical ensemble allowed us to directly examine if unbound TAR 
dynamically samples diverse ligand-bound conformations that have been reported to 
date. Our results suggest that many of the key features of the ligand bound TAR 
conformations, including the global interhelical orientation and local aspects of the 
ligand-binding pocket appear to be dynamically preformed in unbound TAR. However, a 
detailed comparison of the SAS conformations and the ligand bound TAR structures 
remains complicated by a number of factors. As mentioned above, the SAS conformers 
only represent an approximate discrete state ensemble to what is likely a more 
continuous conformational distribution. One also has to consider the uncertainty in ligand 
bound TAR structures, both due to experimental imprecision and because the ligand 
bound states may be flexible themselves. Previous NMR studies reveal significant 
mobility in the TAR bulge especially residues C24 and U25 when in complex with 
argininamide(43,56) and Mg2+(52,57). The ACP bound TAR structure also exhibits a 
large degree of interhelical motions(53). Notwithstanding these complications, our 
results suggest that local dynamics in and around the bulge together with global motions 
of helices can drive much of the conformational adaptation required to bind to different 
ligand targets.  
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Our results also suggest that some of the TAR conformational changes require 
ligand binding to occur efficiently. For example, we do not observe the key U38-A27•U23 
base-triple in either of the TAR or HIV-2 TAR SAS conformers that is known to form in 
the TAR-argininamide complex(46). In this regard, it is interesting to note that larger 
deviations between the SAS and ligand bound conformations are generally observed for 
the weaker binding ligands and vice versa. It is possible that the weaker binding ligands 
expend a greater fraction of the binding energy changing the TAR conformation. 
Additional studies are needed to shed light on these key energetic questions. 
 
This work has been published in the journals Nucleic Acids Research (58) and Methods (59). The idea was conceived by 
Stelzer A. C. and Frank A. T. under the guidance Al-Hashimi H. M. and Andricoaei I. MD simulations were generated and 
SAS program written and implemented by Frank A. T.  Frank A. T. analyzed the A-form nature of the SAS structures. 
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A Conservative Sequence Mutation in HIV-1 TAR Pre-tunes the Free-State 




Previous studies comparing the dynamics of HIV-1 TAR (TAR) and HIV-2 TAR 
show that the internal motions are strongly dependent on the RNA secondary 
structure(1). TAR, which contains a trinucleotide bulge, exhibits greater interhelical 
motions and distinct local dynamics in and around the bulge in comparison to HIV-2 
TAR, which contains a dinucleotide bulge. In this chapter, we investigate whether 
changing the TAR sequence without significantly perturbing the secondary structure 
leads to changes in dynamical behavior. In particular, the local flexibility at the pivotal 
A22-U40 base-pair below the bulge, which does not form a typical Watson-Crick base-
pair, may be important for activating collective helical motions and also affect local 
motions within the bulge. Here, the dynamic properties of a mutant TAR construct, in 
which the labile A22-U40 base pair is replaced with a G22-C40 base-pair (ΔGCTAR), 
are investigated. We test the hypothesis that the stronger GC hydrogen bonds leads to 
base-pairing and attendant changes in the local and global helical dynamics. Note that 
the GC mutant is not strictly a mutant since it is observed in the HIV subtype-O 
isolate(2,3). The effects of perturbing the free-state dynamical properties on ligand 
binding are also investigated by titrating two known TAR-binding small molecules, 
  89 
argininamide (ARG), which stabilizes a linear TAR structure, and neomycin B, which 
stabilizes a bent TAR conformation, on TAR and ΔGCTAR.  
 
3.2 Materials and Methods  
3.2.1 Sample Preparation and Assignments 
 Uniformly 13C/15N labeled RNAs were prepared by run-off in-vitro transcription 
using synthetic double-stranded DNAs containing the T7 promoter and RNA sequence 
of interest (Integrated DNA Technologies). Elongated RNA constructs were purified by 
15% (w/v) denaturing polyacrylamide gel electrophoresis containing 8M urea and 1x 
TBE followed by electroeultion in 20 mM Tris pH 8 buffer and EtOH precipitation. The 
resultant RNA pellet was dissolved and exchanged into NMR buffer (15 mM sodium 
phosphate, 0.1 mM EDTA, and 25 mM NaCl at pH ~6.4) using a Centricon Ultracel YM-3 
concentrator to a final concentration of ~0.5mM (Millipore Corp.). All NMR samples 
contained 10% D2O. The ΔGCTAR NMR spectra were assigned using conventional 
NMR methods such as 3D exchangeable 1H-15N NOESY-HSQC, 2D non-exchangeable 
1H-13C NOESY-HSQC, 2D HCN, 2D IP-COSY (correlated H5/H6 resonances) and 
spectral overlays with similar RNA constructs. 
 
3.2.2 Normalized Intensity and Chemical Shift Analysis 
 Resonance intensities are normalized to a baseline value of 0.1 by dividing all 
resolved resonance intensities by 10x the lowest resonance intensity for a similar 
residue and spin type with known Watson-Crick A-form geometry.  For example, the 





Weighted average chemical shifts were calculated using the equation, 
 
.       [3.1] 
 
3.2.3 RDC Measurements and Order Tensor Analysis 
One bond RDCs for ΔGCTAR were measured by computing the difference in 
splittings measured in NMR buffer (J) and after suspending the RNA sample in ~7mg/ml 
of pf1 bacteriophage (J+D) as described in(4).  Because we implement the elongation 
strategy(1, 2) to decouple internal and overall motions, TROSY detection was employed 
in the pulse sequence to enhance sensitivity(5). CH splittings in the nucleobases 
(C2H2/C8H8 of adenosine and guanosine bases, C5H5/C6H6 of uridine and cytosine, 
and C1’H1’ of the ribose) were measured as the difference between the upfield and 
downfield components of the 1H –13C doublet along the 1H dimension using the narrow 
TROSY component in the 13C dimension. NH splittings in the nucleobases (N1H1 and 
N3H3 of the guanine and uracil bases, respectively) were measured using a coupled 
HSQC experiment. 
The relative orientation and dynamic amplitudes for the helices in ΔGCTAR were 
determined using order tensor analysis as reported previously(6-8). RDCs measured for 
each elongated construct were combined by normalizing adenine and uridine RDCs by a 
coefficient L that minimizes the quality factor Q(1,9). Order tensors describing the partial 
alignment of each helix relative to the magnetic field were determined by fitting 
measured RDCs to idealized A-form helices(6,8). Due to deviations from Watson-Crick 
geometry, terminal base-pairs were excluded from the analysis. The program AFORM-
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RDC was used to estimate errors in the order tensor arising from “structural noise” and 
RDC measurement uncertainty(8).  
 
3.2.4 Calculation of Dissociation Constants  
 Dissociation constants were calculated from the change in weighted average 
chemical shift for each titration point using the equation(10), 
 
,    [3.2] 
 
where [Arg]T is the total argininamide concentration, [RNA]T is the RNA concentration 
based on UV absorbance at 260 nm, ΔδT is the difference in chemical shifts between the 
free and ligand-associated states (in ppm), δobs is the observed chemical shift (in ppm), 
and δFree is the chemical shift in the free state (in ppm). The data was fit using the Origin 
software (OriginLab Corporation) in which ΔδT and Kd were allowed to float during the fit. 
 
3.3 Impact of the G22-C40 Mutation on TAR Structural Dynamics 
Previous studies have shown that while the A22-U40 base-pair exists in an A-
form geometry, there is significant flexibility and no direct evidence for Watson-Crick 
hydrogen bonding(11,12). In particular, the U40 imino resonance has only been 
observed in HIV-2 TAR at low temperatures (13) or for TAR in the ARG bound 
state(TAR-ARG)(11,14). In stark contrast, we were able to directly observe the G22 
resonance in ΔGCTAR, which was assigned using a 3D 1H-15N NOESY-HSQC 
experiment. The observation of this imino proton resonance together with sequential 
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NOEs between G21 and G22 strongly supports Watson-Crick base-pairing for G22-C40 
in ΔGCTAR (Figure 3.1).  
 
Figure 3.1. Overlay of short and elongated ΔGCTAR. The ΔGCTAR construct is 
shown in the left-most panel, where ΔGCTAR contains residues 17 to 45 and EΔGCTAR 
contains residues -22 to +22 where X-Ys refer to sequential AU or GC base pairs used 
in the elongation strategy as previously described(1,15). Similar resonance positions for 
the both RNAs indicate that the elongation does not cause structural perturbations. 
 
3.3.1 Domain-Elongation Does Not Impact the Integrity of ΔGCTAR 
One of the most difficult problems to address when analyzing dynamic motions of 
biomolecules is the coupling between internal and overall motions. Al-Hashimi H. M. and 
co-workers showed that fast-timescale (ps-ns) local and collective motions in TAR are 
masked by the diffusion timescale dependence of internal and interhelical motions, 
which remain unresolved in transverse and longitudinal relaxation rates(15). To 
overcome this problem, they elongated helix-1 to slow overall diffusion  thus resurrect 
previously un-detectable local and collective interhelical motions. More recently we 
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showed that the elongation technique 
can also be used in RDC 
measurements(1). Interhelical motions 
in TAR affect the overall alignment of 
the molecule in the presence of 
alignment media preventing accurate 
definition of the order tensor for each 
helix. Elongating either helix leads to 
well-defined alignment along the axial 
direction of the elongated helix and 
affords accurate calculation of the order 
tensor. Thus, the dynamics of TAR are 
more precisely described. In this study, helix-1 of ΔGCTAR was elongated (EΔGCTAR) 
by 22 base-pairs as previously described(1,2). Aside from resonances belonging to 
terminal residues the close agreement between the short and elongated ΔGCTAR 
spectra indicate no significant structural perturbations result from the elongation (Figure 
3.1).  
 
3.3.2 Analysis of Chemical Shift Perturbations 
To analyze the effects of mutating A22-U40 to G22-C40, we compared 2D CH 
HSQC spectra of EΔGCTAR and ETAR and computed chemical shift perturbations 
(CSPs) that reflect changes in chemical shift due to introduction of the mutation. 
Interestingly, the largest CSPs were observed for residues that have been shown to be 
critical for ARG binding (Figure 3.2)(16-18). A large downfield shift is observed for the 
U23 C6H6 resonance in EΔGCTAR along both the 1H and 13C dimension(Figure 3.3). 
 
Figure 3.2. ETAR constructs. Residues 
exhibiting significant changes in weighted 
average chemical shift are indicated with a 
filled circle and the sequential X-Ys refer to 
sequential AU or GC base pairs used in the 
elongation strategy as previously 
described(1,15). 
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This is consistent with the looping out of the U23 base as observed in the Mg2+ bound 
state (19). Large CSPs are observed for the G26 C8H8 resonance, which moves 
towards a position similar to that observed for HIV-2 TAR and TAR bound to Mg2+ 
(Figure 3.3) suggesting increased coaxial stacking. Likewise, large CSPs are observed 
for C6H6 resonances of C24 and U25 in ΔGCTAR that move toward positions that 
closely agree with those observed for ETAR-ARG (Figure 3.3)(18,20). Indeed, with the 
exception of U23, all of the CSPs observed in EΔGCTAR are along directions that are 
similar to those induced by ARG binding and some fall at a position that is a midway 
between free and ARG-bound ETAR, such as the C5H5 resonance of U25. Thus, the 
GC mutation seems to have the same effects on the conformation of TAR as does ARG 
binding and to a lesser extent Mg2+ binding (Figure 3.3).  
 
Figure 3.3. 2D CH HSQC ETAR, EΔGCTAR, ETAR-ARG, and TAR-Mg2+ spectra. 
EΔGCTAR, ETAR-ARG, and TAR-Mg2+ resonances that do not closely overlay are 
shown in orange, purple, and green respectively. 
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3.3.3 Sub-nanosecond Motions from Motional Narrowing of Resonances and Domain-
Elongation 
Comparison of the normalized resonance intensities observed for ETAR, 
EΔGCTAR, and ETAR-ARG provide additional insights into the effects on fast sub-
nanosecond internal motions.  In unbound ETAR, we observe elevated intensities for 
helix-II compared to helix-I due to collective motions and elevated intensities for residues 
A22, U40, C24 and U25 that reflect local motions. Binding of ARG arrests collective 
motions and local motions involving A22, U40 but leads to increased dynamics of C24 
and U25, which are looped out in the ARG bound state. Remarkably, the corresponding 
 
Figure 3.4. Normalized resonance intensities. Normalized resonance intensities for 
(a) ETAR (b) EΔGCTAR and (c) ETAR-ARG show similarities between ΔGCTAR and 
TAR-ARG. Helix-1 is colored red, the trinucleotide bulge orange, and helix-2 green. 
Open symbols are resonances that could not be measured in all three RNAs. Inset 
correlation plots show a greater correlation between EΔGCTAR and ETAR-ARG 
normalized intensities. 
 
resonance intensities observed in the EΔGCTAR mutant are far more similar to those of 
ETAR-ARG (R=0.94) compared to free ETAR (R=0.73). This is in excellent agreement 
with the above CSP results. The most significant differences between the resonance 
intensities include residues that are involved in the U23-A27-U38 base-triple, which 
forms in TAR upon binding to ARG. For example, much higher intensities are observed 
for U23 C6H6 and C1’H1’ resonances in the EΔGCTAR mutant compared to ETAR-
ARG. The high intensity and local mobility observed for U23 suggests that the U23-A27-
U38 base-triple is not formed in EΔGCTAR as observed for ETAR-ARG. In general, 
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higher intensities are observed for bulge resonances C24 and U25 in ETAR-ARG and 
likely reflect more complete coaxial stacking of the helices and extrusion of the 
nucleobases. Interestingly, much lower intensities are observed for U38 C1’H1’ in 
EΔGCTAR and ETAR-ARG compared to ETAR (Figure 3.4). This likely reflects 
increased co-axial stacking and possibly transient and/or incomplete formation of the 
base-triple. Taken together, the CSP and resonance intensity data strongly suggest that 
that the GC mutation has the same effect on the TAR conformation as does ARG 
binding (Figure 3.3 and 3.4).  
 
3.3.4 Analysis of 15N Relaxation Data 
In order to quantitatively analyze of the global and local dynamic effects of the 
G22-C40 mutation, we measured imino 15N longitudinal (R1) and transverse (R2) rates 
for all resolved 15NH resonances in EΔGCTAR and compared findings with previous 
results reported for ETAR and ETAR-ARG(15). Shown in Figure 3.5 are the R2/R1 
values, which are insensitive to fast local motions occurring at the picosecond timescale 
and report on slower motions occurring at nanosecond timescales including collective 
motions of helical domains(15). Here, 
elongation of helix-1 is critical for 
decoupling collective helix motions from 
overall rotational diffusion(15). 
The R2/R1 values observed in 
ETAR are in very good agreement with 
hydrodynamic predictions(15). The similar 
values observed across different residues is 
consistent with having similar local motions 
 
Figure 3.5. 15N Relaxation. 15N R2/R1 
relaxation data obtained for ETAR 
(black), EΔGCTAR (orange), and 
ETAR-ARG (purple). The Average 
R2/R1 values for each helix are 
indicated by dotted lines. 
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at nanosecond timescales. The R2/R1 values measured in helix-2 are uniformly 
attenuated relative to values in helix-1 indicating that helix-2 residues experience an 
additional internal dynamic process at nanosecond timescales. The uniformity of the 
attenuation across different residues is consistent with having a collective dynamic 
process that leads to similar levels of reorientation for distinct residues. The addition of 
ARG results in near total arrest of these collective motions and the helix-2 R2/R1 values 
become more similar to the helix-1 counterparts. The small changes observed in the 
helix-1 R2/R1 values likely reflect changes in the overall structure of ETAR-ARG and 
thus changes in its overall rotational diffusion.  Interestingly, while the R2/R1 values 
observed for helix-2 in EΔGCTAR are attenuated relative to values in helix-1, the level of 
attenuation is diminished by a factor of 2.5 compared to ETAR-ARG. Thus, the collective 
helical motions are significantly reduced in EΔGCTAR compared to ETAR but not to the 
extent on ARG binding. This again most likely originates from formation of the G22-C40 
base-pair and stronger preference for co-axial stacking of the two helices. The 15N 
relaxation data therefore supports the notion that the GC mutation leads to a 
perturbation towards a TAR conformation similar to that observed in the ARG-bound 
state.  
 
3.3.5 Structural Dynamics at Sub-millisecond Timescales from Residual Dipolar 
Couplings 
We further characterized the impact of the GC mutation by measuring RDCs in 
EΔGCTAR . RDCs probe sub-millisecond motions and thus provide a larger window to 
investigate the G22-C40 mutation effects. In ETAR we observe a systematic reduction in 
helix-2 RDCs suggesting more dynamics compared to helix-1(Figure 3.6).  The bulge 
RDCs exhibit a large range of RDCs indicating dynamic variability, which is not 
unexpected since U23 is known to be looped inside the bulge and stacked on A22(11). 
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On binding ARG, the average RDCs for both helices are nearly identical suggesting 
attenuated interhelical dynamics. As expected, on binding ARG the U23 RDCs are 
significantly increased due to the formation of the U23-A27-U38 base-triple, and the C24 
and U25 RDCs are closer to zero indicative of being looped out. Remarkably, EΔGCTAR 
exhibits similar features as ETAR-ARG where the average RDCs for both helices are  
Figure 3.6. RDCs measured for ETAR, EΔGCTAR, and ETAR-ARG. RDCs measured 
in EΔGCTAR and ETAR-ARG indicate attenuated interhelical dynamics and similar 
bulge dynamics compared to ETAR.  
 
nearly identical. Interestingly, except for U23 in ETAR-ARG, the bulge RDCs for 
EΔGCTAR and ETAR-ARG all have magnitudes near zero indicative of highly isotropic 
motions likely resulting from the looped out bulge conformation (Figure 3.6). The larger 
RDC magnitudes for U23 in ETAR-ARG are due to the formation of the U23-A27-U38 
base triple. In the case of EΔGCTAR, the G22 C1’H1’ RDC is 2.2 Hz.  While it can not 
be ruled out that the orientation of the G22 C1’H1’ bond vector gives rise to the small 
RDC value, it is in agreement with the increased A22 C1’H1’ resonance intensity in the 
more coaxially stacked HIV-2 TAR RNA (1) potentially indicating unexpected increases 
in local dynamics on forming a more coaxially stacked state. Unfortunately, the A22 
C1’H1’ RDC could not be measured for ETAR-ARG due to spectral overlap and line 
broadening on addition of pf1 phage precluding further comparison.   
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To further characterize the structural dynamics of EΔGCTAR, we subjected the 
RDCs measured in A-form helices to an order tensor analysis. Assuming an idealized A-
form helical geometry, the RDCs are used to determine five parameters of an order 
tensor describing the overall alignment relative to the magnetic field. By superimposing 
the order tensor frames obtained for each helix, we were able to compute an average 
interhelical bend angle. In addition, by considering the generalized degree of order 
(GDO) for each helix, which describes dynamic averaging resulting from overall 
alignment and internal motions independent of the average orientation of a molecule 
fragment and the magnetic field, the internal GDO (GDOint) is computed to separate 
contributions from overall alignment and internal motions resulting in a measure of 
interhelical dynamics, where a GDOint of 1 corresponds to interhelical rigidity and a 
GDOint of 0 reflects isotropic interhelical motions.  
 
Figure 3.7. Order tensor analysis derived parameters describing the structure and 
dynamics of ETAR, EΔGCTAR, and ETAR-ARG. The interhelical bend angle (β) 
describes the angle between the principal axis of alignment and helix-2, and the GDOint 
describes the interhelical motional amplitude where 1 corresponds to complete 
interhelical rigidity and 0 to fully isotropic motions. 
 
Previous order tensor analysis of RDCs measured in ETAR and ETAR-ARG 
showed that ETAR exhibits significant interhelical motions (GDOint=0.45±0.10) with an 
average interhelical bend angle (β) of 28.3±3.0o. These motions are significantly reduced 
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on binging ARG resulting in a GDOint of 1.09±0.09 and β of 7.8±3.5o consistent with a 
coaxially stacked and rigid conformation. SVD order tensor analysis was used to probe 
the interhelical dynamics of EΔGCTAR. The measured and back-calculated RDCs 
closely correlate for all three RNAs as indicated by the small RMSD values and Q 
factors reported in Table 3.1. Decreased interhelical bend angle (β=11.9±6.5o) and 
increased GDOint (1.02±0.09) (Figure 3.7 and Table 3.1) indicate that the G22-C40 
mutation significantly reduces interhelical motions. In fact, the β and GDOint values are in 
much closer agreement with ETAR-ARG compared to ETAR (Figure 3.7).  
 
Table 3.1. Structural parameters derived from SVD order tensor analysis of ETAR, 
EΔGCTAR, and ETAR-ARG. N is the number of RDCs included in the analysis for each 
helix, RMSD is the root mean square deviation between measured and back-calculated 
RDCs, CN# is the condition number, Q is the quality factor between the measured and 
back-calculated RDCs, η describes the asymmetry of the order tensor (where 0 
indicates a fully symmetric tensor), R is the correlation between measured and back-
calculated RDCs after the order tensor analysis, GDO, is the generalized degree of 
order for each order tensor, GDOint describes the magnitude of interhelical motions with 
1 describing interhelical rigidity and 0 fully isotropic motions,  and βo is the interhelical 
bend angle, Full descriptions of these parameters can be found in reference (6). 
 
 
3.4 ARG Captures Common Conformations from the Distinct ΔGCTAR and TAR 
Dynamic Ensembles  
Our results suggest that the GC mutation perturbs the TAR structural dynamics 
towards the ARG bound state. Thus, the ARG bound state is still, and perhaps even 
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more, dynamically accessible in ΔGCTAR. Given that A22 and U40 are not involved in 
any sequence specific interactions with ARG, we can expect that ΔGCTAR binds to ARG 
using similar binding modes. To investigate this hypothesis, we performed CSP NMR 
studies with ARG and ΔGCTAR. Titration of ARG led to significant CSPs for many 
residues that are know to interact with ARG including U23, G26, A27, U38, and 
C39(14,21). Remarkably, despite large differences between the starting spectra of 
ΔGCTAR and TAR, the resultant spectra for ΔGCTAR-ARG and TAR-ARG are in 
excellent agreement (Figure 3.8). These results strongly suggest that ARG captures 
similar coaxial conformations from the distinct ΔGCTAR and TAR dynamic ensembles.  
 
Figure 3.8. Comparison of TAR-ARG and ΔGCTAR-ARG spectra. Saturated TAR-
ARG and ΔGCTAR-ARG spectra are overlaid. Resonances that do not closely overlay 
are shown in purple and orange for TAR and ΔGCTAR respectively. The largest 
differences between chemical shifts are observed for residues immediately neighboring 
the A22-U40 to G22-C40 mutation.  
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 In order to assess the changes in binding affinity between ΔGCTAR and TAR-
ARG, dissociation constants were independently calculated for residues exhibiting large 
ARG-induced CSPs in ΔGCTAR and TAR (Figures 3.9). Comparison of the binding 
affinities for the residues A22/G22, U23, and G28 show a 2-4 fold tighter ARG binding 
for ΔGCTAR compared to TAR. Fitting the data globally to determine an overall 
dissociation constant results in ~3 fold increase in binding affinity for ΔGCTAR (47.7±9.3 
µM) compared to TAR (140±9.0 µM).  It is very likely that the GC mutation increases the 
ARG binding affinity by preferentially stabilizing the ARG bound conformation; 
specifically coaxial stacking of the two helices and looping out of U23. The binding 
affinity of ARG to TAR matches that calculated by Gdaniec Z. and co-workers who report 
a 300 ±100 µM Kd using fluorine NMR (22).  
 
Figure 3.9. Enhanced binding affinity for ΔGCTAR-ARG. Dissociation constants for 
similar resolved resonances that shift greater than the weighted average chemical shift 
are shown, indicating that the modest A22-U40 to G22-C40 mutation results in a ~2-4 
fold increase in binding affinity. 
 
3.5 Neomycin B Stabilizes Conformations in TAR that are Inaccessible in ΔGCTAR  
 As a second test the known TAR-binding small molecule neomycin B was 
independently titrated onto ΔGCTAR and TAR. Neomycin B has been shown to stabilize 
a bent TAR conformation that is flexible in the bound state(23). Surprisingly, neomycin B 
does not appear to bind ΔGCTAR (Figure 3.10). In fact, many resonances follow linear 
CSP trajectories at a 2:1 neomycin B:ΔGCTAR ratio and then begin to shift in other 
directions on further addition of neomycin B (Figure 3.10). Also, the CSPs for ΔGCTAR 
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compared to TAR are not in the same directions as was observed in the ARG titrations 
indicating different binding modes. These data most likely indicates non-specific binding 
and precludes the calculation of dissociation constants. Thus, it is likely that the G22-
C40 mutation does not allow access to the bent conformation necessary to bind 
neomycin B.  
 
Figure 3.10. Neomycin B does not specifically bind ΔGCTAR. 2D C6/C8 HSQC 
spectra from titration of neomycin B onto TAR and ΔGCTAR are shown. Initially linear 
changes in chemical shift are observed for ΔGCTAR, but deviate at >2:1 neomycin 
B:ΔGCTAR ratios. Residues that shift significantly on titration of neomycin B are labeled.  
 
3.6 Conclusion  
 This study highlights that small sequence mutations can lead to dramatic 
changes in the average structure and dynamics. Reduction in the average R2/R1 values, 
decreased β, and increased GDOint for EΔGCTAR indicate that stabilizing the labile A22-
U40 base-pair leads to a drastic reduction in collective interhelical motions that closely 
resemble ETAR-ARG. Sequence effects are also observed for local motions where 
hydrogen bonding of the G22-C40 base-pair results in significant reduction of the G22-
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C40 resonance intensities that are accompanied by formation of a U23 looped out 
conformation giving rise to the increased U23 resonance intensities and reduced RDCs. 
Thus, modest sequence mutations can lead to dramatic perturbations of functionally 
important junctions that result in very different local and global motions. The results 
presented here also suggest that the dynamic perturbations observed for ΔGCTAR pre-
tunes the dynamic equilibrium toward a coaxially stacked state. This is analogous to a 
previous study showing that on binding Mg2+ the dynamic equilibrium of TAR is biased 
toward the coaxially stacked state and the population of bent TAR conformations is 
significantly reduced(19). On saturation with argininamide, TAR and ΔGCTAR form the 
same bound-state conformation as indicated by nearly identical chemical shifts, 
however, on titration with neomycin B very different chemical shifts are observed for 
TAR and ΔGCTAR suggesting different binding modes. Thus, biasing the conformational 
ensemble toward the coaxial state increases the affinity for argininamide, which 
stabilizes a linear TAR conformation, but does not allow access to the bent state 
necessary to bind neomycin B.   
 Due to the ever-increasing evidence that RNA is critical in regulating cellular 
processes making it a highly sought drug target, many studies have aimed to 
characterize the physical basis for RNA structural plasticity. One question that remains 
unanswered is the effects of sequence mutations on dynamics and intermolecular 
interactions. Using TAR as a model system to interrogate the effects of sequence 
mutations, we show that by modestly changing one base-pair, the free-state dynamics 
are modified from a flexible and bent state toward a more coaxially-stacked and rigid 
conformation. This leads to an ~3 fold increase in binding affinity for ARG, which could 
indicate that transition to the bound state involves first pre-forming the coaxially aligned 
and looped out bulge conformation prior to binding ARG. Overall, these results show that 
conservative RNA sequence mutations can have dramatic effects on the free-state 
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dynamics and structurally bias RNA-ligand interactions, which is critically important in 
many biological processes. 
  
The idea was conceived by Al-Hashimi H. M. and Stelzer A. C. Stelzer A. C. and Kratz J. D. synthesized RNA 
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Dynamics-Based Screening Affords Efficient Discovery of Novel HIV-1 TAR-




 Structure-based drug design is one of the most ambitious approaches for drug 
discovery and is based on rationally using knowledge of a molecule’s 3D structure to 
identify small molecule binders. The flexible nature of RNA presents a unique challenge 
in this regard because even related ligands can bind very different RNA conformations 
that cannot, in general, be determined a priori. Characterizing the large conformational 
rearrangements that occur in RNA on ligand binding has been impeded by the lack of 
experimental techniques capable of reporting on motions at biologically important 
timescales. Thus, RNA structure-based predictions of RNA-ligand interactions have 
largely not proven successful. In Chapter 2 we showed that NMR and MD can be used 
in concert to characterize RNA dynamics up to millisecond timescales provided that 
internal and overall motions are decoupled. Using a Sample and Select (SAS) approach 
we were able to generate ensembles comprised of 20 HIV-1 TAR (TAR) conformers that 
precisely re-capitulate the experimental RDCs and suggest that bound-state TAR 
conformations are present in the absence of ligands(1). Here, we test the hypothesis 
that computational docking can be used to calculate a docking score, which reports on 
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the RNA-ligand interaction energy, that correlates with the experimentally determined 
change in binding free energy (ΔGexp) provided an accurate description of the ligand-
bound RNA conformation is known. Virtual screening simulations conducted using the 
ensemble of 20 SAS-generated TAR structures result in the identification of the small 
molecule netilmicin, which shows the ability to inhibit HIV-1 replication in-vitro. 
 
4.2 Materials and Methods 
4.2.1 ICM Computational Docking 
 ICM (Molsoft LLC) employs internal coordinate mechanics (based on bond 
angles, bond lengths, torsion angles, and phase angles) in grid-based docking 
simulations to efficiently determine interaction energies and optimal small molecule 
binding conformations in receptor-ligand complexes(2). Since the energy function is 
expressed analytically in internal coordinates, ICM uses a Monte Carlo gradient 
minimization algorithm during docking simulations, which has been shown to greatly 
increases the search area from which the global minimum can be found and also 
significantly reduce computational time(2). In order to rank the interactions of ligands 
with macromolecules, ICM implements a scoring function containing eight terms,  
 
,      [4.1] 
 
where Nat is a correction term to prevent biasing toward larger small molecules, Nflex 
represents the change in energy due to entropy loss of the ligand on binding,  is 
an angle and distance dependent hydrogen bonding term,  characterizes Van der 
Waals interactions between the ligand and receptor accounting for the quality of steric fit, 
 is the internal energy of the ligand calculated using the ECEPP/3 force field, 
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 takes into account the disruption of hydrogen bonds between the ligand and 
solvent,  is the solvation electrostatics energy on binding that is calculated using 
a distance dependent dielectric constant, and reports on the hydrophobic free 
energy gain according to the amount of buried surface area upon binding. Each term is 
weighted using a coefficient, , that affords optimization of the scoring function to 
agree with experimental data. 
 ICM docking simulations were conducted using rigid RNA receptors and fully 
flexible small molecule ligands. In all simulations the RNA binding pocket was pre-
defined in order to efficiently target probable binding sites and minimize the size of the 
calculated grid maps. Small molecule-bound RNA structures used to validate the ability 
of ICM to accurately dock RNA targets were downloaded from the Protein Data Bank 
(PDB) (www.pdb.org). The small molecule was separated from the RNA, the RNA was 
converted into an ICM object, and the RNA binding pocket was defined as all atoms 
within 5 Å of the bound small molecule. For structures with multiple binding sites, each 
site was defined as a receptor, independently docked, and the lowest score recorded as 
the final docking result. Docking simulations against TAR employed individual SAS-
ensemble structures. These RNA structures were first converted into ICM objects and 
probable binding pockets were predicted using the ICM PocketFinder module, which 
calculates the surface area and volume of cavities on the receptor surface. All binding 
pockets that fall within the “druggable” range (volume=150-500 Å3 and surface 
area=200-550 Å2), as determined by ICM(3), were set as receptor centroids and the final 
receptor defined as all atoms within 5 Å of the predicted binding site. In the event that 
multiple “druggable” binding pockets were identified for one structure, all RNA binding 
pockets were docked independently.  
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All small molecules used to dock against the RNA receptors were converted to 
SDF files.  In the validation simulations the small molecule protonation states were 
assigned according to reported studies of the RNA-small molecule complex. In the event 
that the protonation state was not known, all protonation states for pH 5.4-9.4 were 
calculated using the majormicrospecies module of ChemAxon© (www.chemaxon.com) 
and docked against the RNA receptor. When multiple protonation states were found, 
each small molecule protonation state was docked and the minimum score recorded. 
Predicted small molecule protonation states were also used in the docking simulations 
against the SAS-ensemble structures. 
 
4.2.2 Sample Preparation and Assignments 
 All RNAs (both 13C/15N and non-isotopically labeled) were prepared as described 
in section 3.2.1. The same NMR data were collected as described in section 3.2.1 
including an additional 13C-edited-NOESY-HSQC experiment to help determine the 
resonance assignments of TAR bound to netilmicin. N-terminal-labeled-fluorescein Tat 
peptide (FTat), was purchased from Genscript Corp. 
 
4.2.3 Weighted Average Chemical Shift Perturbations, RDC Measurements, and Order 
Tensor Analysis 
 Methods to calculate weighted average chemical shift perturbations are 
described in section 3.2.2, and methods used to measure RDCs and implement order 
tensor analysis are described in section 3.2.3. 
 
4.2.4 Fluorescence Polarization 
 Fluorescence polarization (FP) measurements were collected using 384 well 
plates read with a PHERAstar Plus plate reader (BMG LABTECH) and a 485 nm 
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excitation wavelength and 520 nm detection wavelength optic module. All 
measurements were run in triplicate and averaged to give the final data. Elongated AU 
HIV-1 TAR (EAUTAR) was used to increase the dynamic range of the FP 
measurements. The FP buffer consisted of 50mM Tris (pH 7.4), 100mM NaCl, and 
0.01% nonidet-P40. If soluble in aqueous solution, small molecules were dissolved in the 
FP buffer.  Otherwise, they were initially suspended in DMSO followed by dilution into 
the FP buffer. Determination of the TAR-Tat Kd was performed by adding sequentially 
higher concentrations of TAR to 10nM Tat with a final volume of 32 µL. The Kd was fit 
using the equation,  
,        [4.2]  
 
where Pbound and Pfree are the measured fluorescence polarization values of the bound 
and unbound FTat peptide, respectively, [L]T is the total concentration of FTat, [RNA]  is 
the EAU-TAR concentration, and Kd is the dissociation constant. The data was fit using 
the Origin software (OriginLab Corporation) in which Pbound, Pfree, and Kd were allowed to 
float during the fit. The data was collected for 30 minutes at 5 minute intervals to ensure 
no change in the Kd over time. After 10 minutes no change in the Kd was found. 
Small molecules were tested to inhibit the TAR-Tat interactions using 10 nM 
FTat, 60 nM EAU-TAR, and varying concentrations of small molecule in each well. The 
small molecules were first incubated with TAR for 10 minutes, followed by addition of 
FTat and a second 10 minute incubation period after which the FP was collected for 20 




,                   [4.3] 
 
where Pbound and Pfree are the measured fluorescence polarization values of the RNA-
bound and RNA-unbound FTat peptide, respectively, [I] is the log of the concentration of 
the small molecule inhibitor, IC50 is the 50% small molecule inhibitory concentration, and 
m is the slope of the linear portion of the sigmoidal curve. The data was fit using the 
Prizm software (GraphPad Software Inc.).  Inhibition constants (Ki) were calculated with 
the Prizm software (GraphPad Software Inc.) using the equation, 
 
 
,          [4.4] 
 
where [FTat] is the concentration of FTat and Kd is the dissociation constant of the FTat-
TAR complex. The Kis reported in this manuscript are the exact Kis calculated from the 
IC50 and a range of Kis based on the 95% confidence interval. On identification of a 
FTAR-Tat inhibitor, the UV absorption spectrum was recorded to ensure no spectral 
overlap with fluorescein. 
 
4.3 Validation of ICM to Computationally Dock RNA Targets 
 A database of 107 small molecule-bound RNA crystal and NMR structures, which 
is the largest set of small molecule-bound RNA structures interrogated by docking to 
date, was constructed by downloading previously determined RNA-small molecule 
complexes from the PDB (www.pdb.org). These structures included a number of 
bacterial/human A-site, riboswitch, ribozyme, and aptamer structures that provide a 
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representative example of diverse RNA-ligand interactions. 56 of the 107 structures had 
reported Kds and were used to test the accuracy of the ICM scoring function to predict 
the experimental change in binding free energy (ΔGexp=RTLn(Kd)), and all 107 structures 
were used to assess the accuracy of predicting the bound-state small molecule 
conformation. It should be noted that structures with metal-mediated RNA-small 
molecule interactions were omitted from testing the correlation between the docking 
score and ΔGexp because ICM fails to accurately score these interactions.  
 All small molecule-bound RNA crystal and NMR structures were “self-docked”. 
For each structure, the small molecule was removed and the protonation states 
assigned as described in section 4.2.1. The small molecule was subsequently docked 
onto the RNA using the suggested “maximum” number of Monte-Carlo iterations 
according to the ICM manual (thoroughness=10), and the lowest scoring binding pose 
recorded. A larger number of Monte-Carlo iterations were tested without improvement in 
the scoring predictions (data not shown). For the A-site structures with two internal loop 
binding sites, each site was defined as a receptor, independently docked, and the lowest 
score was recorded as the final docking result. For the 56 structures tested, ICM predicts 
the binding scores relatively well resulting in a correlation of R=0.62 between the 
docking score and  ΔGexp (Figure 4.1a). The two outliers in Figure 4.1a (shown in open 
circles) are (i) the FMN aptamer, for which the solved RNA structure is different than that 
used to determine the Kd(4), and (ii) the 2,4,6-triaminopyrimidine bound purine 
riboswitch, which exhibits a substantially different Kd (>1 order of magnitude) in the 
reported study when using different biochemical methods(5). Interestingly, the 
agreement between docking score and ΔGexp continuously improves as the small 
molecule flexibility decreases (defined by the number of flexible torsion angles; Nflex), 
most likely because conformational sampling and entropic contributions become less 
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problematic. Very good agreement (R = 0.73) is observed for 43 of the 56 small 
molecules that have Nflex <15 (Figure 4.1b), and 25 of the 56 small molecules with 
Nflex<10 (Figure 4.1c). Thus, even without further MD refinement of initial or final poses, 
the binding affinity can be predicted at a useful level of accuracy provided the bound 
RNA structure is well defined.   
 
Figure 4.1. Crystal and NMR docking validation. Small molecules were “self-docked” 
to their respective crystal and NMR structures and correlated to ΔGexp. The correlation 
increases with decreasing Nflex. All 56 structures are plotted in (a), structures with 
Nflex<15 are plotted in (b) and Nflex<10 plotted in (c). The success rate of predicting the 
bound small molecule conformation for all 107 RNA-small molecule structures is plotted 
in (d). Error bars in (a-c) are obtained from experimental studies reporting the Kd or ΔG. 
 
 
The success rate is a second metric used to determine the accuracy of ICM to 
dock RNA targets.  The success rate is defined as the percentage of small molecules 
whose predicted bound conformation matches the crystal or NMR structure to within a 
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defined heavy-atom root mean square deviation (RMSD) cutoff. An RMSD threshold of 
2.5 Å was used, which is the same cutoff reported in recent RNA-docking studies(6,7). 
The lowest scoring small molecule pose was used as the final docking result for 
comparison to the solved structure. We calculate a success rate of ~45% when 
considering all 107 structures. While this is disappointingly low, the success rate rapidly 
increases with decreasing Nflex, where the success rate is ~53% for Nflex<15 and ~65% 
for Nflex<10 (Figure 4.1d). Thus, it is likely that the increased success rate on decreasing 
Nflex is also a result of conformational sampling and entropic contributions.   
Potential errors in the success rate could result from the dynamics of RNA-small 
molecule complexes(8). Often, small molecules bound to RNA are solvent-exposed and 
in some cases regions of the small molecules are not directly interacting with the RNA.  
Since it is likely that the regions of the small molecule not in contact with the RNA 
remain flexible in the bound state, which is not accurately represented in crystal or NMR 
structures, prediction of these small molecule conformations cannot be expected.  The 
variability in NMR structure determination results in an average RMSD of 1.8Å between 
different models for RNA-ligand structures in the PDB and in some cases can exhibit 
RMSDs >3Å(7). Each member of an NMR ensemble represents a solution to the 
observed NMR and the dynamics of the RNA-small molecule complex will influence the 
variability in the ensemble structures.  When considering only RNA-small molecule 
structures solved by X-ray crystallography, we calculate a dramatic increase in success 
rate, where ~65% of small molecules with Nflex<15 and ~83% with Nflex<10 are accurately 
predicted(Figure 4.1d).  This is likely a result of more accurately defined RNA and ligand 
conformations. Also, it is likely that more strongly interacting complexes will exhibit less 
dynamics in the bound state. When only considering small molecules from NMR and X-
ray structures with a Kd<1 µM, the success rates increase to ~60% for Nflex<15 and 
~70% for Nflex<10. Thus, using a static representation of an otherwise flexible system 
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precludes accurate prediction of the bound state small molecule conformation.  
However, the flexibility of the bound state could explain why the docking scores correlate 
with ΔGexp while the correct small molecule binding conformation is not always predicted.  
 
 
Table 4.1. Small molecule-bound RNA structures used to validate ICM. A (**) 
indicates that the structure was used to correlate docking scores with  ΔGexp. 











rosamine 2.80 1 0.98 -42.89 ** 
1F27 Biotin aptamer Biotin 1.30 5 1.77 -14.91 ** 
1I9V tRNA Neomycin 2.60 17 11.30 -30.15  
1J7T rRNA A-site Paromomycin 2.50 17 3.16 -27.62 ** 
1LC4 rRNA A-site Tobramycin 2.54 11 2.76 -16.69 ** 
1MWL rRNA A-site Genticin 2.40 12 10.95 -21.10 ** 
1NTA 
Streptromycin 
aptamer Streptomycin 2.90 16 4.43 -5.15  
1NTB 
Streptromycin 
aptamer Streptomycin 2.90 16 2.05 -29.21  
1O9M rRNA A-site Antibiotic 2.40 23 6.77 -6.05 ** 
1U8D Guanine riboswitch Hypoxanthine 1.95 0 0.16 -29.98 ** 
1Y26 Adenine riboswitch Adenine 2.10 0 2.41 -36.56 ** 
1Y27 Guanine riboswitch Hypoxanthine 2.40 0 0.20 -53.38 ** 
1YRJ rRNA A-site Apramycin 2.70 12 9.04 -26.12 ** 
1ZZ5 rRNA A-site 
Restricted 
neomycin 3.00 10 4.64 -25.02 ** 





purine 2.15 0 0.19 -50.50 ** 
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2BE0 rRNA A-site JS5 2.63 22 11.01 -25.07  
2BEE rRNA A-site JS4 2.60 23 13.70 -30.97  
2CKY TPP riboswitch TPP 2.90 8 2.66 -24.44  
2EES 
Guanine riboswitch 
Mutant Hypoxanthine 1.75 0 0.12 -32.35 ** 
2EET 
Guanine riboswitch 
Mutant Hypoxanthine 1.95 0 0.20 -33.02 ** 
2EEU 
Guanine riboswitch 
Mutant Hypoxanthine 1.95 0 0.16 -23.91 ** 
2EEV 
Guanine riboswitch 
Mutant Hypoxanthine 1.95 0 0.18 -27.26 ** 
2EEW 
Guanine riboswitch 
Mutant Hypoxanthine 2.25 0 0.30 -27.57 ** 
2ESI rRNA A-site Kanamycin A 3.00 13 6.36 -15.29 ** 
2ESJ rRNA A-site Lividomycin A 2.20 22 9.98 -29.56 ** 
2ET3 rRNA A-site Gentamicin C1A 2.80 9 0.33 -18.56 ** 
2ET4 rRNA A-site Neomycin B 2.40 16 7.31 -26.71 ** 
2ET5 rRNA A-site Ribostamycin 2.20 12 10.61 -18.48 ** 
2ET8 rRNA A-site Neamine 2.50 7 11.23 -16.79 ** 
2F4S rRNA A-site Neamine 2.80 7 11.85 -17.26 ** 
2F4T rRNA A-site Antibiotic 3.00 6 2.35 -26.99 ** 
2F4U rRNA A-site Antibiotic 2.60 19 10.04 -19.67 ** 
2FCX DIS Neamine 2.00 7 1.37 -19.00 ** 
2FCY DIS Neomycin B 2.20 16 8.54 -32.40 ** 
2FCZ DIS Ribostamycin 2.01 12 1.70 -21.29 ** 
2FD0 DIS Lividomycin A 1.80 22 8.23 -17.59 ** 
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2G5K rRNA A-site Apramycin 2.80 12 7.03 -15.32 ** 
2G5Q rRNA A-site Amikacin 2.70 19 13.30 -14.39  
2G9C Purine riboswitch 
2,4,6-
Triaminopyrimidi
ne 1.70 0 0.22 -49.44 ** 
2GDI TPP riboswitch TPP 2.05 8 1.92 -15.84  
2GIS SAM riboswitch 
 S-
adenosylmethion
ine 2.90 10 1.24 -40.69 ** 
2HOJ TPP riboswitch TPP 2.50 8 1.52 -25.45  
2HOK TPP riboswitch TPP 3.20 8 1.76 -41.78  
2HOL TPP riboswitch TPP 2.90 8 1.79 -26.79  
2HOM TPP riboswitch TMP 2.89 6 1.61 -14.90  
2HOO TPP riboswitch Benfotiamine 3.00 11 5.04 -39.90  
2HOP TPP riboswitch Pyrithiamine 3.30 5 5.78 -19.60 ** 
2NZ4 GlmS ribozyme GL6P 2.50 7 2.52 -0.98  
2O3V rRNA A-site 
Paromamine 
derivative 2.80 15 8.94 -19.03  
2O3W rRNA A-site Paromomycin 2.80 17 9.60 -23.99  
2O3X rRNA A-site 
Paromamine 
derivative 2.90 12 8.69 -20.18  
2OE5 RNA fragment Apramycin 1.51 12 3.56 -27.58 ** 
2OE8 RNA fragment Apramycin 1.80 12 4.64 -25.02 ** 
2PWT rRNA A-site 
LHABA 
aminoglycoside 1.80 28 9.82 -13.53 ** 
2QWY SAM II riboswitch 
 S-
adenosylmethion
ine 2.80 10 0.87 -32.96 ** 
3C44 DIS Paromomycin 2.00 18 8.80 -39.84  
3D0U Lysine riboswtich Lysine 2.80 7 1.30 -34.17  
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3D2G TPP riboswitch TPP 2.25 8 2.14 -16.22  
3D2V TPP riboswitch 
Pyrithiamine 
Pyrophosphate 2.00 8 4.30 -27.38  
3D2X TPP riboswitch 
Oxythiamine 
Pyrophosphate 2.50 8 2.60 3.10  
3DIG Lysine riboswtich 
S-(2-
aminoethyl)-L-
cystine 2.80 7 1.00 -55.72  
3DIL Lysine riboswtich Lysine 1.90 7 1.30 -48.54  
3DIM Lysine riboswtich Lysine 2.90 7 1.40 -41.29  
3DIO Lysine riboswtich Lysine 2.40 7 1.30 -48.03  
3DIQ Lysine riboswtich Homoarginine 2.70 7 0.80 -51.31  
3DIR Lysine riboswtich 
N6-1-iminoethyl-
L-Lysine 2.90 7 1.60 -34.81  
3DIX Lysine riboswtich Lysine 2.90 7 1.30 -53.32  
3DIY Lysine riboswtich Lysine 2.71 7 1.30 -46.84  
3DIZ Lysine riboswtich Lysine 2.85 7 1.40 -54.19  
3DJ0 Lysine riboswtich L-4-oxalysine 2.50 7 0.80 -43.80  
3DJ2 Lysine riboswtich Lysine 2.50 7 1.70 -45.62  
3DVV DIS 
Ribostamycin(U
267OMe) 2.00 12 2.30 -24.99  
3E5C SAM III riboswitch 
 S-
adenosylmethion
ine 2.25 10 3.00 -33.92 ** 
3E5E SAM III riboswitch 
 S-
adenosylmethion
ine 2.90 10 8.00 -27.25  
3E5F SAM III riboswitch 
 S-
adenosylmethion
ine 2.70 10 5.30 -25.48  
1FUF Mismatched Duplex Spermine 1.70 13 0.96 -39.95  
1YKV Ribozyme 
N-
pentylmaleamide 3.30 6 0.67 -17.98  
 121 
1XPF DIS Spermine 2.30 13 7.91 -25.46  
2TOB Aptamer Tobramycin NA 11 0.70 -42.85 ** 
1TOB Aptamer Tobramycin NA 11 1.36 -26.23 ** 
1BYJ rRNA A-site Gentamicin C1A NA 13 1.44 -30.75 ** 
1UTS TAR Rbt550 NA 8 9.03 -25.62  
1Q8N Aptamer 
Malachite green 
A NA 1 7.52 -27.92 ** 
2AU4 Aptamer GTP NA 11 4.35 -19.93 ** 
1LVJ TAR Acetylpromazine NA 4 6.83 -12.16 ** 
1NEM Aptamer Neomycin B NA 17 0.54 -33.17 ** 
1PBR rRNA A-site Paromomycin NA 22 0.74 -26.11 ** 
1EHT Aptamer Theophylline NA 0 3.53 -28.71 ** 
1O15 Aptamer Theophylline NA 0 3.30 -20.65 ** 
1FMN Aptamer 
Flavin 
Mononucleotide NA 11 2.61 -53.56 ** 
1EI2 Tau exon 10 Neomycin NA 16 6.97 -18.06  
1UUD TAR Rbt203 NA 10 2.81 -45.79  
1AM0 Aptamer AMP NA 7 3.63 -47.76  
1QD3 TAR Neomycin B NA 22 13.38 -25.39 ** 
1FYP rRNA A-site Paromomycin NA 22 1.31 -38.03 ** 
1KOC Aptamer Arginineamide NA 8 9.74 -21.70 ** 
1KOD Aptamer Citrulline NA 6 10.28 -26.09 ** 
1AJU HIV-2 TAR Arginineamide NA 8 2.74 -25.26  
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1RAW Aptamer AMP NA 7 12.78 -7.04 ** 
1UUI TAR Rbt158 NA 6 8.89 -22.26  
1NBK Aptamer Arginineamide NA 8 2.38 -22.98  
3C3Z DIS Duplex Ribostamycin NA 12 -21.81 14.39  
3C7R DIS Duplex Lividomycin A NA 22 -0.1829 0.8  
3C5D DIS Duplex Neomycin B NA 16 -28.69 8.59  





Neomycin B NA 22 -30.15 11.2  
 
4.4 Docking to the TAR SAS Ensemble Recapitulates ΔGexp 
 Results from the validation simulations suggest that ICM can be used to 
accurately calculate a score that correlates with ΔGexp provided that the bound-state 
RNA conformation is known. Structures in the SAS-generated TAR ensemble were 
shown to recapitulate the experimental RDCs and closely resemble previously 
determined ligand-bound TAR conformations, suggesting that the bound-state TAR 
conformations are present in the absence of ligand (see Chapter 2). Thus, using the 20 
SAS ensemble TAR structures as docking receptors should afford docking scores that 
re-capitulate ΔGexp for known TAR-binding small molecules. To test this hypothesis, 
known 33 TAR-binding small molecules with reported Kds and Nflex<15 were docked 
against the SAS ensemble structures. Remarkably, docking scores are calculated that 
correlate with ΔGexp (R=0.69) (Figure 4.2a). In fact, the correlation coefficient is only 
slightly lower than the results of the solved RNA structure validation simulations. The 
error bars in Figure 4.2 are calculated from the average residual error in the crystal and 
NMR structural validation simulations for small molecules with Nflex<15. Within the 
 123 
residual error, only two small molecules do not agree with the best-fit line. Interestingly, 
the best-fit lines are different for the validation and SAS ensemble simulations. This 
likely arises from the increased accuracy of the crystal and NMR structures, which 
provide details of local RNA rearrangements on small molecule binding that is not 
accounted for when docking small molecules to the SAS structures.  
 
Figure 4.2. Docking known TAR binders to the SAS structures affords scores that 
correlate with ΔGexp. (a) Docking scores of 33 known TAR binders with Nflex<15 onto 
the 20 SAS ensemble structures strongly correlate with ΔGexp. Control simulations using 
(b) the apo-TAR crystal structure(9), (c) all 20 models of the apo-TAR structure solve by 
NMR(10), and (d) 20 random MD structures as docking receptors do not afford a strong 
correlation between docking score and ΔGexp. 
 
Control simulations were run using the Mg2+-bound TAR structure (PDB ID# 397D)(9) 
(Figure 4.2b), the 20 ensemble structures from the apo-TAR structure determined using 
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NMR (PDB ID# 1ANR)(10) (Figure 4.2c), and 20 random snapshots from the MD 
simulation  (Figure 4.2d). In all three cases the docking scores failed to correlate with 
ΔGexp. The crystal structure fails to generate docking scores that correlate with ΔGexp 
likely because TAR is highly dynamic and a static representation does not accurately 
represent the TAR structure. The apo-TAR structure solved by NMR and the random MD 
conformers afford an increased correlation between the docking score and ΔGexp 
compared to the apo-TAR crystal structure, but the correlation coefficient is still much 
lower than when using the SAS-generated TAR structures. These results suggest that 
the longer timescale (sub ms) and angular sensitivity of RDCs afford a more robust 
ensemble compared to NOEs (ps-ns) used to determine the apo-TAR structure by NMR, 
and force-field errors present in the random MD conformers give rise to artificial 
conformations that are filtered using the SAS approach.    
 
4.5 Virtual Screening Using TAR SAS Ensemble Structures 
 The SAS-generated TAR ensemble structures were virtually screened against 
two small molecule libraries: (i) ~60,000 small molecules used at the Center for 
Chemical Genomics (CCG) at the University of Michigan used in high-throughput  
screening assays and (ii) ~2500 small molecule library that was built in-house and 
represents published RNA-binding small molecules. The former collection includes 
various small molecules obtained from commercial suppliers such as Chembridge, 
ChemDiv, and Maybridge, and also includes collections from the National Cancer 
Institute as well as FDA approved drugs. The in-house library includes RNA-binding 
small molecule scaffolds including macrocyclic antibiotics, aminoglycosides, and various 
combinations of aromatic and charged moieties. Only small molecules with Nflex<15 were 
docked against the 20 SAS structures. Of the ~60,000 small molecules in the CCG 
library and ~2500 in the in-house library, 49,166 and 2045 small molecules have an 
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Nflex<15. Two rounds of docking were used with the initial round using less Monte-Carlo 
iterations (thoroughness=1) and the top 20% scoring small molecule re-docked with the 
maximum number of Monte-Carlo iterations (thoroughness=10). The lowest score for 
each small molecule was recorded.   
Virtual screening results from both libraries yield Gaussian distributions. The 
distribution of scores for the CCG library gives an average of -17.3 kcal/mol and a 
standard deviation of 4.17 (Figure 4.3a). Interestingly results from docking the in-house 
library yields two Gaussian distributions, one giving an average of -19.5 kcal/mol and a 
standard deviation of 5.97, and the second an average of 4.47 kcal/mol and a standard 
deviation of 5.90 (Figure 4.3b).  The latter of the two histograms calculated for the in- 
 
Figure 4.3. Minimum scores of the CCG and in-house small molecule libraries 
against the SAS ensemble structures. (a) and (b) are the histograms of the minimum 
scores for the CCG and in-house libraries for small molecules with Nflex<15, respectively. 
(c) and (d) Score distributions of small molecules with Log(P)<-1 for the CCG and in-
house libraries, respectively. 
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house library is largely comprised of the erythromycin-like ribosome-binding small 
molecules that are too large to form favorable interactions with TAR. Small molecules 
with predicted Log(P)<-1, where P is the octanol:water ratio of small molecule 
concentration in the two phases of a water-octanol mixture, also yield Gaussian 
distributions with slightly more negative average scores (Figure 4.3c-d). The significance 
of the soluble distributions will be discussed below. A “good” score is defined here as <-
20 kcal/mol. 
  Top scoring small molecules from the virtual screening simulations were 
validated to bind TAR using fluorescence polarization (FP) measurements and NMR 
chemical shift perturbations (CSPs). In the FP assay, a N-terminal-labeled-fluorescein 
Tat peptide (FTat), comprised of 9 
residues of the Tat arginine rich 
motif(11), was bound to EAU-TAR 
and displaced by small molecules. 
To confirm that a small molecule 
inhibitor binds TAR and not the 
Tat peptide, CSPs were monitored 
on titration of the small molecule 
to TAR. Initially, the Kd was 
measured for the TAR-FTat binding (40.6±11.4 nM) (Figure 4.4), which agrees with 
previous studies using similar Tat peptides(12,13). Displacement of FTat from TAR was 
tested using known TAR-binding small molecules with nM-mM dissociation constants 
(Kd)(Figure 4.5).   
Many small molecules from the CCG library can be purchased from commercial 
vendors, while most of the in-house library was derived from literature and thus could not 
be easily obtained. Only three small molecules from the in-house library were tested due  
 
Figure 4.4. FTAR-Tat Kd determined by FP. (a) 
The EAU-TAR and N-labeled-fluorescein Tat 
peptides using the FP assay. (b) Binding isotherm 
for titrating EAU-TAR onto FTat. 
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Figure 4.5. Known TAR-binding small molecules displace the FTat peptide. Three 
known TAR-binders were tested to displace FTat peptide. 
 
to commercial unavailability.  Initially we obtained the top 39 commercially available hits 
from the CCG library with scores ranging from -45.53 to -33.22 kcal/mol, and the three 
commercially available small molecules from the in-house library. These 42 small 
molecules were tested to inhibit the TAR-Tat interaction. The three aqueous-soluble 
small molecules (10 mM) from the in-house library, butirosin (score= -35.18 kcal/mol), 
netilmicin (score= -29.58 kcal/mol) and amikacin (score= -25.65 kcal/mol), inhibited 
TAR-Tat binding interaction with inhibition constants (Kis) of 12.7  µM, 11.5  µM and 13.1 
µM, respectively, and were confirmed to bind TAR by monitoring CSPs (Figure 4.6a-c). 
However, only three of the 39 small molecules from the CCG library were soluble in 
aqueous solution at 10 mM, and of these only mitoxantrone displaced FTat (Ki=1.54 µM) 
and was confirmed to interact with TAR using CSPs (Figure 4.6e). The other 36 
aqueous-insoluble small molecules were dissolved in DMSO at 10mM and serially 
diluted into aqueous buffer and failed to displace the Tat peptide. To ensure that 
suspending these 36 small molecule in DMSO followed by dilution into aqueous buffer 
did not prevent detection of small molecule binding, DMSO was titrated onto the TAR-
Tat complex up to 20% DMSO. No perturbations that indicate interference from DMSO 
were observed (data not shown). We hypothesize that the source of scoring 
inaccuracies are a result of the hydrophobic and aromatic small molecules in the CCG 
library not being amenable to binding the solvent exposed grooves of TAR. ICM uses a 
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distant dependent dielectric to simulate an aqueous environment, which is not as 
accurate as using a higher-level approximation such as the Generalized-Born, Poisson-
Boltzmann, or explicit solvent models, which could be a source of error in the ICM 
scoring function. Also, the ΔGHphob term in the ICM scoring could be over-approximated 
for RNA docking resulting in artificially low docking scores for hydrophobic small 
molecules. 
To experimentally test the hypothesis that soluble molecules will give rise to 
more accurate docking predictions, only hits with a Log(P)<-1 were considered. Out of 
the initial 49,166 small molecules with Nflex<15, only 446 have a predictedLog(P)<-1. Of 
these 446 small molecules, the top 38 commercially available hits were obtained from 
commercial vendors. Interestingly, three of these small molecules are previously known 
TAR binders kanamycin (score= -27.72 kcal/mol), ribostamycin (score= -25.37 kcal/mol), 
and tobramycin (score= -24.86 kcal/mol), which were tested by FP and shown to inhibit 
the FTAR-Tat interaction with Kis of 4.89  µM, 85.6 µM, and 2.83 µM, respectively. Of 
the remaining 35 small molecules, 32 were soluble in aqueous solution and subjected to 
the FP displacement assay. Remarkably, four small molecules inhibit the TAR-FTat 
interaction. In fact, this is the first evidence that the small molecules amiloride (score= -
23.73 kcal/mol) and 5-(N,N)-diemthyl amiloride (14) (score= -28.31 kcal/mol) bind RNA. 
In total, of the 35 water-soluble small molecules tested, seven more inhibitors were 
discovered with Kis ranging from 5.85-300 µM (Figure 4.6). The four hits other than the 
previously known TAR binders were also shown to bind TAR using CSPs (Figure 4.6e-
4.7h). Thus, only considering the CCG library, the hit rate increases from 2.6% to 25% 
when pre-filtering the docking scores according to the predicted Log(P)<-1, and overall 
the SAS ensemble affords the discovery of 11 TAR binders resulting in a 31% hit rate. 




Figure 4.6. Eight newly discovered TAR binders. FP and CSP data validate that the 
eight newly discovered small molecules (a) amikacin, (b) butirosin, (c) netilmicin, (d) 
sisomicin, (e) mitoxantrone, (f) amiloride, (g) DMA, and (h) spermine bind TAR. Each 
panel displays the C2/C6/C8 NMR spectra from titration of the small molecule (left), the 
Tat-displacement FP data (bottom right), and the docking model (top right). Atoms 
depicted by red spheres are resonances that shift >0.1 ppm. Red spheres are not shows 
for mitoxantrone, amiloride and DMA because they intercalate with TAR and cause 
perturbations throughout the entire RNA. 
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Table 4.2. Summary of FTat displacement assay results. 
Molecule Score (kcal/mol) IC50 (µM) Ki (µM) 
Neomycin1, 2 -30.49 1.3 0.492 (0.310-0.780) 
Paromomycin1, 2 -27.81 68.4 23.6 (13.9-40.3) 
Argininamide1, 2 -26.43 2260 450 (320-633) 
Mitoxantrone -45.53 1.54 0.627 (0.382-1.03) 
Tobramycin2 -24.86 8.73 2.83 (1.61-4.96) 
Sisomicin -33.04 14 5.85 (3.77-9.07) 
Netilmicin -29.58 28.7 11.5 (5.93-22.4) 
Butirosin -35.18 36.8 12.7 (8.47-19.1) 
Amikacin -25.65 43.6 13.1 (6.65-25.8) 
Kanamycin2 -27.72 48.1 4.89 (2.33-10.3) 
5-(N,N-dimethyl)-amiloride -28.31 398 137 (70.4-267) 
Ribostamycin2 -25.37 435 85.6 (59.2-124) 
Amiloride -23.73 517 128 (83.7-194) 
Spermine -29.25 2340 300 (215-418) 
 1Small molecules used to test FP assay 
 2Previously known TAR binders 
 
4.6 Docking Model Accuracy 
4.6.1 Chemical Shift Perturbations 
 While changes in chemical shift of RNA resonances can arise for many different 
reasons, such as interaction with a small molecule or a conformational change, they do 
provide a means to qualitatively validate the accuracy of the docking predicted models. 
All small molecules were titrated in the same TAR:ligand ratio except for netilmicin and 
mitoxantrone which precipitate TAR at ratios of >2:1 and >4:1, respectively. All 
C8H8/C6H6/C2H2, C5H5, C1’H1’, and NH spectra are shown at the end of this section. 
On titration with mitoxantrone, amiloride and DMA many TAR resonances become 
progressively weaker and coalesce, indicating that all three likely intercalate with TAR. 
The docking models agree with this mode of action for amiloride and DMA where the 
small molecules stack on top of the C30-G34 apical loop base-pair and insert into the 
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apical loop (Figure 4.6f-g).  However, the model for mitoxantrone only predicts stacking 
with G26 suggesting intercalation is less likely (Figure 4.6e). This could be explained by 
the larger size of mitoxantrone compared to amiloride and DMA and is a potential source 
of error in the docking predictions. Resonances that exhibit significant CSPs are not 
indicated on the structure models due to the large change in chemical for shift for many 
resonances. This highlights one disadvantage of being unable to simulate binding 
induced RNA conformational changes. CSPs are observed in many regions of TAR on 
binding the four newly discovered aminoglycosides, amikacin, butirosin, netilmicin, and 
sisomicin. The  
 
Figure 4.7. Weighted average CSPs indicate differentiating binding modes for the 
four newly discovered aminoglycosides. Examples of interesting weighted average 
CSPs for amikacin (red), butirosin (green), netilmicin (yellow), and sisomycin (blue) are 
shown. Weighted average CSPs are calculated between the saturated and free TAR. 
 
docking predictions for all four aminoglycosides indicate a helix-2 binding mode, which 
largely agrees with the helix-2 CSPs(Figure 4.6a-d). However, the CSPs in the bulge 
region and helix-1 cannot be explained by the lowest scoring binding modes. 
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Perturbations in these regions could result from >1 stoichiometry, conformational 
changes on binding, and/or incorrect docking predictions. More positive scoring poses 
are predicted to bind the bulge, loop, and the major groove of helix-1 suggesting that 
alternative small molecule conformations or >1 binding stoichiometry is possible. Some 
CSPs also agree with spermine docking model, but the small size and linearity of 
spermine affords predictions of largely buried poses, whereas it is more likely spermine 
binds the major groove similar to argininamide(15). 
Comparison of the CSPs on titration of the four newly discovered 
aminoglycosides also reveals interesting trends that in some cases can be explained by 
the docking predicted binding conformations. The difference in weighted average 
chemical shift for the endpoints of amikacin, butirosin, netilmicin, and sisomicin were 
computed. As expected, similar shifts are observed for many resonances such as the 
C6H6 resonance of U23 (Figure 4.7), which shifts downfield in both dimensions 
indicative of a looped out conformation similar to TAR binding to Mg2+(16,17).  Also, the 
C5H5 resonance of C24, the C8H8 resonance of G34, the C8H8 resonance of A22, and 
the C5H5 resonance of U40 exhibit similar CSP directions, albeit different magnitudes, 
likely indicating similar bound state conformations (Figure 4.7). Interestingly, there are 
differentiating chemical shifts between the four aminoglycosides that group together 
according to the chemically similar amikacin and butirosin, and netilmicin and sisomicin. 
Some of the perturbations can be explained by the different predicted bound-state 
conformations. For example, the C8H8, C2H2, and C1’H1’ resonances of A35 shift in 
two general directions with similar shifts for amikacin and butirosin, and netilmicin and 
sisomicin (Figure 4.7). These varying shifts for the two groups of aminoglycosides can 
be explained by the different docking-predicted TAR-aminoglycoside interactions. 
Amikacin and butirosin both have the L-haba substituent that interacts with the RNA 
backbone below A35 likely giving rise to the similar chemical shifts, whereas only 
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netilmicin interacts with the A35 nucleobase and neither netilmicin or sisomicin interact 
with the A35 backbone region. While not clearly re-capitulated in the docking models, 
other data such as the C8H8 resonance of G33, the C1’H1’ resonance of G32, the C5H5 
resonance of C30, and the C8H8 resonance of G28 indicate differential binding for 
amikacin compared to the other three aminoglycosides (Figure 4.7). While these data 
suggest that the four aminoglycosides likely stabilize alternative RNA conformations, the 
subtle differences cannot be adequately characterized with the current methodology. 












Figure 4.8. NMR spectra of TAR on titration with the eight docking-predicted hits. 
  
4.6.2 RDC Validation of the Netilmicin-TAR Docking Model 
 To quantitatively test the ability of docking to accurately predict the small 
molecule bound RNA structure, RDCs measured for TAR bound to netilmicin were 
compared to predicted RDCs based on the docked SAS ensemble structures. SVD order 
tensor analysis was performed to determine the time-averaged netilmicin-bound TAR 
conformation. Results from the order tensor analysis show that the back-calculated and 
measured RDCs closely match to within experimental uncertainty (~2 Hz) (Figure 4.9). 
Euler angles calculated from the RDC determined structure indicate that on binding 
netilmicin, TAR exhibits a β of 22.92±2.7o, an α of 51.21o, and a γ of -56.17o (Figure 4.9) 
(A description of the interhelical Euler angles can be found in section 2.3). These angles 
are in relatively close agreement with the docking predicted top-scoring SAS structure, 
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which exhibits an α of 114.9o, a β of 56.94o, and a γ of -46.19o. Interestingly, the 
interhelical generalized degree of order (GDOint) describing the interhelical dynamic 
amplitude, where 1 corresponds to complete interhelical rigidity and 0 to fully isotropic 
motions, is 0.68±0.09 indicating that TAR remains dynamic when bound to netilmicin.  
 
Figure 4.9. SVD order tensor analysis of TAR bound to netilmicin. Results from 
SVD order tensor analysis of TAR bound to netilmicin measured RDCs. Helix-1 RDCs 
are shown in blue and helix-2 in red. N is the number of RDCs included in the analysis 
for each helix, RMSD is the root mean square deviation between measured and back-
calculated RDCs, CN# is the condition number, Q is the quality factor between the 
measured and back-calculated RDCs, η describes the asymmetry of the order tensor 
(where 0 indicates a fully symmetric tensor), R is the correlation between measured and 
back-calculated RDCs after the order tensor analysis, GDO, is the generalized degree of 
order for each order tensor, GDOint describes the magnitude of interhelical motions with 
1 describing interhelical rigidity and 0 fully isotropic motions, and αo, βo, and γo are the 
interhelical Euler angles. Full descriptions of these parameters can be found in 
reference(18). 
 
To further probe the accuracy of netilmicin-bound TAR model, RDCs were 
predicted based on the SAS structure structures docked to netilmicin and compared to 
experimental values. A previous study by Al-Hashimi H. M. and co-workers showed that 
on average all RNA structures in the PDB exhibit A-form helices(19), thus A-form helices 
were used in place of the SAS ensemble helices. Since the experimentally determined 
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principal axis of the order tensor (Szz) for TAR bound to netilmicin is greater for helix-2 
(1.75x10-3) compared to helix-1 (1.20x10-3), we assumed that helix-2 aligned collinear 
with the z-axis and all 20 SAS structures were superimposed onto the experimentally 
determined helix-2 principal axis system (PAS). Next, A-form helices comprising 
residues 17-22 and 40-45 
(Figure 4.10) were 
superimposed onto helix-1 of 
the SAS structures. The 
resulting structure for each SAS 
snapshot consisted of an 
idealized A-form helix-1 and 
helix-2, and the trinucleotide 
bulge and apical loop from the 
SAS structures. These 
structures were then used to calculate theoretical RDCs. Since TAR remains dynamic 
when bound to netilmicin, RDCs calculated for each SAS structure were weighted using 
a partition function. The netilmicin-bound docking score for each SAS structure was 
converted into a ΔG using the best-fit line equation from the Nflex<15 crystal and NMR 
structure validation data. These free energies were then used to calculate a probability 
(P) using a partition function, 
 
.                         [4.5] 
 
 
Figure 4.10. Normalized resonance intensities 
for TAR bound to netilmicin. 
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P was used to weight contribution from each SAS structure to the predicted RDCs. 
RDCs for atoms that exhibit large normalized intensities (>0.15) were eliminated from 
comparison to experimental RDCs because these nuclei likely exhibit fast local motions 
that cannot be accurately determined in this analysis (Figure 4.10).  Since apical loop 
RDCs were not used in the  
 
Figure 4.11. Netilmicin-bound SAS structures predict experimental RDCs. (a) The 
experimental RDCs are plotted against the back-calculated RDCs that are partition 
weighted according to the docking score for each structure. Helix-1 RDCs are shown in 
blue, helix-2 RDCs in red, bulge RDCs in orange, and apical loop RDCs in green. RDCs 
that were excluded based on high resonance intensity are shown as open circles. (b) 
RMSDs for each SAS structure generally increase as the docking score becomes more 
positive and all are significantly larger than the partition weighted (PW) RMSDs. 
 
generation of the SAS ensemble, only atoms for residues that contact the small 
molecule should be stabilized on binding netilmicin and were used in the predictions. 
Remarkably, the resulting theoretical and experimental RDCs exhibit an RMSD of 5.55 
Hz (Figure 4.11a). Although the trend is not uniform, increasing RMSDs are calculated 
for poorer scoring snapshots, and the lowest RMSD is calculated for the partition 
weighted RDCs from all 20 structures (Figure 4.11b). These data suggest that docking 
against the 20 SAS structures affords an accurate prediction of the experimental RDCs 
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that cannot be accounted for by one structure. This is consistent with TAR being flexible 
in the netilmicin-bound state.  
 
4.7 Netilmicin Inhibits HIV-1 Replication 
Results from the FP assay indicate that netilmicin binds TAR and inhibits binding 
of the Tat peptide. To determine if netilmicin inhibits the TAR-Tat interaction in a more 
biological setting, we tested the ability to inhibit Tat-mediated activation of the HIV-1 LTR 
using a luciferase reporter assay. Mammalian cells were transiently transfected with an 
HIV-1 LTR luciferase reporter, a reporter plasmid for normalization of transfection 
efficiency (Renilla luciferase), and either an expression vector expressing HIV-1 Tat 
(Tat101) or the vector alone (Tat0). The LTR contains the same TAR sequence used in 
the NMR, FP, and computational studies. The cells were then incubated with netilmicin 
or PBS and then harvested for measuring luciferase activity. As can be seen in Figure 
4.12a, addition of 100 µM netilmicin inhibits the Tat-mediated activation of the HIV-1 
promoter by ~71% when compared to the PBS-treated control. Addition of phorbol 12-
myristate 13-acetate (PMA) to the cells can activate the HIV-1 LTR in the absence of 
Tat. Since this activation is also independent of TAR, we would expect no inhibition of 
PMA-mediated HIV-1 LTR activation by netilmicin, and this was indeed the case. Mock 
treatments of cells not containing the LTR or Tat expression vector with netilmicin further 
ensures that netilmicin decreases luciferase expression by binding TAR.  
Having shown that netilmicin inhibits Tat-mediated activation of the HIV-1 LTR in 
reporter gene assays, we next asked whether this would translate into inhibition of HIV-1 
replication by netilmicin. Sisomicin, which differs from netilmicin by an ethylene group, 
was also tested in these experiments (Figure 4.12b). An HIV-1 indicator cell line, TZM-bl, 
was used in this experiment. The cells contain the luciferase and β-galactosidase genes 
under the control of the HIV-1 promoter, as well as the HIV-1 receptors CD4, CXCR4, 
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and CCR5. Thus, when they are 
infected with HIV, the replication 
genes are activated, allowing for 
assessment of HIV-1 infection by 
measuring reporter gene 
expression. The virus used was 
the HIV-1 isolate NL4-3 virus 
containing the same TAR 
sequence used NMR, FP, and 
computational studies. When 
netilmicin was added to the cells 
prior to infection, we observed 
decreased HIV-1 LTR activation, 
demonstrating a decrease in 
infection (Figure 4.12b). Using 
non-linear regression, we 
calculated the IC50 value of 
netilmicin to be 23.1 µM, which is nearly identical to the value measured using the Tat 
displacement assay. The IC50 value for sisomicin (157 µM) is approximately 100X 
greater than the value measured in the FP assay. These results corroborate the results 
of the transient transfection experiment and show that netilmicin can inhibit HIV-1 
replication. Therefore, netilmicin, a compound selected through the use of NMR and 
computational modeling, can block TAR-Tat interaction in vitro, specifically inhibit Tat-




Figure 4.12. Netilmicin inhibits Tat mediated 
HIV-1 transcription and HIV-1 replication.  (a) 
Netilmicin reduces HIV-1 LTR-controlled luciferase 
expression. Tat101 indicates a cell line transfected 
with a Tat expression vector, Tat0 cells contain 
the LTR but no Tat expression vector, PMA 
indicates Tat-independent activation of the LTR, 
and Mock indicates cells were not transfected but 
were treated with (b) Netilmicin and sisomicin 





 Computational docking provides the ability to rapidly screen small molecules 
against an RNA provided the structure is known a-priori. Validation of docking to 
accurately predict  ΔGexp is shown here to depend on the accuracy of the RNA structure 
and the conformational flexibility of the small molecule. When the structure of the RNA-
small molecule complex is well characterized using X-ray crystallography or NMR, ICM 
can be used to accurately calculate docking scores that correlate strongly with the ΔGexp. 
Also, the small molecule conformation is more accurately predicted for less flexible small 
molecules, X-ray structures, and small molecules with tight binding affinities likely due to 
less flexibility in the bound-state. The ability to use the SAS ensemble structures as 
docking receptors was investigated by docking 33 known TAR-binding small molecules 
with Nflex<15 and reported ΔGexp. Remarkably, ICM is able to predict docking scores that 
correlate strongly with ΔGexp (R=0.69). Virtually screening ~60,000 small molecules from 
the CCG and ~2500 from an in-house RNA-binding small molecule library resulted in the 
identification of 11 TAR binding small molecules that inhibited the TAR-Tat interaction 
with Kis ranging from 5.85-300 µM, resulting in a 31% hit rate. The eight small molecules 
were confirmed to bind TAR using NMR CSPs. The CSPs strongly suggest that 
mitoxantrone, amiloride, and DMA intercalate with TAR, and all four aminoglycosides 
exhibit similar helix-2 binding profiles.  Support for the docking predicted models of the 
eight newly discovered TAR-binders is reinforced by the CSP data, however there are 
outlying data that suggest higher stoichiomety binding or alternative binding 
conformations, which could be due to the inaccuracy of the SAS and docking methods. 
These potential errors may be alleviated with more input NMR data. Validation that the 
SAS ensemble predicts the correct netilmicin-bound TAR conformation suggests that the 
SAS ensemble is able to capture dynamical features of TAR that afford accurate docking 
 144 
predictions and together recapitulate the experimental RDC data. Overall, the SAS 
ensembles can be used to generate RNA conformational ensembles that are beneficial 
as a pre-processing docking method and provides more accurate predictions of small 
molecule docking scores, efficient identification of lead compounds, and reliably predict 
experimental small molecule-bound RNA structures. 
 
The idea was conceived by Al-Hashimi H. M. and Stelzer A. C. Stelzer A. C. and Kratz J. K. synthesized RNA 
oligonucleotides and collected and analyzed NMR and FP data. Docking simulations were conducted and analyzed by 
Stelzer A. C. The in-cell experiments were conducted in the Markovitz D. laboratory by Gonzalez-Hernandez M. (gene 
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5.1 Conclusion  
 The role of RNA dynamics in biological processes has been extensively studied 
over the past few decades(1, 2).  Recent discoveries continue to highlight the need to 
extensively characterize the change in global and local RNA conformation on recognition 
of an effector molecule(1, 2). The realization that RNA exhibits complex tertiary 
structure, allosterically mediates biological processes, and can be targeted by small 
molecules birthed the field of RNA-targeted drug discovery. However, specifically 
targeting cellular RNA molecules has been largely unsuccessful. While some of the 
classic principles learned from protein-targeted drug-discovery can be applied when 
binding RNAs, many are not suited to tackle their highly dynamic nature. A complete 
description of the biophysical principles governing the large global and local 
conformational changes that take place between the unbound and ligand-bound state(s), 
would greatly increase our understanding of RNA-mediated recognition processes and 
advance the field of RNA-targeted drug discovery.   
While no technique can probe the vast range of timescales and large amplitude 
motions necessary to fully characterize RNA motions, employing a combination of 
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experimental (i.e. NMR) and theoretical (i.e. Molecular Dynamics) techniques can 
overcome the shortages of information garnered from each technique and afford the 
necessary temporal and spatial accuracy. The RDC SAS approach is a large step 
forward in this regard. However, SAS currently remains limited by (i) NMR data density 
(ii) RDC timescale sensitivity (<ms). A recent theoretical study by Al-Hashimi H. M. and 
co-workers shows that all 25 elements of the Wigner matrix, which fully describes the 
order-tensor, and in this case RNA helix, orientation and dynamics, can be obtained with 
five independent sets of RDCs(3). However, we are currently limited to two, obtained by 
elongating either helix of a helix-bulge-helix RNA. To obtain all 25 Wigner matrix 
elements, alternative RNA alignment frames need to be designed. Using the RDC data 
from five linearly independent RDC sets with the SAS method would afford more 
accurate refinement of the MD trajectory. Incorporation of NOEs and RCSAs into the 
SAS methodology will also aid in a higher-definition ensemble. New developments by Al-
Hashimi H. M. and co-workers show that lowly populated (~1%) nucleic acid 
conformations can be characterized using NMR relaxation dispersion measurements(4). 
While these methods do not give angular description of bond vectors like RDCs, they 
can be used to bias MD simulations toward RNA ensembles that agree with 
experimental data. Incorporation of these data will entail using novel MD methods (e.g. 
Replica Exchange, steered MD, and variable temperature MD) to theoretically generate 
these lowly populated species.  
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NMR Study of an Immunomodulatory Benzodiazepine Binding to its Molecular 




Bz-423 is a 1,4-benzodiazepine that potently suppresses disease in autoimmune 
mice by selectively killing pathogenic lymphocytes(1,2).  Affinity-based screening of a 
phage-display human cDNA expression library identified the oligomycin-sensitivity 
conferring protein (OSCP), a component of the mitochondrial F1F0-ATPase, as the 
molecular target of Bz-423(3).  Binding of Bz-423 to the OSCP in the context of intact 
enzyme inhibits both synthesis and hydrolysis of ATP(4).  Consistent with inhibition of 
the F1F0-ATPase, Bz-423 increases the generation of superoxide from the mitochondrial 
respiratory chain and this reactive oxygen species is the signal initiating apoptosis (as 
opposed to changes in ATP concentration)(5,6). 
The OSCP is a 213 amino-acid long protein (including the 23 amino acid 
mitochondrial leader sequence) that is conserved among mammals and is not present in 
other ATPases(7).  The OSCP along with subunits b, d, and F6 form the peripheral stalk 
in mammalian F1F0-ATPases(8). The stalk links the integral membrane F0 component of 
the enzyme with its soluble catalytic F1 domain, which is located in the mitochondrial 
matrix. The peripheral stalk is believed to act as a stator, holding the F1 α3β3 hexamer 
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static while the central stalk (γδεc10) rotates(9,10).  In order to function properly, the stalk 
subunits must act in concert with one another; while the peripheral stalk subunits do not 
need to move in relation to one another during catalysis, disrupting the connections 
between the subunits disrupts coupling between F0 and F1(11).  In addition, the stalk 
must be anchored at each end for proper function:  the transmembrane domain of 
subunit b holds the stalk in the mitochondrial membrane, while the N-terminal end of the 
OSCP sits on top of the α3β3 hexamer with the C-terminus protruding almost 100 Å 
along the surface of F1 towards F0(12).  The N-terminal tails of the α-subunits are critical 
for binding to OSCP(13).   
The structure of a 134-amino acid long N-terminal fragment of the δ-subunit from 
E. coli, the equivalent of the bovine OSCP, has been studied by NMR spectroscopy(14).  
The protein adopts a 6-helix bundle with a disordered C-terminus.  NMR studies using 
the N-terminal domain of the bovine OSCP (OSCP-NT, residues 1–120) reveals a 
similar fold(15,16).  Binding experiments with peptide fragments from the N-termini of F1 
α-subunits suggests that the interaction site on OSCP-NT comprises a hydrophobic 
groove between helices I and V.  Hence, this interface, which is essential for the rotary 
mechanism of the enzyme, probably consists of helix–helix interactions.   
Since Bz-423 does not bind at the active site of enzyme, we hypothesized that it 
may bind at, or near the F1-OSCP interface where it can perturb one or more of the 
conformational transitions associated with the rotary (binding-change) mechanism of 
catalysis(4).  To gain support for this hypothesis, we studied the binding of water soluble 
Bz-423 analogs (Figure 1) with OSCP-NT and a construct representing amino acids 1-
145 by NMR spectroscopy using chemical shift perturbation and cross-relaxation 
experiments to localize the binding site.  Our data identified a recognition site near the 
F1-OSCP interface and a conformational change in the protein upon drug binding.  
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Collectively, these data suggest that Bz-423 like inhibitors may function in an allosteric 
manner inducing a conformational change that hinders catalysis.   
 
 
Figure 1.  Chemical structure of (a) Bz-423 and the molecules used in this study: (b) 5-
(3-(aminomethyl)phenyl)-7-chloro-1-methyl-3-(naphthalen-2-ylmethyl)-1H-
benzo[e][1,4]diazepin-2(3H)-one (1) and (c) (aminomethyl)phenyl)-7-chloro-1-methyl-1H-
benzo[e][1,4]diazepin-2(3H)-one (2). Protons of 1 that were saturated in cross-relaxation 
experiments are labeled. Based on prior structure-reactivity studies as a guide, 1 was 
designed to replace the critical phenolic proton with an ammoninum group to enhance 
aqueous solubility.  The activity of 1 in enzyme and cellular assays is comparable.   
Removing the naphthyl group in 2 abolishes all activity against the enzyme. 
 
A1.2 Materials and Methods 
A1.2.1 Synthesis of Benzodiazepines 
Benzodiazepines 1 and 2 were synthesized and characterized as previously 
described(15).  Samples of both compounds used in the NMR titration experiments were 
>98% pure.   
 
A1.2.2 OSCP Isolation 
A 360-base-pair long insert encoding a truncated bovine OSCP, containing 
amino acids 1-120, was prepared via PCR using forward 
(5’CACCATGTTTGCCAAGCTTGTGAGGCC3’) and reverse 
(5’CTAAACTGTGCATGGTACTTCTCC3’) oligonucleotide primers (25 µM each) in the 
presence of dNTPs (0.5 mM), pOSCP (1 ng), PFU Turbo DNA polymerase (3-5 U; 
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Stratagene, La Jolla, CA), and 1X PFU Turbo DNA polymerase buffer.  PCR conditions 
consisted of 30 s at 94 oC, 30 s annealing at 55 oC, and a 1 min extension at 72 oC for 31 
cycles(17)  A 435-base-pair long insert encoding a truncated bovine OSCP containing 
amino acids 1-145 was prepared in a similar manner using the same forward 
oligonucleotide primer as above together with a reverse 
(5’CTGGCCTTTACTTAGGAAGCTCTTCAGG3’) oligonucleotide primer.  The PCR 
products were purified using a Qiagen (Valencia, CA) PCR Clean Up kit following the 
manufacturer’s instructions.  Both inserts were cloned into expression vectors provided 
in the TOPO 10 kit following the manufacture’s instructions (Invitrogen, Carlsbad, CA). 
The OSCP 1-120 insert was ligated into pCRT7/NT-TOPO which contains both an 
ExpressTM Epitope coding sequence and a hexa-his tag, placing the OSCP 1-120 coding 
region C-terminal to these sequences.   The OSCP 1-145 insert was ligated into 
pCRT7/CT-TOPO, which contains both a V5 Epitope coding sequence and a hexa-his 
tag, placing the OSCP 1-145 coding region N-terminal to these sequences.  Thus, 
OSCP120 contains an N-terminal hexa-his tag connected by the linker sequence 
GMASMTGGQQMGRDLYDDDDKDPTL, while the OSCP145 construct contains a C-
terminal hexa-his tag connected by the linker sequence 
KGNSKLEGKPIPNPLLGLDSTRTG. Primary structures for all OSCP constructs are 
shown in Figure A1.2.  Ligation products were transformed into TOP-10 cells and 
selected on LB-ampicillin (50 µg/mL) plates.  Colonies were screened for inserts via 
PCR using mini-prep plasmid DNA and both the forward and reverse T7 primers.  The 
presence of the correct inserts was confirmed by automated DNA sequencing 
(Sequencing Core Facility, University of Michigan, Ann Arbor, MI). 
 
NT-OSCP120   





51         60           70          80          90          100 
GRYATALYSAASKQNKLEQVEKELLRVGQILKEPKMAASLLNPYVKRSVK  
 




1          10          20          30          40          50 
FAKLVRPPVQIYGIEGRYATALYSAASKQNKLEQVEKELLRVGQILKEPK     
 
51         60          70           80         90          100 
MAASLLNPYVKRSVKVKSLSDMTAKEKFSPLTSNLINLLAENGRLTNTPA        
 
101        110         120         130        140          150 
VISAFSTMMSVHRGEVPCTVTTASALDETTLTELKTVLKSFLSKGQKGNS 
 
151       160         170            
KLEGKPIPNPLLGLDSTRTGHHHHHH 
 
OSCP190   
1                   10                   20                    30                   40                   50 
FAKLVRPPVQIYGIEGRYATALYSAASKQNKLEQVEKELLRVGQILKEPK        
 
51                  60                   70                     80                 90                    100 
MAASLLNPYVKRSVKVKSLSDMTAKEKFSPLTSNLINLLAENGRLTNTPA               
 
101               110                  120                130                140                 150 
VISAFSTMMSVHRGEVPCTVTTASALDETTLTELKTVLKSFLSKGQVLKL       
 
151              160                 170                 180                 190 
EVKIDPSIMGGMIVRIGEKYVDMSAKTKIQKLSRAMREIL 
 
Figure A1.2. Sequences of OSCP120, OSCP145, and OSCP190. Hexa-his tag and 
linker sequences are shown in blue. 
 
 OSCP constructs pCRT7/NT- OSCP120 and pCRT7/CT-OSCP145 were 
transformed into One Shot BL21(DE3)pLysS (Invitrogen, Carlsbad, CA) using the 
manufacturer’s procedure.   Individual colonies were picked immediately to inoculate 1-
10 mL LB overnight cultures supplemented with ampicillin (200 µg/mL).   Cultures were 
incubated at 37 oC with rotary shaking at 250 RPM.   One-liter cultures containing either 
Spectra 9-N (>98% 15N), Spectra 9-CN (>98% 15N, >98% 13C, or Spectra 9-dCN (>97% 
D2O, >98% 15N, >98% 13C) media (Spectra Stable Isotopes, Columbia, MD), were 
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supplemented with ampicillin (200 µg/mL) and inoculated with the overnight culture.  
Cultures were grown at 37 oC with rotary shaking at 250 RPM until A595 reached 0.6-1 
(Spectra 9-dCN required double the growth time compared to the other media) at which 
point cultures were removed to 4 oC while the rotary shaker temperature was brought 
down to 20 oC using a heat exchanger over a period of 1 h.  IPTG was added to a final 
concentration of 0.02 mM.  Growth and expression continued for 20 h at 20 oC.  Cell 
pastes were harvested via centrifugation in a Beckman JLA8.1 at 6,000 X g for 10 min at 
4 oC.  Cell pastes were re-suspended in ice-cold Nickel NTA buffer (25 mL; 50 mM Tris-
HCl pH 8, 300 mM NaCl, 0.001% phenylmethanesulfonyl fluoride, and Roche Complete 
protease inhibitors w/o EDTA as per manufacturers instruction).  The suspension was 
transferred to a 50 mL Falcon tube on ice and stored at -80 oC. 
Cell paste was thawed at room temperature and placed immediately on ice.  The 
suspension was transferred to a 50 mL beaker on ice and sonicated using the standard 
horn (set at output = 8.5) for 6 20-s long intervals between which was a 2-min long rest 
on ice to dissipate heat.  After sonication, the mixture was transferred to two Beckman 
JA35.5 centrifuge tubes and centrifuged at 21,000 RPM at 4 oC for 45 min.  The soluble 
extract was loaded (0.5 mL/min) onto a Ni-NTA affinity column (1 cm diameter X 5 cm 
long) equilibrated in Nickel NTA Buffer at 4 oC.  The column was washed with Nickel 
NTA Buffer-25 mM imidazole (25 mL) and protein was eluted with Nickel NTA Buffer-250 
mM imidazole (25 mL).  Fractions of about 1 mL were collected and those from fractions 
3-14 were direct placed into snakeskin dialysis tubing (7,000 MWCO, Pierce, Rockville 
IL) immersed in of OSCP Buffer (4 L; 50 mM Tris-Cl pH 8, 30 mM NaCl, 1 mM EDTA, 5 
mM β-mercaptoethanol).  Complete Protease inhibitors (with or without EDTA) were 
added following the manufacturer’s instructions, directly to the fractions in the dialysis 
bag.  Following overnight dialysis at 4 oC with stirring, the dialysate was cleared by 
centrifugation using a Beckman JA 25.5 rotor for 20 min at 21,000 RPM and 4 oC.  The 
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clarified extract was loaded into a ÄKTA prime super loop (50 mL) at 4 oC and injected at 
1.3 mL/min onto a 5 mL HiTrap SpHP column (Pharmacia) equilibrated in at least 5 
volumes of modified OSCP Buffer (50 mM Tris-Cl pH 8, 30 mM NaCl, 1 mM EDTA, 
0.001% phenylmethanesulfonyl fluoride, Roche Complete protease inhibitors w/o EDTA, 
5 mM β-mercaptoethanol; MOB) at 4 oC.  The column was washed with two bed volumes 
of the same buffer and then eluted with a 75 mL linear gradient (MOB and MOB + 500 
mM NaCl) at 1 mL/min while collecting 1 mL fractions.  OSCP 120NT eluted in a sharp 
band centered around 250 mM NaCl while OSCP 145CT eluted in a similar manner at 
280 mM NaCl. 
A1.2.4 NMR Spectroscopy 
All NMR experiments were performed at 25 °C unless indicated otherwise using 
an Avance Bruker 600 MHz spectrometer equipped with a 5 mm triple-resonance 
cryogenic probe. NMR spectra were processed and analyzed using NMRPipe and 
SPARKY 3(18,19) The NMR buffer consisted of 90/10% H2O/D2O containing 50 mM 
Tris, 5 mM KCl, 5 mM β-mercaptoethanol, 0.001% PMSF and protease inhibitor cocktail 
at pH ~7. For cross-relaxation experiments, a 2H/15N labeled OSCP120 (0.3 mM) sample 
was used in an NMR buffer consisting of 90/10% D2O/H2O containing deuterated TRIS 
(50 mM) and deuterated β-mercaptoethanol (5 mM) at pH ~7 without PMSF and 
protease inhibitor cocktail to minimize spectral overlap with 1. 93% of the OSCP120 
backbone amides could be assigned based on a previous NMR study (BMRB entry 
6564) (Figure A1.3).(20)  The OSCP120 resonances in OSCP145 were assigned by 
overlaying spectra and using standard triple resonance experiments on a doubly labeled 
(13C/15N) OSCP145 sample (0.5 mM).  
Two-dimensional 1H-15N HSQC spectra of 15N labeled OSCP were recorded 
following incremental addition of 1 from a stock solution (20 mM) in NMR buffer for 
 
 156 
protein:ligand ratios of 1:1, 1:2, 1:4, and 1:8. Weighted average chemical shift 
perturbations were calculated using,  
 
,                                                                
[A1.1] 
 
where δH and δN are the proton and nitrogen amide chemical shift values in ppm. 
Weighted average chemical shifts >0.01 ppm were considered significant.  
Cross-relaxation experiments were performed at 14 oC to improve cross-
relaxation efficiency by modifying a 2D 1H-15N HSQC experiment from the Bruker pulse 
program library (hsqcfpf3gpphwg)(21). A 1.8 s adiabatic Wurst pulse was applied 




Figure A1.3. Spectrum of free OSCP120 with resonance assignments taken from the 
Biological Magnetic Resonance Databank (BMRB Entry 6564). A (*) indicates a 
resonance resulting from the hexa-his tag linker sequence.  
 
delay of 1.4 s for saturating one of three different ligand proton resonances (protons 7, 
10, and 24 see Figure 1) with a total saturation bandwidth of ~30 Hz(22). An additional 
reference experiment was also recorded with off-resonance (-50 ppm) saturation. Each 
experiment required ~23 h of acquisition time. Peak intensity errors were calculated 
using NMRPipe and ranged between 4-19%(18,19). Cross-relaxation intensity ratios 
were calculated by taking the ratio of peak intensities measured with on-resonance (Isat) 
and off-resonance (Io) saturation. Only well resolved resonances with a signal:noise ratio 
>10 were analyzed. Chemical shift perturbations and cross-relaxation results were 
mapped onto OSCP structures and visualized using Pymol.(23)  
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A1.3 Bz-423 Specifically Binds to the Shoulder Region of OSCP  
In a first group of studies, we attempted chemical shift perturbation experiments 
using full-length, 15N labeled OSCP (OSCP190) (Figure A1.2).  However, the 2D HSQC 
spectra of OSCP190 were intractable due to aggregation identified by uniform reduction 
in NMR signal intensities(16,20).  We subsequently prepared two truncated constructs 
for binding measurements.  The first protein comprised residues 1-120 (OSCP120) and 
has been studied previously by NMR, and the second construct contained residues 1-
145 (OSCP145).   Titration of 1 into 15N labeled OSCP120 at protein:ligand ratios of 1:1, 
1:2, 1:4, and 1:8 led to chemical shift perturbations that suggest rapid exchange on the 
NMR timescale consistent with µM affinity, which agreed with previous data for Bz-423 
(Figures 1 and 2 and Table A1.1)(4).  To assess the significance of the OSCP chemical 
shift perturbations, a second set of titration experiments were conducted using an analog 
lacking the naphthalene substituent (2).  This analog possesses no activity in the F1F0-
ATPase or cell based assays (data not shown) and therefore we hypothesized should 
not to bind to the protein. Indeed, chemical shift perturbations were not observed in 
titration experiments with 2 (Figure A1.4), indicating that the perturbations observed with 
1 reflect specific binding interaction(s) that presumably are related to its inhibitory 
activity. 
The chemical shift perturbations induced by 1 were distributed at different sites 
within the OSCP120 construct (Figure A1.4). This observation suggests that 1 either 
binds at multiple sites and/or binding at one site causes conformational changes 
elsewhere in the protein. The range of intensities observed in OSCP120 suggests that 
the protein is highly flexible and potentially prone to ligand-induced (allosteric) 
conformational changes. In addition, previous studies of Bz-423 suggest a 1:1 
stoichiometry upon binding to the F1F0-ATPase(4). Collectively, these observations are 
consistent with ligand-induced conformational changes away from the binging site.  
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Table A1.1: Chemical shift perturbations for OSCP120 and OSCP145 where (--) 
represents unmeasurable resonances, (NS) represents no significant chemical shift, and 
(S) indicates a significant shift greater than the threshold cutoff. A (*) indicates residues 
that had similar free resonance positions in free OSCP120 and OSCP145, which were 
used to compare titration data. Cross-relaxation data for OSCP120 is also shown where 
(--) represents unmeasurable resonances, (NR) represents no significant intensity 
reduction, and (R) indicates a reduction in intensity greater than the threshold cutoff of 
0.8. 
Residue 120 CSP  145 CSP  120 CR   
2ALA -- -- --  
3LYS NS -- NR  
4LEU -- NS --  
5VAL -- -- --  
6ARG -- -- --  
9VAL -- -- --  
10GLN -- -- --  
11ILE -- -- --  
12TYR -- S --  
13GLY -- S --  
14ILE -- -- NR  
15GLU -- -- --  
16GLY NS S --  
17ARG -- -- --  
18TYR NS -- --  
19ALA -- -- --  
20THR S S --  
21ALA -- NS --  
22LEU S -- --  
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23TYR -- S --  
24SER NS NS --  
25ALA S S --  
26ALA NS NS --  
27SER NS S --  
28LYS NS NS R  
29GLN NS NS -- * 
30ASN NS NS -- * 
31LYS NS S R * 
32LEU -- NS -- * 
33GLU NS NS NR * 
34GLN -- -- --  
35VAL -- -- --  
36GLU S S NR  
37LYS NS NS -- * 
38GLU NS -- --  
39LEU NS NS --  
40LEU S S --  
41ARG NS S R  
42VAL NS NS -- * 
43GLY NS NS -- * 
44GLN NS NS -- * 
45ILE -- -- --  
46LEU NS S -- * 
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47LYS S S R * 
48GLU NS S -- * 
50LYS NS NS R * 
51MET S S NR * 
52ALA NS S R * 
53ALA NS NS NR * 
54SER NS NS -- * 
55LEU -- S --  
56LEU S S -- * 
57ASN -- NS -- * 
59TYR NS NS NR * 
60VAL NS NS R * 
61LYS NS NS NR * 
62ARG -- -- --  
63SER NS NS --  
64VAL -- S -- * 
65LYS S S -- * 
66VAL S S R * 
67LYS NS S -- * 
68SER NS NS NR * 
69LEU -- -- --  
70SER NS NS NR * 
71ASP -- -- --  
72MET -- -- --  
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73THR NS S -- * 
74ALA NS NS -- * 
75LYS S S -- * 
76GLU NS NS -- * 
77LYS S NS NR * 
78PHE NS NS --  
79SER NS S R  
81ILE -- -- --  
82THR S NS --  
83SER S S NR  
84ASN NS -- --  
85LEU -- -- --  
86ILE NS -- R  
87ASN NS -- R  
88LEU S NS NR  
89LEU NS NS --  
90ALA -- -- --  
91GLU NS S --  
92ASN S S --  
93GLY NS NS NR  
94ARG NS S --  
95LEU NS NS NR * 
97ASN NS NS --  
98THR NS S --  
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100ALA NS NS --  
101VAL -- S --  
102ILE S -- -- * 
103SER NS NS -- * 
104ALA NS S -- * 
105PHE S S --  
106SER NS NS -- * 
107THR -- -- --  
108MET S -- --  
109MET -- NS --  
110SER S S NR  
111VAL S -- R  
112HIS -- NS --  
113ARG S -- NR  
114GLY NS NS NR  
115GLU NS -- NR  
116VAL S NS --  
118CYS S NS --  
119THR S S --  





Figure A1.4. Chemical shift perturbations from titrations of 1 and 2 onto OSCP120 are 
shown in (a) and (b), respectively. Free OSCP120 (red), 1:2 OSCP120:1 (24), 1:4 
OSCP120:1 (blue), and 1:4 OSCP120:2 (gray) spectra are shown. Only resonances that 
exhibited significant chemical shift perturbations are labeled in (a), and peaks labeled in 
(b) are for comparison purposes. Weighted average of chemical shift perturbations (c) 
are color coded to match coloring on the OSCP120 structure (d) with blue representing 
resonances that showed no significant perturbation and red showing those resonances 
with shifts greater than the threshold of 0.01 ppm. Residues that could not be monitored 
are colored in gray and the shoulder region is circled in (d). Protein precipitation was 
observed at 1:8 OSCP:ligand ratios, which precluded further increasing the ligand 
concentration.   
 
The chemical shift perturbations caused by 1 fall in three general regions of 
OSCP120; one is located between helices III, IV, and V (“shoulder”) and includes 
residues M51, L56, K65, V66, K75, K77, T82, S83, and N92; the second is located at the 
C-terminal tails of helices I and VI (“tail region”) and includes residues V111, R113, 
V116, C118, and T119; a third potential locus is located between the “tail” and “shoulder” 
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regions (Figure A1.5).  Interestingly, the latter region includes residues A35 and L88, 
which were previously shown to interact directly with the α peptide mimicking the F1 
domain of the F1F0-ATPase(16,20).  
  
Figure A1.5. The structure of OSCP120 (PDB ID# 2BO5) is shown with helices, termini, 
shoulder, and tail regions labeled. 
 
To confirm the data obtained with OSCP120, we used a second OSCP construct 
comprising 145 amino acids (OSCP145).  Unlike the OSCP190, this truncated protein 
did not aggregate and was amenable to chemical shift perturbation experiments with 1. 
Comparing the OSCP120 and OSCP145 spectra reveals that the majority of the 
OSCP120 resonances are not altered due to the additional 25 amino acids in the 
OSCP145 construct (Figure A1.6).  Not surprisingly, residues that showed significant 
differences between the two constructs were primarily located at the N- and C- termini.  
However, chemical shift differences were observed at helix V, which interacts with the F1 
peptide(16). This region, which also undergoes perturbations with 1, may be subject to 
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allosteric conformational perturbations that could be important in mediating OSCP 
interactions with the F1F0-ATPase F1 domain(4).  
 
Figure A1.6. The overlay of OSCP120 (red) and OSCP145 (24) is shown in (a) with 
overlapping residues labeled. Spectra from the titration of 1 onto OSCP145 (b) show 
chemical shift perturbations (labeled) of similar residues between OSCP120 and 
OSCP145. Chemical shift perturbations from the titration of 1 on OSCP120 (c) and 
OSCP145 (d) show that the shoulder region is common in both sets of data and thus is 
likely the biologically relevant binding site. In (c) and (d), residues with weighted average 
chemical shift perturbations greater than the threshold cutoff of 0.01 are shown in red, 
and amino acids showing no significant weighted average chemical shift perturbations 
are colored in blue. Residues that could not be measured are colored in gray and the 
shoulder region is circled in (c) and (d). 
 
Titration with 1 induced chemical shift perturbations in OSCP145 whereas 2 did 
not (Figure A1.7). Several resonances from the shoulder (M51, L56, K65, V66, K75, and 
N92) and middle region of the protein (A35, E36, L40, K47, I102, and F105) that overlaid 
in OSCP120 and OSCP145 showed similar perturbations with 1, including A35, which 
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interacts with the F1 helix (Figure A1.6). Many residues in the shoulder region (E48, A52, 
K67, T73, S79, S83, E91, and R94) also showed larger perturbations with 1 in OSCP145 
compared to OSCP120.  By contrast, some of the perturbations observed in the “tail” 
(residues V116 and C118), middle (L88), and shoulder (T82) regions were less 
pronounced in OSCP145.  Taken together, these data indicate that the shoulder region 
is the most probable binding site for 1 on OSCP. 
 
Figure A1.7. Overlay of free OSCP145 (red) and titration of 2 at a protein:ligand ratio of 
1:4 (gray). The magnitude of chemical shift perturbations is null compared to titrations 
with 1. A (*) indicates peaks that were identified as C-terminal hexa-his tag resonances 
that perturb upon titration with 2 but are not relevant in the biologically native form of 
OSCP. 
 
Since chemical shift perturbations can arise from binding and/or conformational 
changes, cross-relaxation experiments were employed to localize the binding site of 1 on 
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OSCP120(25)  For these studies, 2D HSQC spectra of OSCP following saturation of 
specific 1H resonances in 1, and an equivalent reference spectrum with off-resonance (-
50 ppm) saturation were measured.  A reduction in OSCP resonance intensities in the 
on-resonance (Isat) versus off-resonance (Io) experiment indicates cross-relaxation 
processes due to proximity of ligand protons to OSCP amide protons resulting from a 
specific binding interaction.   
 
Figure A1.8. Intensity ratios (Isat/Io) from cross-relaxation experiments saturating protons 
at positions (7), (10), and (24) and their average is shown in (a). The 32 residues that 
were measured are color coded according to intensity reductions with those showing no 
significant reduction in intensity colored in blue and resonances showing intensity 
reductions greater than the threshold cutoff of 0.8 colored in red. The same color 
scheme is used in (b) with labeled residues being those that showed significant intensity 
reductions in any of the three sets of cross-relaxation data. Residues that could not be 




Although the cross-relaxation experiment is inherently insensitive since it 
recorded in 90% D2O to avoid saturation of the water resonance, and despite the limited 
solubility of OSCP, which further limited sensitivity, 32 well-resolved resonances with 
sufficient signal:noise were observed in the OSCP120•1 complex.  As shown in Figure 
A1.8, significant intensity reductions (>20%) are observed for a number of residues.  The 
majority of these residues (R41, K50, A52, V60, V66, S79, I86, and N87) fall in the 
“shoulder” region.  Cross-relaxation to residues in the tail region (K28, K31 and V111) 
was also observed and V111 corresponds to a residue for which significant chemical 
shift perturbations upon titration of 1 were measured. However, this site is most likely 
cryptic and only present in the truncated OSCP constructs since the perturbations are 
diminished or otherwise significantly altered in OSCP145.  Taken together, the chemical 
shift perturbation and cross relaxation studies are consistent with a unique binding site 
for 1  on the OSCP.   
 
A1.4 Conclusion 
 Inhibitors of the mitochondrial F1F0-ATPase are powerful tools for probing the 
structure and function of the enzyme and like Bz-423, some have therapeutic potential. 
A diverse group of molecules inhibit the enzyme by binding within the F1 domain(26-28).  
Representative compounds here include the antibiotics aurovetrin and efrapeptin, 
phytochemicals like resveratrol, and the naturally occurring peptide inhibitor, IF1.  
Aurovetrin binds to βTP and βE states of the enzyme and is thought to function by 
preventing closure of the interfaces necessary for catalytic cycling between subunit 
conformational states(4,29-32). Efrapeptin interacts with the γ and βE subunits where it 
can block re-charging after catalysis(29). Similarly, resveratrol inhibits the F1F0-ATPase 
by binding between the γ and βTP subunits where it can block the rotation of the γ subunit 
so that the catalytic cycle cannot progress(33). IF1 inhibits ATP hydrolysis when the 
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ability of the enzyme to synthesize ATP is compromised.  IF1 is thought to function by 
hindering the closure of the αDP-βDP catalytic interface thereby blocking ATP 
hydrolysis(34).  Several molecules such as the macrolide oligomycin inhibit the F1F0-
ATPase by binding to the embedded F0 domain(8). Biochemical studies suggest that 
oligomycin binding blocks the flow of protons through the c-subunit.  
Here we used NMR spectroscopy to investigate binding of a water-soluble Bz-
423 analog to OSCP constructs of varying length in an effort to define the binding site for 
these inhibitory benzodiazepines on the protein.  The chemical shift perturbation data on 
both OSCP120 and OSCP145 together with cross-relaxation data for OSCP120 suggest 
that 1 most likely binds to the shoulder region in a pocket defined by residues M51, L56, 
K65, V66, K75, K77, and N92. The peak intensities of unbound OSCP120 suggest that 
both the shoulder and tail regions are more flexible relative to the rest of the protein, 
potentially allowing for local rearrangements to occur upon ligand binding (data not 
shown).  While we cannot rule out a possible secondary binding site in OSCP120 
involving the tail region, this interaction was diminished in OSCP145, indicating that 
interactions at this site are not likely relevant and probably result as a consequence of 
the truncation only present in the 120-amino acid long OSCP construct.  
Several residues show chemical shift perturbations in the titration experiments 
but no significant cross-relaxation, which is most consistent with conformational changes 
on binding to 1.  These residues include A35 and L88, which are thought to directly 
interact with the F1 (16,35). L88 along with other residues in its vicinity also shift when 
comparing free OSCP120 and OSCP145, even though the 25 amino acids are added to 
the C-terminal end of OSCP145. Based on the NMR structure of OSCP120, L88 is 
distant from the additional 25 amino acids.  These data further support the hypothesis 
that this region of the OSCP is susceptible to conformational changes, which may be 
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important for the function of the protein in the fully assembled enzyme and the activity of 
Bz-423 like inhibitors.   
Based on our data, we propose an allosteric model for the inhibitory action of 1.  
Binding of 1 to the shoulder region of OSCP results in conformational rearrangements at 
a site that contacts the F1 domain of F1F0-ATPase, which interferes with the rotary 
mechanism of catalysis (Figure A1.9).  Allosteric communication between 1 and F1 
binding sites may be achieved by relative twisting motions of helices I and VI.  Such a 
structural rearrangement could explain the widespread perturbations observed in the 
middle region linking 1 and the F1 binding site.  
 
Figure A1.9. Proposed allosteric model where binding of 1 causes conformational 
rearrangements (at helices I, V, and VI) in OSCP thus altering OSCP-F1 interactions. 
Stars indicate site for the OSCP-F1 peptide interaction that were perturbed during 
titration experiments with 1. 
 
Another group of benzodiazepines have been reported that are structurally 
similar to Bz-423(24).  Unlike Bz-423, these compounds selectively inhibit ATP 
hydrolysis catalyzed by the mitochondrial F1F0-ATPase and may have use as anti-
ischemia drugs.  Preliminary studies suggest that these benzodiazepines also function 
through binding to the OSCP(36).  Together, these data highlight the important role the 
OSCP plays in regulating both the synthetic and hydrolytic the function of the 
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mitochondrial F1F0-ATPase.  A better understanding how these compounds interact with 
the OSCP and inhibit the enzyme should assist in further elucidating the function of the 
OSCP and may also provide additional opportunities for drug discovery.   
 
This work was published in the journal Biopolymers(37). Experimental Design was conceived by Al-Hashimi H. M. and 
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A2.1 Design of “NMR invisible” elongated RNA 
 The elongation of an RNA target is typically preformed by extending the length of a 
terminal helix using a stretch of Watson-Crick base-pairs(1). To avoid increasing spectral 
overlap due to elongation residues, an isotopic labeling strategy is used to render 
elongation residues “NMR invisible”(1). Here, two constructs are prepared in which 
stretches of alternating unlabelled A–U/U-A (E-AU-RNA) and G–C/C-G (E-GC-RNA) 
base-pairs are employed for elongation using otherwise uniformly 13C/15N labeled G–C 
and A–U nucleotides, respectively(1). Two G-C base pairs are added to the terminal end 
of E-AU-RNA to facilitate RNA synthesis by in vitro transcription. Structure prediction 
software such as mfold 3.3 are used to ensure that no alternate structures form as the 
result of elongation (34). The two constructs thus allow acquisition of NMR data over the 
entire RNA target while keeping elongation residues “NMR invisible”.  
 One must ensure that the elongation does not perturb the structural and functional 
integrity of the RNA. This can be conveniently done by comparing spectra of elongated 
and non-elongated RNA samples. In general, elongation of terminal helices is not 
expected to give rise to significant RNA structural perturbations. However, depending on 
the RNA context, elongation of other non-terminal helices, which can allow the 
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measurement of independents set of RDCs (and RCSAs) that can be applied to 
generate structural dynamics with enhanced spatial resolution (2), may cause unwanted 
perturbations and should be carefully analyzed.  
 The degree of helix elongation needed to sufficiently decouple internal and overall 
motions will vary depending on the RNA target. In general, the elongation should render 
a target helix at least 4-5-fold longer than other helices in the RNA. If a structure for the 
RNA target is available, one can perform simulations using programs such as PALES(3), 
using idealized A-form helices to model the elongated helix(2), to examine the degree of 
motional coupling. In these simulations, one computes the variance in the predicted 
overall alignment tensor relative to the elongated helix as a function of varying the 
relative orientation of other shorter helices in the RNA. In general, the principal direction 
of order (Szz) should not vary more than ±7 degrees about the elongated axis and the 
asymmetry (η) should always be <0.15. The secondary structure of an E-RNA construct 
should be verified using a secondary structure prediction programs such as mfold 3.3 to 
make sure that no alternative secondary structures can form(4). The E-RNA NMR 
samples (> 0.2 mM) are prepared using standard in vitro transcription reactions 
employing the appropriately 13C/15N labeled nucleotides(5,6). Formation of the elongated 
helix can be verified using NMR(1). First, one expects to observe an intense 1H signal 
corresponding to the chemically degenerate Watson-Crick hydrogen bonded imino 
protons of guanines and uridines used in the elongation in 1D 1H spectra. Second, one 
expects to observe signals that are characteristic of sequential 13C/15N enriched terminal 
GC base-pairs in the elongated helix, which are included to enhance transcription 
efficiency. 
 
 A2.2 Partial alignment of E-RNA  
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 The measurement of RDCs in solution NMR is contingent upon inducing an 
appropriate degree of alignment typically on the order of 10-3(7). These levels of 
alignment can now be routinely achieved by dissolving biomolecules in inert ordered 
media (for reviews see(8,9)) that transmit some of their order to solute molecules 
through mechanisms that are believed to involve a combination of steric obstruction and 
charge-charge interactions. The most popular and commercially available ordering 
medium is Pf1 phage(10,11). Relative to other media, Pf1 phage is tolerant to the high 
salt concentrations used in nucleic acid samples and is negatively charged thus reducing 
the possibility for adverse inter-molecular interactions. Pf1 phage is available 
commercially or can be prepared using the methods described in reference(10). 
Typically, a Pf1 solution is exchanged into NMR buffer by repeated (at least three) 
rounds of ultracentrifugation (1hr in a Beckman TLA-100.3 rotor at 95,000 rpm, or 3-6 
hrs in a VTi50 rotor at 40,000 rpm) followed by re-suspension of the pellet into the NMR 
buffer. Alternatively, one can dialyze Pf1 phage into the desired buffer. After completing 
the aligned experiments, the same ultracentrifugation procedure can in principle be used 
to recover the nucleic acid (supernatant) from the phage solution (pellet). Note that it will 
generally be difficult to achieve perfect separation of the nucleic acid sample from the 
phage medium.  
 Owing to their large structural anisotropy, the concentration of Pf1 phage needed 
to align E-RNA samples (~6-8 mg/ml) is usually considerably smaller than for non-
elongated RNA (~20-25 mg/ml). If a model structure for the RNA is available, programs 
for predicting steric alignment such as PALES(3) can be used to assess relative levels of 
order and the Pf1 phage concentration be adjusted accordingly. The aligned RNA 
sample is typically prepared by adding a pre-concentrated RNA solution (~0.5-1.5 mM) 
in NMR buffer to a desired volume of Pf1 phage (50 mg/mL) in NMR buffer in an 
Eppendorf tube and the sample gently transferred into the NMR tube avoiding formation 
 178 
of bubbles. It is important to verify that the ordering medium does not interfere with the 
RNA conformation by comparing chemical shifts obtained in the unaligned and aligned 
samples. Note that small variations in the chemical shifts of nucleobase carbons and 
nitrogens are expected between unaligned and aligned samples due to incomplete 
averaging of Residual Chemical Shift Anisotropies (RCSAs) (12-14). These RCSA 
contributions scale linearly with the magnetic field and degree of order.  
 It should be noted that an alternative approach for aligning nucleic acids involves 
spontaneous alignment due to interactions with the magnetic field itself. Although the 
degree of field induced alignment remains smaller than optimal, there are reasons to 
believe that optimal levels will inevitably be reached as larger nucleic acids are 
investigated and magnetic field strengths continue to rise. This approach is not 
described here and the reader can consult reviews on this topic. 
 
A2.3 Measurement of RDCs in E-RNA 
 A large number of pulse sequences have been reported for the measurement of a 
wide variety of RDCs in nucleic acids. These experiments are not described in detail 
here as they have been reviewed elsewhere.(52) The RDCs are generally computed 
from the difference in splittings observed in the absence (J) and presence of alignment 
media (J+D). For large E-RNA, it is important to employ TROSY schemes for measuring 
RDCs in the nucleobases(15). For example, CH splittings in the nucleobases are 
measured as the difference between the upfield and downfield components of the 1H –
13C doublet along the 1H dimension using the narrow TROSY component in the 13C 
dimension. For E-RNA, the most commonly targeted RDCs are those between directly 
bonded C-H and N-H nuclei (e.g. C2H2/C8H8 of the adenine and guanine bases, 
C5H5/C6H6 of the uracil and cytosine bases, N1H1 and N3H3 of the guanine and uracil 
bases, and C1’H1’ of the ribose), which yield the largest RDC magnitudes. While 
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additional one, two, and three bond RDCs can also be measured, these RDCs are 
smaller and may prove difficult to measure in larger E-RNAs (>60 nt).   
 When using frequency domain experiments to measure splittings, phase distortions 
due to improper calibration of timing delays and/or imperfections in shaped pulses can 
yield splitting measurement errors that are larger than theoretical limits (approximately 
given by 0.7*Linewidth*(1/Signal:Noise))(16). To avoid differential contributions from 
magnetic field induced RDCs and relaxation interference effects, splittings in unaligned 
and aligned samples should be measured at the same magnetic field strength. It is 
advisable to estimate the experimental RDC uncertainty from the standard deviation in 
duplicate measurements. Resonances exhibiting significant differences (>3σ) as a result 
of considerable broadening, overlap, presence/absence of unresolved multiplets should 
not be used in subsequent data analysis.  
 
A2.4 Normalizing RDCs measured in distinct E-RNA samples 
 The RDCs measured in the different E-AU and E-GC samples need to be 
normalized to take into account possible differences in the degree of alignment before 
the data can be pooled together and analyzed in constructing atomic-resolution 
ensembles(2). The normalization is carried out using RDCs measured in contiguous 
Watson-Crick base-pairs, which can be modeled assuming an idealized A-form 
geometry (see below). The errors introduced due to A-form structural noise can be 
estimated as described previously(53). The normalization is accomplished by repeatedly 
fitting the total pool of RDCs to individual idealized A-form helices following uniform 
scaling of the RDCs measured in one sample (typically the sample with the lesser 
number of measured RDCs) by a normalization factor L. The L value that minimizes the 
Quality factor (Q)(17) is computed using(2): 
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.        
 (4) 
 
Fitting of the RDCs to the A-form helices can be accomplished using various programs 




A2.5 Determining the overall order tensor 
  The interpretation of E-RNA RDCs is greatly simplified by determining the overall 
order tensor governing alignment. The overall order tensor can be determined using 
RDCs measured in the reference elongated helix using a procedure that has been 
described in detail elsewhere(22,23). The procedure is briefly outlined below: 
1. Build idealized A-form helices (PDB files) corresponding to the sequence of the 
reference helix. For example, to build an A-form helix using the Biopolymer 
module of Insight II 2000.1 (Molecular Simulations, Inc): click on the module icon 
in the upper left corner and select append from the nucleotide menu. In the pop-
up box, select “A_RNA_Duplex”.  Input a name for the molecule into the text 
field. Next, select the appropriate Watson-Crick base-pair in the Nucleotide text 
field. Continue to append base-pairs – following along in sequence from 5’ to 3’ – 
until you have completed building the desired helix. Click cancel and then select 
the File menu and choose the desired export option for the helix coordinates. The 
idealized A-form helices should conform to published parameters(23-25). If 
building helices using INSIGHT II 2000.1 (Molecular Simulations, Inc.), care 
 181 
needs to be taken to correct the propeller twist angles to the proper value of -
14.50. We have a program named HPmod to correct for the improper propeller 
twist (available from Author upon request). Programs such as Curves 5.1(26), 
FreeHelix98(27), 3DNA(25,28) , SCHNAaP(29), NUPARM and NUCGEN(30) 
can be used to compute relevant helix parameters.  
2. Compute five order tensor elements for each A-form helix by fitting the RDCs to 
the A-form PDB coordinates. Several programs are available to carry out such 
calculations including ORDERTEN-SVD(18), REDCAT(19), PALES(3), iDC(20), 
CONFORMIST(21) and RAMAH(12). Note, non-ideal WC base-pairs are 
excluded from this analysis. In our lab RAMAH is used to determine the five 
order tensor elements.  
3. Examine the correlation between measured and back-calculated RDCs. Major 
outliers should be interrogated for possible measurement errors.  
4. Use AFORM-RDC(23) or other approaches(31) to estimate the order tensor error 
due to structural noise and RDC measurement uncertainty.  
 Owing to the uniform distribution of charge in polyanionic nucleic acids, the steric 
and electrostatic forces are believed to have a similar functional form(32,33). 
Consequently, E-RNAs are expected to align in ordering media with the principal 
direction of order (Szz) oriented along the elongated axis. In general, one expects 
positive alignment (Szz> 0) with the Szz direction being, on average, oriented parallel to 
the magnetic field(2). The asymmetry of alignment is also expected to be nearly axially 
symmetric (η~0)(2). 
 
A2.6 Molecular Dynamics (MD) simulations of RNA 
 MD simulations are used in this case to generate a large conformational pool that 
can be filtered using experimental RDCs so as to generate a more accurate ensemble of 
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RNA conformers. A variety of MD simulation packages and force-fields can be employed 
to simulate nucleic acids. Here we describe a protocol for simulating RNA using the 
CHARMM MD package(34) with force-field parameter set 27 for nucleic acids(35). 
A) System Preparation using MMTSB Toolkit: To prepare the system for simulation with 
CHARMM, the MMTSB Toolset (http://blue11.bch.msu.edu/mmtsb/Main_Page)(36) is 
used. The Toolset consists of a set of perl scripts that can be used to prepare, initiate 
and analyze a system for MD simulation. Here they are only described in terms of 
preparing a system for an MD simulation: 
i. Obtain coordinates for the RNA from the Protein Data Bank (PDB) 
(http://www.pdb.org) or the Nucleic Acid Database (NDB) 
(http://ndbserver.rutgers.edu/). Use the MMTSB toolset script convpdb.pl to 
add solvent and ions to the system using the command: convpdb.pl -solvate -
cutoff 15 -cubic -ions SOD:27 hivtar-0.pdb > hivtar-0-solvated-ions.pdb. In this 
example -solvate flag indicates that pdb solvent molecules will be added,  
-cutoff 15 specifies the distance (15 Å) from the RNA to the edge of the 
solvent cube, -cubic specifies a solvent shape (alternatively a octahedron 
water box could be specified with -octahedron flag), -ions SOD:27 specifies 
that 27 sodium ions be added to make the system charge neutral, and hivtar-
0.pdb indicates the input pdb file.    
ii. Use the MMTSB toolset script genPSF to generate protein structure file (PSF) 
and CHARMM formatted coordinate file using the command: genPSF.pl -par 
nodeoxy -crdout hivtar-0-solvated-ions.cor hivtar-0-solvated-ions.pdb > hivtar-
0-solvated-ions.psf. Here the -par nodeoxy flag specifies that the system is an 
RNA molecule, -crdout and hivtar-0-solvated-ions.cor specifies the filename 
for the output CHARMM formatted coordinate, and is hivtar-0-solvated-
ions.psf is the output PSF file.  
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B)  Equilibration using CHARMM 
i) Read in parameter and topology file set 27 for nucleic acids 
ii) Read in generate PSF and coordinates files 
iii) Do 500 steps Steepest Descent (SD) minimization to remove bad contacts 
using the CHARMM MINI SD module 
iv) Place harmonic constraints on heavy atoms of the RNA using CONS HARM 
(see CHARMM’s cons.doc manual) and perform 1000 steps of SD 
minimization, followed by 2000 steps of Adopted Basis Newton-Raphson 
(ABNR) minimization or until energy converges (see CHARMM’s minimiz.doc 
manual). This process allows solvent and counter-ions to relax around the 
RNA. 
v) The energy minimized structure is heated up to 300 K, by carrying out a 
series of constant temperature simulations starting at 0 K for ~20 ps at each 
temperature. The temperature is increased by 25 K each incremental time-
step using coordinates from the previous run as input for the next 20 ps 
simulation. We usually use the Nosé Hoover thermostat with a coupling 
constant of 100 ps -1 together with the Velocity Verlet (VVER) integrator with a 
integration time-step of 1 fs. Periodic boundary conditions are used, with 
electrostatics calculated using particle-mesh Ewald and Lenard-Jones 
interaction truncated at 12 Å, with a switching function applied between 10 to 
12 Å. 
vi) At 300 K the harmonic constraint is gradually removed by decreasing the 
force constant. 
vii)  Equilibration is continued at 300 K and without any harmonic constraints for 
an additional 500 ps. 
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viii) Generation of trajectory: Generation of structural ensembles from an MD 
derived pool of conformations hinges on the ability to adequately sample the 
relevant regions of conformational space. It has been shown that using 
multiple short trajectories may enhance the rate of conformational 
sampling(37,38) when compared to a single long trajectory of same effective 
length, which is advantageous to our methods since we use experimental data 
to filter unrealistic conformations. In this protocol we will describe the use of 
multiple short trajectories to generate such selection pools. 
ix) Initiate a set of independent MD constant temperature replica trajectories 
starting from the same equilibrated structure generated in part-A. We have 
found 50 replicas to be sufficient. The thermostat, integrator and non-bonded 
energy calculation options are same as stated above. 
x) Assign each replica a different set of initial velocities by specifying a different 
seed value for the random number generator used to assign initial velocities 
using the ISEED input flag into DYNA. 
xi) Generate trajectories of about ~ 3 ns, while saving conformations each 1 ps.  
xii) Discard the first 1 ns and pool the remaining ~ 2 ns trajectories for each 
replica to create a selection pool.  In this case we generated ~100,000 
conformations. Use this pool for selection of structural ensembles as 
described below. 
 
A2.7 Combine NMR RDCs and MD to generate a structural ensemble – Sample and 
Select 
 he Sample and Select method was originally implemented as a tool to generate 
structural ensembles of proteins using a combination of MD and NMR derived NH spin 
relaxation order parameters (S2)(39). The basic idea is to sample the relevant 
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conformational space and then select a sub-ensemble that is most consistent with the 
experimental data. We adapted this method to use RDCs measured on E-RNA to select 
structural ensembles of RNA from a selection pool derived from an MD simulation(40). 
The SAS selection is preformed following the recently described procedure(40) in which 
one minimizes a cost function utilizing a Monte-Carlo simulated annealing approach: 
i) Randomly select an N-membered subset of structures from the total pool of M 
structures and calculate  using , where  and 
 are the calculated and measured RDCs, respectively, and L is the total 
number of bond vectors. 
ii)  Randomly replace one of the N-membered structures with a randomly chosen 
structure from the remaining M-N conformational pool. Accept the move for 
step k to k+1 if . If , accept the move with a 
probability , where Ti is the effective temperature. We 
typically use a linear cooling schedule, specifically Ti+1 = 0.9Ti, where the 
index i runs over the temperature increments.  
iii) Continue Monte-Carlo annealing simulations until  converges. In our    
simulations with M = 80000, N=20 and L=82, convergence was achieved within 
100 temperature increments with each consisting of 100,000 MC steps. 
  
Once an ensemble is constructed, it is important to have the means to establish 
its validity. This can be done using experimental data that is not included in the selection 
process. In addition to RDCs, future studies can also include RCSAs(43, 45), NOEs, as 
well as spin relaxation order parameters(69, 70), or data from other experimental 
techniques such as SHAPE foot printing(71) data and fluorescence(72). The constructed 
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ensembles can also be compared with expected parameters. For example, average and 
standard deviations for various base angles have been reported for Watson-Crick base-
pairs that are flanked by other Watson-Crick base-pairs in A-form helices(53). Last but 
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